Document:

Callaboration and Option Agreement

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

EXHIBIT 10.21 
 COLLABORATION AND OPTION AGREEMENT 
 by and between 

NOVARTIS VACCINES & DIAGNOSTICS, INC. 
 and 
 FLUIDIGM CORPORATION 

DATE: MAY 17, 2010 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

TABLE OF CONTENTS 
  

							
	 ARTICLE I Definitions
	  	 	1	  
		
	 ARTICLE II Committees
	  	 	10	  
			
	 2.1
	  	 Joint Steering Committee
	  	 	10	  
	 2.2
	  	 Alliance Managers
	  	 	11	  
		
	 ARTICLE III Collaboration
	  	 	11	  
			
	 3.1
	  	 Project Plan
	  	 	11	  
	 3.2
	  	 Phase 1 Collaboration Milestones
	  	 	12	  
	 3.3
	  	 Phase 2 and 3 Collaboration and Quality Milestones
	  	 	13	  
	 3.4
	  	 General Conduct of Collaboration Activities
	  	 	13	  
	 3.5
	  	 Principal Scientist
	  	 	13	  
	 3.6
	  	 Record Keeping
	  	 	13	  
	 3.7
	  	 Cooperation
	  	 	14	  
	 3.8
	  	 Costs
	  	 	14	  
		
	 ARTICLE IV Supply
	  	 	14	  
			
	 4.1
	  	 Collaboration and Clinical Supply Obligations
	  	 	14	  
	 4.2
	  	 Audit and Inspection
	  	 	15	  
	 4.3
	  	 Supply Agreement
	  	 	15	  
		
	 ARTICLE V License Grants, Option Rights and Related Matters
	  	 	16	  
			
	 5.1
	  	 License Grants
	  	 	16	  
	 5.2
	  	 Option
	  	 	17	  
	 5.3
	  	 Right of First Negotiation
	  	 	17	  
	 5.4
	  	 Non-Compete
	  	 	18	  
	 5.5
	  	 No Encumbrance
	  	 	19	  
	 5.6
	  	 Use of Materials
	  	 	19	  
		
	 ARTICLE VI Payments and Royalties
	  	 	19	  
			
	 6.1
	  	 Collaboration Milestone Payments
	  	 	19	  
	 6.2
	  	 Royalties to Novartis
	  	 	20	  
	 6.3
	  	 Royalty Payments
	  	 	21	  
	 6.4
	  	 Records Retention; Audit
	  	 	21	  
	 6.5
	  	 Mode of Payment
	  	 	22	  
	 6.6
	  	 Taxes
	  	 	22	  
		
	 ARTICLE VII Intellectual Property Rights
	  	 	23	  
			
	 7.1
	  	 Intellectual Property Ownership
	  	 	23	  

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 

							
	 7.2
	  	 Prosecution of Collaboration Patents
	  	 	24	  
	 7.3
	  	 Enforcement and Defense of Collaboration Patents
	  	 	25	  
		
	 ARTICLE VIII Confidentiality and Nondisclosure
	  	 	26	  
			
	 8.1
	  	 Restricted Fluidigm Information
	  	 	26	  
	 8.2
	  	 Confidentiality Generally
	  	 	27	  
	 8.3
	  	 Permitted Disclosures
	  	 	27	  
	 8.4
	  	 Exclusions
	  	 	28	  
	 8.5
	  	 Confidentiality of Terms of Agreement
	  	 	28	  
	 8.6
	  	 Use of Name
	  	 	29	  
	 8.7
	  	 Press Releases
	  	 	29	  
	 8.8
	  	 Publications and Presentations
	  	 	29	  
		
	 ARTICLE IX Term and Termination
	  	 	29	  
			
	 9.1
	  	 Term
	  	 	29	  
	 9.2
	  	 Termination of this Agreement for Material Breach
	  	 	29	  
	 9.3
	  	 Termination Upon Insolvency
	  	 	30	  
	 9.4
	  	 Additional Termination Rights
	  	 	30	  
	 9.5
	  	 Consequences of Expiration or Termination
	  	 	30	  
	 9.6
	  	 Remedies; Accrued Rights; and Surviving Obligations
	  	 	35	  
		
	 ARTICLE X Indemnity; Limitation of Liability
	  	 	35	  
			
	 10.1
	  	 Indemnification of Fluidigm
	  	 	35	  
	 10.2
	  	 Indemnification of Novartis
	  	 	36	  
	 10.3
	  	 Notice of Claim
	  	 	37	  
	 10.4
	  	 Indemnification Procedures
	  	 	37	  
	 10.5
	  	 Limitation on Damages
	  	 	38	  
	 10.6
	  	 Insurance
	  	 	39	  
		
	 ARTICLE XI Representations, Warranties and Covenants
	  	 	39	  
			
	 11.1
	  	 Representations, Warranties and Covenants
	  	 	39	  
	 11.2
	  	 Additional Representations, Warranties and Covenants of Fluidigm
	  	 	40	  
		
	 ARTICLE XII Miscellaneous
	  	 	43	  
			
	 12.1
	  	 Force Majeure
	  	 	43	  
	 12.2
	  	 Assignment; Change of Control
	  	 	43	  
	 12.3
	  	 Severability
	  	 	45	  
	 12.4
	  	 Governing Law
	  	 	45	  
	 12.5
	  	 Notices
	  	 	45	  
	 12.6
	  	 Dispute Resolution
	  	 	46	  
	 12.7
	  	 Entire Agreement; Modifications
	  	 	47	  

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -ii-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 

							
	 12.8
	  	 Relationship of the Parties
	  	 	47	  
	 12.9
	  	 Equitable Relief
	  	 	47	  
	 12.10
	  	 Waiver
	  	 	48	  
	 12.11
	  	 Counterparts
	  	 	48	  
	 12.12
	  	 No Benefit to Third Parties
	  	 	48	  
	 12.13
	  	 Further Assurance
	  	 	48	  
	 12.14
	  	 References; Construction
	  	 	48	  

 Schedules and Exhibits 

 

			
	Exhibit A	  	Novartis Development Quality Agreement
	Exhibit B	  	Collaboration Plan
	Exhibit C	  	Assay Patents
	Exhibit D	  	Description of Current Fluidigm Technology
	Exhibit E	  	Fluidigm Patents
	Exhibit F	  	License Agreement
	Exhibit G	  	Key Supply Terms in Supply Agreement
	Schedule 11.2(d)	  	Owned Core Fluidigm Patents, In-Licensed Core Fluidigm Patents, and Core In-License Agreements

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -iii-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

COLLABORATION AND OPTION AGREEMENT 
 THIS COLLABORATION AND OPTION AGREEMENT (this “Agreement”) is made and entered into effective as of
[            , 2010] (the “Effective Date”), by and between NOVARTIS VACCINES AND DIAGNOSTICS,
INC., a Delaware corporation, with offices at 4560 Horton Street, Emeryville, CA 94608 (“Novartis”), and FLUIDIGM CORPORATION, a Delaware corporation with offices at 7000 Shoreline Court,
Suite 100, South San Francisco, CA 94080 (“Fluidigm”). 
 RECITALS 

WHEREAS, Fluidigm has developed a digital PCR/digital array chip reader instrument system and approach towards non-invasive
prenatal and pregnancy related diagnostics using cell-free DNA in maternal blood, urine, saliva, bloodspot or stool; 

WHEREAS, Novartis has specialized experience in, among other things, the research, development and commercialization of
diagnostics and Fluidigm has specialized experience in digital PCR and has developed certain technology of interest to Novartis; 
 WHEREAS, Novartis and Fluidigm desire to enter into an exclusive (as described in this Agreement) research and development collaboration to identify and develop reagents to be used in connection
with the Fluidigm Technology (as defined below) and, if applicable, to modify such Fluidigm Technology, to develop a Test (as defined below) in the Primary Field (as defined below); 

WHEREAS, Fluidigm desires to grant Novartis an option to exclusively license Novartis the Fluidigm Technology, Fluidigm Know-How
and Fluidigm Patents in the Primary Field and Secondary Field (each as defined below), and an option to exclusively supply Novartis the Fluidigm Products for use in the Primary Field and Secondary Field, and Novartis may desire to exercise such
options as set forth herein. 
 NOW, THEREFORE, in consideration of the foregoing premises, the mutual promises and
covenants of the parties contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, do hereby agree as follows: 

ARTICLE I 

Definitions 
 Unless otherwise specifically provided herein, the following terms shall have the following meanings: 
 “Affiliate” shall mean, with respect to a party, any Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with such
party. For purposes of this definition, “control” and, with correlative meanings, the terms “controlled by” and “under common control with” shall mean (a) the possession, directly or indirectly, of the power to
direct the management or policies of such a Person, whether through 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
the ownership of voting securities, by contract relating to voting rights or corporate governance, or otherwise, or (b) the ownership, directly or indirectly, of more than fifty percent
(50%) of the voting securities or other ownership interest of such Person. 
 “Ancillary Agreement” shall mean
the Supply Agreement, the License Agreement and any other agreement entered into pursuant to this Agreement or the Supply Agreement, including the Novartis Development Quality Agreement. 

“Applicable Law” shall mean the applicable laws, rules, regulations, including any rules, regulations, guidelines, or other
requirements of any applicable regulatory authorities, that may be in effect from time to time in the Territory. 

“ASR” shall mean an analyte specific reagent, including nucleic acid sequences, or similar reagent which, through specific
binding or chemical reaction with substances in a specimen, is intended for use in a Test. 
 “Change of Control”
shall mean the occurrence of any of the following events: (a) any Person acquires, either directly or indirectly, (i) at least fifty percent (50%) of the then-outstanding shares of common stock of Fluidigm or any direct or indirect
parent of Fluidigm or (ii) securities of Fluidigm or any direct or indirect parent of Fluidigm entitled to cast at least fifty percent (50%) of the votes that may be cast in an election of directors of Fluidigm or such parent; (b) a
reorganization, merger or consolidation with a Person to which Fluidigm or any direct or indirect parent of Fluidigm is a party, unless, after the occurrence of such reorganization, merger or consolidation, Fluidigm’s or such direct or indirect
parent of Fluidigm’s outstanding common stock immediately prior to the effectiveness of such transaction constitutes or is converted into securities of the surviving company entitled to cast a majority of the votes that may be cast in an
election of directors of the surviving company; (c) a sale or transfer of all or substantially all of Fluidigm’s or any direct or indirect parent of Fluidigm’s assets to a Person; or (d) a liquidation or dissolution of Fluidigm
or any direct or indirect parent of Fluidigm. 
 “Collaboration Activities” shall mean those tests, studies and other
activities set forth in, or performed in order to obtain the information set forth in, the Collaboration Plan and such other tests, studies and other activities as may be agreed upon from time to time by the JSC. 

“Collaboration Information and Inventions” shall mean any and all Information and Inventions that are (a) in the case of
inventions, conceived or (b) in all other cases, developed or made, in each case ((a) and (b)) by or on behalf of either party (or its Affiliates or subcontractors) or jointly by or on behalf of one party (or its Affiliates or subcontractors)
and the other party (or its Affiliates or subcontractors) in the performance of or pursuant to the Collaboration Plan or otherwise in the performance of any Collaboration Activities. “Collaboration Information and Inventions” shall not,
however, include any Information and Inventions that are (i) in the case of inventions, conceived, or (ii) in all other cases, developed or made, in each case ((i) and (ii)) by or for a party (or its Affiliates or subcontractors) prior to
the Effective Date, or after the Effective Date and solely outside the performance of the Collaboration Activities (“Excluded Information and Inventions”). (For example, Excluded 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -2-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
Information and Inventions developed prior to the Effective Date and incorporated into Collaboration Information and Inventions shall not thereby become Collaboration Information and Inventions,
and, similarly, Collaboration Information and Inventions incorporated into Information and Inventions developed after termination of this Agreement shall not cause such later-developed Information and Inventions to be Collaboration Information and
Inventions). 
 “Collaboration Know-How” shall mean all Collaboration Information and Inventions that are not
generally known, but excluding any Collaboration Information and Inventions to the extent claimed by a Collaboration Patent. 

“Collaboration Patents” shall mean any Patents to the extent that they claim any Collaboration Information and Inventions. For
the avoidance of doubt, “Collaboration Patents” shall not include any Patents existing prior to the Effective Date (or any resulting Patent rights), nor any Patents to the extent claiming inventions within the Excluded Information and
Inventions. 
 “Collaboration Plan” shall mean that detailed work plan attached hereto as Exhibit B, as amended
from time to time by the JSC in accordance with this Agreement. 
 “Completion” shall mean, with respect to a Phase,
the date on which all the Collaboration Activities for such Phase are completed and the Final Report for such Phase has been provided by each party. 
 “Confidential Information” of a party shall mean all Information and Inventions and other confidential information and data of a financial, commercial or technical nature which the disclosing
party or any of its Affiliates has supplied or otherwise made available to the other party or its Affiliates, whether made available orally, visually (e.g., by access to facilities or property), in writing or in electronic form, and whether before,
on or after the Effective Date, including information comprising or relating to concepts, discoveries, inventions, data, designs or formulae in relation to this Agreement. 
 “Control” shall mean, with respect to any item of Information and Inventions, Patent or other intellectual property right, possession of the right, whether directly or indirectly, and whether by
ownership, license or otherwise, to assign, or grant a license, sublicense or other right to or under, such Information and Inventions, Patent or right without violating the terms of any agreement or other arrangement with any Third Party.

 “Core Fluidigm Know-How” shall mean Fluidigm Know-How required to practice the inventions as claimed in the Core
Fluidigm Patents. 
 “Core Fluidigm Patents” shall mean, for Patents set forth on Schedule 11.2(d), those
certain claims covering Core Fluidigm Technology and, after the Effective Date, any additional Fluidigm Patents covering the Core Fluidigm Technology that the parties agree in writing shall constitute Core Fluidigm Patents, such agreement by
Fluidigm not to be unreasonably withheld. 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -3-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 “Core Fluidigm Technology” shall mean the Fluidigm
Technology (a) constituting Fluidigm Chips and other chips manufactured by Fluidigm specifically for conducting digital PCR, (b) directed to the use of the chips specified in clause (a) hereinabove for conducting digital PCR in the
Primary Field or Secondary Field, (c) constituting the Fluidigm Instrument(s) for conducting digital PCR using the chips specified in section (a) herein, (d) directed to the use of such Fluidigm Instrument(s) for conducting digital
PCR, or (e) for conducting digital PCR specifically in the Primary Field or Secondary Field. 
 “Exploit” or
“Exploitation” shall mean to make, have made, import, export, use, sell, offer for sale, or otherwise dispose of, including all discovery, research, development, registration, modification, enhancement, improvement, manufacture, storage,
formulation, exportation, transportation, distribution, promotion and marketing activities related thereto. 
 “Final
Report” shall have the meaning set forth in Section 3.1(d). 
 “Fluidigm Assay Patent Claims” shall mean
those certain assay claims, existing as of the Effective Date and filed prior to [***], of the Fluidigm Patents Controlled by Fluidigm, which claims are set forth on Exhibit C. 

“Fluidigm Chip” shall mean the [***], and any Improvements thereto developed by or on behalf of Fluidigm or any of its
Affiliates during the term of this Agreement, or, if the License Option is exercised, during the term of the License Agreement. “Fluidigm Chip” includes any additional buffers and reagents (excluding assay reagents) and other consumables
(e.g., oils) required for operation of the applicable chip and that are customarily provided by Fluidigm with the sale of its chips. 
 “Fluidigm Instrument” shall mean that certain Fluidigm digital PCR/digital array chip reader instrument system (including software required to run the instrument and to conduct the applicable
analysis) currently sold by Fluidigm, including any Improvements to such instrument (including such software) developed by or on behalf of Fluidigm or any of its Affiliates during the term of this Agreement, or, if the License Option is exercised,
during the term of the License Agreement. 
 “Fluidigm Know-How” shall mean all Information and Inventions Controlled
(other than pursuant to a license or other right granted to Fluidigm in this Agreement) by Fluidigm or an Affiliate of Fluidigm as of the Effective Date or at any time during the term of this Agreement (or, if the License Option is exercised, during
the term of the License Agreement), including the Fluidigm Method, Fluidigm Technology, and the Fluidigm Solely-Owned Collaboration Information and Inventions, that are not generally known and are reasonably necessary or useful for, or otherwise
related to, the Exploitation of any Novartis Licensed Products (including generating results from Tests, but excluding the manufacture of Fluidigm Technology) in the Primary Field and the Secondary Field, but excluding any Information and Inventions
to the extent claimed by one or more of the Fluidigm Patents. 
 “Fluidigm Method” shall mean the Fluidigm Know-How
and the inventions claimed in the Fluidigm Patents, in each case, that relate to non-invasive prenatal and pregnancy related 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -4-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
diagnostics using digital PCR and cell-free DNA in maternal blood, urine, saliva, bloodspot or stool in the Primary Field or Secondary Field. 

“Fluidigm Patents” shall mean all Patents Controlled by Fluidigm or an Affiliate of Fluidigm as of the Effective Date or at any
time during the term of this Agreement, including any Patents claiming (a) the Fluidigm Method or the Fluidigm Technology, or (b) the Fluidigm Solely-Owned Collaboration Information and Inventions, in each case that are reasonably
necessary or useful for, or otherwise related to, the Exploitation (but excluding the manufacture of Fluidigm Technology) of any Novartis Licensed Products, including the generation of results from Tests, in the Primary Field and the Secondary
Field. The “Fluidigm Patents” shall include (i) all Patents listed in Exhibit E, (ii) all patents issuing on such patent applications, and any divisionals, continuations, continuations-in-part, reissues, reexaminations,
extensions, substitutions, registrations, additions, confirmations and renewals of such patents and patent applications, including any patents and patent applications that claim priority to a common priority document in the priority chain of any of
the foregoing, (iii) supplemental protection certificates and the like relating to any of the foregoing, and (iv) counterparts or substantial equivalents of any of the foregoing in any country. 

“Fluidigm Products” shall mean the Fluidigm Chips and the Fluidigm Instruments, collectively. 

“Fluidigm Royalty-Bearing Product” shall mean any instrument, chip or chip system, sold by or on behalf of Fluidigm or any of
its Affiliates or (sub)licensees, that infringes any Valid Claim(s) of the Collaboration Patents. 
 “Fluidigm Solely-Owned
Collaboration Information and Inventions” shall mean the Collaboration Information and Inventions that (a) in the case of inventions, are described in written claims solely directed to, or (b) in all other cases, is specifically
about, the design, development, or manufacture of Fluidigm Chips or any other chips, Fluidigm Instruments or any other instruments, or associated control software. 
 “Fluidigm Technology” shall mean Fluidigm’s current digital PCR and associated chips, including the Fluidigm Chips, and digital array chip reader instrument system, including the Fluidigm
Instruments, each as further described in Exhibit D, including Improvements to any of the foregoing and any other technology that Fluidigm Controls at any time during the term of this Agreement relating to or applicable in the Primary Field
or Secondary Field. 
 “FTE” shall mean the equivalent of the work of one (1) employee full time for one
(1) calendar year. 
 “Improvement” shall mean (a) any modification, variation or revision to Fluidigm
Technology, including Fluidigm Instruments and Fluidigm Chips, as they exist on the Effective Date, or (b) inventions for which patent applications are or may be filed that incorporate or expand on the Fluidigm Patents claiming Fluidigm
Technology, including Fluidigm Instruments and Fluidigm Chips, as they exist on the Effective Date. 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -5-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 “Indemnified Party” shall mean a party, its
Affiliates or its or their respective directors, officers, employees, agents, partners and shareholders seeking to recover a Loss under Section 10.1 or 10.2. 
 “Indemnifying Party” shall mean a party from whom recovery of a Loss is sought under Section 10.1 or 10.2. 
 “Information and Inventions” shall mean all technical information, know-how and data (including clinical, analytical, and quality control data), inventions (whether patentable or not),
discoveries, trade secrets, specifications, instructions, processes, formulae, materials, expertise and other technology applicable to diagnostics, formulations, compositions, products or to their manufacture, research, development, registration,
use or commercialization or methods of assaying or testing them or processes for their manufacture, formulations containing them, compositions incorporating or comprising them, kits incorporating or comprising them, and including all biological,
chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical and analytical, safety, quality control, manufacturing, preclinical and clinical data, instructions, processes, formulae, expertise and information relevant to the
research, development, manufacture, use or commercialization of or which may be useful in studying, testing, development, production or formulation of products, but excluding the Regulatory Documentation. Notwithstanding any other provision (but
without limiting any obligation that Fluidigm may have under any Ancillary Agreement), Fluidigm shall have no obligation under this Agreement to disclose to Novartis (or its Affiliates) any information with respect to the manufacture of Fluidigm
products other than certain related information specifically identified in this Agreement (e.g., for quality standards). 

“IVD [***]” shall mean an in vitro diagnostic product [***]. 

“JSC” shall mean the joint steering committee as established in Section 2.1. 

“Knowledge” of a party shall mean such party’s and its Affiliates’ best knowledge of the facts and information after
due inquiry and performing a diligent investigation with respect to such facts and information. “Known” to a party shall have a corresponding meaning. 
 “License Agreement” shall mean a license agreement in the form of Exhibit F. 
 “License Option” shall mean that certain exclusive option set forth in Section 5.2. 
 “Net Sales” shall mean, with respect to any [***] that is subject to a royalty under this Agreement (“Royalty [***]”), the gross amount invoiced by or on behalf of (x) Fluidigm or
any of its Affiliates or (sub)licensees to Third Parties other than (sub)licensees, or (y) in the case of Results as the subject of the royalty, Fluidigm or any of its Affiliates or (sub)licensees, Third Party commercialization partners or
customers, in each case in bona fide, arms-length transactions, determined in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) standard accounting methods as generally and consistently applied by Fluidigm or such
other Person, less the following customary deductions to the extent included in the gross invoiced sales price of any such Royalty [***] or otherwise directly paid or incurred by Fluidigm 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -6-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
or any of its Affiliates or (sub)licensees with respect to the sale or provision of such Royalty [***], such as: 
 (a) free goods to the extent the value thereof is included in the gross invoiced sales price; 
 (b) cash discounts taken for timely payments; 
 (c) direct to customer discounts
actually granted at or about the time of, and in conjunction with, the sale; 
 (d) charge backs and other amounts paid on sale
or dispensing of Royalty [***]; 
 (e) amounts payable resulting from Medicaid rebates and other governmental (or agency
thereof) mandated rebate programs; 
 (f) discounts actually granted pursuant to discount card programs, indigent patient
programs and patient discount programs, including “Together Rx” and coupon discounts; 
 (g) amounts repaid or
credited by reasons of defects, rejections, recalls or returns; 
 (h) tariffs, duties, excise, sales, value-added and other
taxes (other than taxes based on income), if separately stated on the invoice; 
 (i) all freight, postage and insurance
expenses, if separately stated on the invoice; and 
 (j) amounts repaid or credited for uncollectible amounts on previously
sold or provided Royalty [***]. 
  

	 	(i)	For the avoidance of doubt, in the event of any sale or other disposal of a Royalty [***] between or among Fluidigm or any of its Affiliates shall not be considered Net
Sales and in such cases Net Sales shall be calculated only on the value charged or invoiced on the first arm’s-length sale thereafter to a Third Party. 

 

	 	(ii)	In the case of any sale which is not invoiced or is delivered before invoice, Net Sales shall be calculated at the time of shipment or when the Royalty [***] is paid
for, if paid for before shipment or invoice. 

  

	 	(iii)	In the case of any sale or other disposal for value, such as barter or counter-trade, of any Royalty [***], or part thereof, other than in an arm’s-length
transaction exclusively for money, Net Sales shall be calculated to also include the value of the non-cash consideration received, or shall be the fair market price (if higher) of the Royalty [***] in the country of sale or disposal.

 In the event the Royalty [***] is sold as part of a bundled [***] (“Bundled [***]”), the Net Sales of
the Royalty [***], for the purposes of determining royalty payments under this Agreement, shall be determined by multiplying the Net Sales of the Bundled Product by the fraction, A/(A+B) where A is the weighted (by sales volume) average sale price
in a particular country of the Royalty [***] when sold separately in finished form and B is the weighted (by sales volume) average sale price in that country of the other product(s)/service(s) sold separately in finished form. In the event that such
average sale price cannot be determined for both the Royalty [***] and the other product(s)/services in the applicable bundle, Net Sales for purposes of determining royalty payments shall be agreed by the parties based on the relative value
contributed by each component [***], such agreement not to be unreasonably withheld. 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -7-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 “Novartis Know-How” shall mean Information and
Inventions owned or Controlled by Novartis or an Affiliate of Novartis as of the Effective Date or any time during the term of this Agreement, including the Novartis Solely-Owned Collaboration Information and Inventions, that (a) are necessary
or useful for the Exploitation of any Novartis Licensed Product, and (b) are not generally known, but excluding any Information and Inventions to the extent claimed by the Novartis Patents. 

“Novartis Licensed Products” shall mean the [***]. 
 “Novartis Patents” shall mean all Patents that claim any Novartis Licensed Products Controlled (other than pursuant to a license or other right granted to Novartis in this Agreement) by Novartis
or an Affiliate of Novartis as of the Effective Date or any time during the term of this Agreement, including those written claims within Patents that claim Novartis Solely-Owned Collaboration Information and Inventions. 

“Novartis Solely-Owned Collaboration Information and Inventions” shall mean any Collaboration Information and Inventions that
(a) (i) in the case of inventions, are described in written claims that are solely directed to, or (ii) in all other cases, are specifically about, sample enrichment or assay(s) (including any sample enrichment-related or
assay-related algorithms constituting Collaboration Information and Inventions), but in each case ((i) and (ii)) excluding any improvements to the inventions claimed in the Fluidigm Assay Patent Claims (including Fluidigm algorithms or mathematical
models claimed in the Fluidigm Assay Patent Claims) or (b) constitute improvements of any Novartis Know-How or any invention claimed in any Novartis Patents, but excluding such improvements if they constitute Fluidigm Solely-Owned Collaboration
Information and Inventions. For purposes of this definition only, the Novartis Know-How and the Novartis Patents shall be deemed to include any Patents or Information and Inventions to which Novartis or any of its Affiliates have, from a Third
Party, an exclusive license that falls within the Primary Field or the Secondary Field or an exclusive option for an exclusive license that falls within the Primary Field or the Secondary Field, in each case as of the Effective Date or at anytime
during the term of this Agreement (and, for clarity, excluding any such license or option under this Agreement or any Ancillary Agreement). 
 “Option Term” shall mean the period commencing from the Effective Date until ninety (90) days after the Completion of Phase 1. 

“Patents” shall mean (a) patents and patent applications, (b) all patents issuing on such patent applications, and
any divisionals, continuations, continuations-in-part, reissues, reexaminations, extensions, substitutions, registrations, additions, confirmations and renewals of such patents and patent applications, including any patents and patent applications
that claim priority to a common priority document in the priority chain of any of the foregoing, (c) supplemental protection certificates and the like relating to any of the foregoing, and (d) counterparts or substantial equivalents of any
of the foregoing in any country. 
 “Person” shall mean an individual, sole proprietorship, partnership, limited
partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -8-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government.

 “Phase” shall have the meaning set forth in Section 3.1(c). 

“Primary Field” shall mean the Testing of fetal aneuploidies of a fetus in a pregnant woman. 

“Primary Field Competitor” shall mean a Person that is commercializing (including promoting, selling, offering for sale or
otherwise commercially distributing) (a) the reporting of a result of any Test for a fee or (b) an IVD [***], in each case in the Primary Field. 
 “Regulatory Documentation” shall mean all applications, registrations, licenses, authorizations and approvals (including all regulatory approval), all correspondence submitted to or received
from regulatory authorities (including minutes and official contact reports relating to any communications with any regulatory authority) and all supporting documents and all clinical studies and tests, relating to any Novartis Licensed Product, and
all data contained in any of the foregoing, including any and all investigational new device exemptions, 510K notifications (if required) or premarket approvals (if required) within the meaning of the United States Federal Food, Drug, and Cosmetic
Act, as amended from time to time, and the regulations promulgated thereunder, and any corresponding foreign application, registration or certification, to market a Novartis Licensed Product in the Territory, and manufacturing records maintained
pursuant to the Supply Agreement. 
 “Results” shall mean reporting a result of any Test for a fee. 

“Secondary Field” shall mean the Testing of (a) a genetic abnormality, disease or condition in a fetus or in a pregnant
woman as associated with her pregnancy (other than that Tested in the Primary Field), (b) the RhD genotyping or carrier status in a pregnant woman, or (c) the genetic carrier status of a prospective mother-to-be and her male partner or
donor, as the case may be. 
 “Side Letter” shall mean that certain disclosure letter provided by Fluidigm’s
designated counsel to Novartis’ designated counsel on or before the Effective Date. 
 “Territory” shall mean the
entire world. 
 “Test” shall mean any non-invasive (including human blood, urine, saliva, bloodspot or stool)
screening, diagnostic, prognostic, predictive or other clinical test. “Testing” shall have a corresponding meaning. 

“Third Party” shall mean any Person other than Novartis, Fluidigm and their respective Affiliates. 

“Valid Claim” shall mean, with respect to any country, a claim of an issued and unexpired patent in such country which patent
has not been held unenforceable, unpatentable or 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -9-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
invalid by a decision of a court or other governmental agency of a competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which patent has not been admitted to
be invalid or unenforceable through reissue, disclaimer or otherwise. 
 ARTICLE II 

Committees 

2.1 Joint Steering Committee. The parties shall establish a joint steering committee (the “JSC”) to review and
discuss matters relating to the performance of the parties’ respective obligations and the exercise of the parties’ respective rights under this Agreement. Each party shall appoint its Alliance Manager and two (2) senior executives as
representatives of the JSC. The Alliance Managers shall be co-chairs of the JSC. A party’s representative may be removed or replaced at any time by the party that appointed such representative by written notice to the other party. 

(a) Responsibilities. The JSC shall have only the responsibilities and authority delegated to or vested in it in this
Section 2.1 or elsewhere in this Agreement. The JSC shall: (i) oversee the Collaboration Activities; (ii) review and approve amendments to the Collaboration Plan, provided that if such approval is not unanimous, the dispute
shall be resolved as set forth in Section 12.6; (iii) establish subcommittees, as appropriate; (iv) seek to resolve disputes arising under this Agreement; and (v) perform such other functions with respect to this Agreement as the
parties may mutually agree in writing from time to time. 
 (b) Decision-Making and Dispute Resolution. Decisions of the
JSC shall be made by unanimous vote, with each party’s representatives collectively having one (1) vote. The representatives of the JSC shall use reasonable efforts to reach unanimous agreement on all matters. If, despite such efforts,
agreement on a particular matter cannot be reached by the JSC within ten (10) days after the JSC first considers such matter (or such shorter time as may be reasonable under the circumstances), then, unless otherwise expressly provided in this
Agreement, Novartis shall have the right to make the final decision with regard to the disputed matter following good faith consideration of Fluidigm’s comments. Notwithstanding anything to the contrary in this Section 2.1(b), Novartis
shall have sole decision-making authority with respect to all quality to the extent so specified in the Novartis Development Quality Agreement if and when the parties execute the Novartis Development Quality Agreement. Subject to the preceding
sentence and the other terms of this Agreement and the Ancillary Agreements, Fluidigm shall have sole decision-making authority with respect to all matters pertaining to the design, development, or manufacture of Fluidigm Chips and Fluidigm
Instruments (and Novartis’ right of final decision set forth in the third sentence of this clause (b) shall not apply with respect to such matters). 
 (c) Meetings. The JSC shall meet at least bi-weekly either in person, at a location in California as designated on an alternating basis by each party unless otherwise determined by the JSC, or by
telephone, video conference equipment or similar means in which each participant can hear what is said by, and be heard by, the other participants. A quorum shall be required and shall exist whenever there is present at a meeting at least one
(1) representative appointed by each party. 
 (d) Minutes. The JSC shall keep minutes of its meetings that record
in reasonable detail all decisions and all actions recommended or taken. The parties shall alternate 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -10-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
responsibility for the preparation and circulation of draft minutes. Each JSC representative shall have the opportunity to provide comments on the draft minutes. The draft minutes shall be sent
to the other party for review or comment within five (5) days following the meeting to which the minutes pertain. The minutes shall be approved by the JSC at the next JSC meeting. Upon approval, final minutes of each meeting shall be circulated
to each representative of the JSC. 
 (e) Expenses. Each party shall bear all costs of its representatives related to
their participation on the JSC and attendance at JSC meetings. 
 2.2 Alliance Managers. Each party shall designate
within its respective organization an alliance manager (an “Alliance Manager”) with responsibility for facilitating the interaction and cooperation between the parties with respect to the activities conducted hereunder. Each party
may change its designated Alliance Manager from time to time upon written notice to the other party. Each Alliance Manager shall be charged with creating and maintaining a collaborative work environment and facilitating the interaction and
cooperation between the parties. Each Alliance Manager shall (a) be the point of first referral in all matters of conflict resolution; (b) coordinate the relevant functional representatives of the parties in developing and executing
strategies and plans under the Collaboration Plan; (c) provide a single point of communication for seeking consensus both internally within the respective parties’ organizations and between the parties regarding key strategy and plan
issues; (d) identify and bring disputes to the attention of the JSC in a timely manner; (e) plan and coordinate cooperative efforts and internal and external communications; (f) create the meeting agenda, co-chair the meetings, share
resources and to ensure alignment for completion of action items; and (g) take responsibility for ensuring that governance activities, such as the conduct of required meetings and production of meeting minutes occur as set forth in this
Agreement, and that relevant action items resulting from such meetings are appropriately carried out or otherwise addressed. 

ARTICLE III 

Collaboration 
 3.1 Collaboration Plan. 
 (a) General. Under the direction and
supervision of the JSC, each party shall perform, or cause to be performed, its respective Collaboration Activities in accordance with this Agreement and the Collaboration Plan. 

(b) Scope of the Collaboration. Subject to Section 5.4, the parties shall collaborate in the Primary Field (i) to
identify and develop reagents, including ASR reagents, that are necessary or useful for development of a Test in the Primary Field, (ii) to develop or modify the Fluidigm Technology as necessary or useful for development of a Test in the
Primary Field, and (iii) to develop a Test in the Primary Field using reagents and the Fluidigm Technology (including Fluidigm Chips and Fluidigm Instruments). To achieve such purpose, the parties have developed the detailed work plan attached
hereto as Exhibit B, as amended from time to time by the JSC in accordance with this Agreement (the “Collaboration Plan”). From time to time, either party may propose to the JSC for review any proposed amendments to the
Collaboration Plan. Each party shall have the opportunity to review and 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -11-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
comment upon the proposed updates to the Collaboration Plan through its representatives on the JSC prior to its approval by the JSC (which approval shall require the consent of both parties’
representatives). 
 (c) Performance of the Collaboration Plan. The Collaboration Plan shall have three (3) phases
(each, a “Phase”). The first Phase of the Collaboration Plan is anticipated to begin [***] and be completed [***] ([***] months). The second Phase is anticipated to take approximately [***] months. The third Phase is anticipated to
take [***] months. The Collaboration Activities shall not progress from one Phase to the next Phase without the written consent of Novartis, which consent may be withheld in Novartis’s sole discretion. 

(d) Reports. Every month in which Collaboration Activities are performed, each party shall provide to the JSC a written progress
report, which shall describe the Collaboration Activities it has performed, or caused to be performed during such calendar quarter, evaluate the Collaboration Activities performed and provide such other information as may be required by the
Collaboration Plan or reasonably requested by the JSC with respect to such activities, including progress made, issues arising, and inventions made during that month. If the JSC reasonably believes that a Phase is complete (other than the final
report), the JSC shall request from each party a final written report for such Phase (a “Final Report”), which report shall be completed within thirty (30) days after the date of such request (the “Final Report Due
Date”). 
 (e) FTE Obligations. During the term of this Agreement, each party shall dedicate research and
development FTEs, as set forth on the Collaboration Plan, [***] time commitment to the Collaboration Plan (or such other time commitment as set forth in the Collaboration Plan). 

3.2 Phase 1 Collaboration Milestones. 
 (a) Subject to Section 3.2(b), during Phase 1, Fluidigm shall be diligent and use reasonable efforts to achieve the following milestones within the time periods set forth in the Collaboration Plan:

  

	 	(i)	Collaboration Milestone 1. [***] 

  

	 	(ii)	Collaboration Milestone 2. [***] 

  

	 	(iii)	Collaboration Milestone 3. [***] 

  

	 	(iv)	Collaboration Milestone 4. [***] 

  

	 	(v)	Collaboration Milestone 5. [***] 

  

	 	(vi)	Collaboration Milestone 6. [***] 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -12-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 (b) During Phase 1, Novartis shall be diligent and use
reasonable efforts to achieve the following milestones: 
  

	 	(i)	[***] 

  

	 	(ii)	[***] 

  

	 	(iii)	[***] 

  

	 	(iv)	[***] 

  

	 	(v)	[***] 

 If Novartis fails to achieve the
milestones listed above in Sections 3.2(b)(i) to (iv) in the time allotted above or in the Collaboration Plan, then Fluidigm shall have no obligation to achieve its milestone listed in Section 3.2(a)(v) to the extent and for so long as its
failure is attributable to such failure by Novartis. 
 3.3 Phase 2 and 3 Collaboration and Quality Milestones. Prior to
execution of the License Agreement (if applicable), the Parties shall amend the Collaboration Plan and this Agreement to include collaboration and quality milestones for Phase 2 and Phase 3 and the compensation of Fluidigm with respect thereto.

 3.4 General Conduct of Collaboration Activities. Under the direction and supervision of the JSC, each party shall
(a) perform, or cause to be performed its Collaboration Activities in good scientific manner, and in compliance in all material respects with all Applicable Law and in accordance with the quality milestones set forth in Exhibit B and
(b) allocate reasonable time, effort, equipment and skilled personnel to complete such activities successfully and promptly and in accordance with the Collaboration Plan. In general, Fluidigm shall be responsible for chip and instrument reader
design and manufacturing with design requirements from Novartis. 
 3.5 Principal Scientist. The day-to-day Collaboration
Activities shall be conducted under the joint direction and supervision the principal scientists, [***] (each, a “Principal Scientist”). The Principal Scientists shall be the primary contacts for the parties with respect to the
Collaboration Activities. Each party shall ensure that it shall not substitute or materially reduce the time commitment of its Principal Scientist to the Collaboration Activities without the prior written approval of the other party, not to be
unreasonably withheld, provided that a party may appoint a substitute if its Principal Scientist dies, resigns, or is terminated for cause, or to the extent that its Principal Scientist is disabled. 

3.6 Record Keeping. Each party shall maintain, or cause to be maintained, records of its respective Collaboration Activities in
sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, which shall be complete and accurate and shall fully and properly reflect all work done and results achieved in the performance of its respective
Collaboration Activities, and which shall be retained by such party for at least five (5)

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -13-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
years after the expiration or the termination of this Agreement, or for such longer period as may be required by Applicable Law. Each party shall have the right, during normal business hours and
upon reasonable notice, to inspect and copy any such records maintained by the other party solely as reasonably required for the purpose of exercising its rights and performing its obligations under this Agreement or any Ancillary Agreement.

 3.7 Cooperation. 
 (a) General Assistance. Each party shall cooperate with any and all reasonable requests for assistance from the other party with respect to the Collaboration Activities and regulatory processes
with respect thereto, including by making the assisting party’s, and its Affiliates’, employees, consultants and other scientific staff available upon reasonable notice during normal business hours at their respective places of employment
to consult with the requesting party on issues arising with respect to the Collaboration Activities. 
 (b) Information
Disclosure. Fluidigm shall, and shall cause its Affiliates to, without additional compensation, in the normal course of the Collaboration Activities reasonably disclose and make available to Novartis, as reasonably required for Novartis to
exercise its rights or perform its obligations under this Agreement using the Core Fluidigm Technology, in whatever form Novartis may reasonably request, Fluidigm Know-How and Collaboration Information and Inventions and Regulatory Documentation
relating to the Fluidigm Technology in the Primary Field or Secondary Field. In addition, at Novartis’ written request, Fluidigm will so disclose and make available to Novartis, as reasonably required for Novartis to exercise its rights or
perform its obligations under this Agreement using the Core Fluidigm Technology, in whatever form Novartis may reasonably request, such additional Fluidigm Know-How and Collaboration Information and Inventions and any Regulatory Documentation
relating to the Fluidigm Technology in the Primary Field or Secondary Field as Novartis may specifically request. 
 3.8
Costs. Each party shall bear its own costs related to the Collaboration Activities, subject solely to the payment obligations set forth in ARTICLE VI. 
 ARTICLE IV 
 Supply 

4.1 Collaboration and Clinical Trial Supply Obligations. Novartis may purchase from Fluidigm and Fluidigm shall supply to Novartis
commercially available Fluidigm chips as well as Fluidigm Chips, Fluidigm Instruments, including, for clarity, any additional buffers and reagents (excluding assay reagents) and other consumables (e.g., oils) required for the operation of the
foregoing and that are customarily provided by Fluidigm with its sales of its chips, at Novartis’s sole discretion, for purposes of conducting the Collaboration Activities. If (following exercise of the License Option) Novartis commences with
Fluidigm any research and development project in the Secondary Field other than as provided for herein, Fluidigm shall provide supplies analogous to the foregoing for such project on such terms and the cost bases described below. 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -14-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 (a) During Phase 1, Fluidigm shall supply Fluidigm’s
commercially available [***] chips as well as Fluidigm Chips as are designated by Novartis and associated materials (as described above) as deemed necessary by Novartis and in quantities deemed necessary by Novartis [***], for Novartis to fulfill
its obligations herein, [***]. Additional chips (and associated materials) requested by Novartis [***]. 
 (b) During Phases 2
and 3, Fluidigm shall supply Novartis up to [***]. 
 (c) During Phase 2 and Phase 3, Fluidigm shall supply Novartis Commercial
Chips and associated materials [***] as deemed necessary by Novartis and in quantities deemed necessary by Novartis for Novartis to fulfill its obligations under this Agreement, [***]. 

(d) For clinical trials, Fluidigm shall supply Novartis Commercial Chips at a price of [***]. 

(e) During each Phase, Fluidigm shall supply [***]. 
 (f) The Fluidigm chips, including Fluidigm Chips, associated materials, and Fluidigm Instruments may be purchased at the terms set forth above by Novartis or an Affiliate thereof from Fluidigm under a
separate purchase order at the discretion of Novartis. 
 (g) Fluidigm shall maintain, or cause to be maintained, in accordance
with Applicable Law relating to the Fluidigm Technology, and giving due consideration, in good faith, to any written instructions from Novartis, (i) all records necessary to comply with all Applicable Law relating to the Fluidigm Technology,
(ii) all manufacturing records, standard operating procedures, equipment log books, laboratory notebooks and all raw data relating to the manufacturing of the Fluidigm Technology, and (iii) such other records as Novartis may reasonably
require in order to ensure compliance by Fluidigm of its obligations under this Agreement and any Ancillary Agreement. During Phase 2 and Phase 3, the parties shall comply with that certain development quality agreement executed by the parties
simultaneously with this Agreement, which development quality agreement is attached hereto as Exhibit A (the “Novartis Development Quality Agreement”). Without limitation of Section 3.2(a), the parties shall have no
obligation to comply with the terms of such agreement during Phase 1. 
 4.2 Audit and Inspection. Fluidigm agrees that
Novartis and its agents or other designees shall have the right from time to time, upon reasonable prior notice to Fluidigm, and during regular business hours, to inspect any facility in which Fluidigm or its Affiliates manufacture the Fluidigm
Technology, and interview personnel of Fluidigm or its Affiliates, including inspection of and interviews with respect to (a) the materials used or to be used in the manufacture of the Fluidigm Technology, (b) the equipment used in
connection with the manufacture of the Fluidigm Technology, and (c) all records relating to such manufacturing of the Fluidigm Technology. 
 4.3 Supply Agreement. Fluidigm hereby grants to Novartis the exclusive option, at no additional charge and exercisable simultaneously with or after the parties execute the

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -15-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
License Agreement, to enter into an exclusive commercial supply agreement for Fluidigm Instruments and Fluidigm Chips for use in the Primary Field or Secondary Field (the “Supply
Agreement”) and a related manufacturing quality agreement. If Novartis exercises such option, the parties shall negotiate in good faith for a period of thirty (30) days, the terms of the Supply Agreement, which terms shall include the
terms set forth on Exhibit G. If at the end of such period the parties fail to reach agreement on the terms of the Supply Agreement, the areas of disagreement shall be referred to the JSC, provided that if the JSC decision is not
unanimous, the dispute shall be referred to the Executives pursuant to Section 12.6 for resolution. If the Executives fail to reach a resolution within thirty (30) days after the matter is first brought before them, the terms set forth on
Exhibit G shall constitute the Supply Agreement. If after Completion of Phase 1 that demonstrates to Novartis a successful proof of concept, Novartis is unable to show commercial feasibility in models prior to commercial launch, then the
parties shall enter into good faith negotiations to renegotiate the chip supply pricing set forth on Exhibit G. 

ARTICLE V 

License Grants, Option Rights and Related Matters 
 5.1 License Grants.  
 (a) Subject to the terms and conditions of
this Agreement, each party hereby grants to the other party a non-exclusive right and license in the Primary Field and Secondary Field in the Territory, to perform its obligations or exercise its rights under this Agreement during the term of this
Agreement, under its and its Affiliates’ rights, titles, and interests in and to the Fluidigm Patents (in the case of Fluidigm) and Novartis Patents (in the case of Novartis) necessary to perform such obligations or exercise such rights;
provided, however, that such license shall not extend to any activities of either party outside the scope of this Agreement or to the exercise by Fluidigm of the license granted to it in Section 5.1(b). The license granted in this
Section 5.1(a) shall be sublicensable only to the party’s Affiliates and permitted subcontractors and only to the extent reasonably required in connection with the performance of such obligations or exercise of such rights by such Persons.
For avoidance of doubt, (i) each party shall have no rights, express or implied, under the other party’s Patents or Know-How, except as expressly provided in this ARTICLE V or in a separate written agreement, and (ii) without
limitation of any rights of Novartis under any Ancillary Agreement, Novartis is not granted any right under this Agreement to manufacture any Fluidigm products. For clarity, Novartis shall have no obligation to disclose to Fluidigm any Novartis
Patents or Novartis Know-How. 
 (b) Subject to the restrictions in Section 5.4 and Section 7.1(b) and the other
terms and conditions of this Agreement, Novartis hereby grants Fluidigm a worldwide, royalty free (except as otherwise provided herein), non-exclusive and non-sublicensable (except as set forth below in this Section 5.1(b)) right and license
under the Novartis Solely-Owned Collaboration Information and Inventions and any Novartis solely-owned Collaboration Patents claiming such Information and Inventions solely for research (i.e., not clinical) purposes, including sales of individual
components of Fluidigm Technology for research purposes, 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -16-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
provided, however, that such license shall include such intellectual property only if and to the extent that Novartis is able to make such grant without incurring a payment obligation to any
Third Party in connection with the grant of such license or its exercise by Fluidigm. Such right and license shall be limited to activities conducted outside the Primary Field and Secondary Field except to the extent otherwise provided in
Section 9.5(c). Notwithstanding the above prohibition on sublicensing, Fluidigm shall be entitled grant sublicenses of these rights in connection with sales or other transfers of Fluidigm products, which sublicense shall be limited to use of
the Fluidigm product so sold or transferred. 
 5.2 Option. Fluidigm hereby grants Novartis an exclusive option,
exercisable at any time during the Option Term, to enter into the License Agreement (the “License Option”), under which Fluidigm grants Novartis an exclusive license to the Fluidigm Patents and the Fluidigm Know-How (including any
Collaboration Know-How and Collaboration Patents solely owned by Fluidigm) in the Primary Field and the Secondary Field (as such license is more fully described in the License Agreement). If Novartis desires to exercise the License Option, it shall
notify Fluidigm of its intention to do so prior to the end of the Option Term. Within thirty (30) days after such notice is delivered to Fluidigm, the parties shall execute the License Agreement. 

5.3 Right of First Negotiation. If Fluidigm desires to Exploit any Collaboration Information and Inventions at any time during the
Option Term (or if the License Agreement is executed, during the term of the License Agreement) for any type of screening, diagnostic, prognostic, predictive or other product used by Fluidigm or a Third party to perform clinical services and report
a result for a fee or sold to a laboratory performing services and reporting results for a fee, outside of the Primary Field and the Secondary Field, then Fluidigm shall notify Novartis in writing and Novartis shall have thirty (30) days from
receipt of such notice in which to respond and, if applicable, begin negotiations for an exclusive, worldwide license under the Fluidigm Patents and Fluidigm Know-How to Novartis for clinical applications in such field. If (a) Novartis does not
respond to Fluidigm’s notice within such thirty (30)-day period, (b) Novartis declines its right of first negotiation, or (c) the parties are unable to execute a definitive agreement within one hundred and twenty (120) days after
Novartis notifies Fluidigm that it desires such a license pursuant to this Section 5.3, then if Fluidigm proceeds with commercialization in such field on its own, by or with a Third Party, then Novartis shall receive, in addition to the royalty
set forth in Section 6.2, an additional non-refundable royalty of [***] on the Net Sales of the Results, where (i) the generation of such Results is covered by a Valid Claim of the Collaboration Patents in the country in which such Results
are generated, or where (ii) such Results are generated using a Fluidigm Product, the sale of which is covered by a Valid Claim of the Collaboration Patents in the country of sale. For the avoidance of doubt, (A) Fluidigm will be entitled
to Exploit all Fluidigm Solely-Owned Collaboration Information and Inventions, and all jointly owned Collaboration Information and Inventions, outside the Primary Field and the Secondary Field without any royalty obligation under this
Section 5.3 if such Exploitation is not covered by a Valid Claim of the Collaboration Patents in the country in which such Results are generated (as described in clause (i) above), or if such Results are generated using a Fluidigm Product,
the sale of which is not covered by a Valid Claim of the Collaboration Patents in the country of sale (as described in clause (ii) above); and (B) if Novartis does not exercise its right of first negotiation, or if it does so but the
parties are unable to execute a 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -17-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
definitive agreement within the above one hundred and twenty (120) day period, with respect to any field, then Fluidigm will have fully performed its notice and negotiation obligations under
this Section 5.3 with respect to that field and shall have no further obligation with respect to such right of first negotiation at any time. 
 5.4 Non-Compete. During the term of this Agreement, Fluidigm covenants that, except for the performance of Fluidigm’s Collaboration Activities and the performance of Fluidigm’s
obligations under this Agreement or any Ancillary Agreement, it and its Affiliates shall not (a) Exploit any product or service in the Primary Field or Secondary Field (other than the conduct of research, and the sale and other disposal
(including manufacture, storage, exportation, transportation, distribution, promotion and marketing activities related thereto) of products for conducting research in the Secondary Field, which research shall not include providing clinical results
for a fee or for use in the medical management of a patient), (b) conduct any activity with, for the benefit of, or sponsored by, any Person, that has as its goal or intent Exploiting any product or service in the Primary Field or Secondary
Field, or (c) grant any license or other rights to any Person to utilize any intellectual property Controlled by Fluidigm or its Affiliates (including any Fluidigm Patents or Fluidigm Know-How) to Exploit any product or service in the Primary
Field or the Secondary Field (other than licenses to Third Parties to perform research in the Secondary Field, which research shall not include providing clinical results for a fee or for use in the medical management of a patient).
Fluidigm acknowledges that the restrictions contained in this Section 5.4 are reasonable, valid and necessary for the adequate protection of the Novartis Licensed Products business in the Primary Field and the Secondary Field and that
Novartis would not have entered into this Agreement without the protection afforded to it by this Section 5.4. Notwithstanding the foregoing, Fluidigm may grant, in connection with the sale of the Fluidigm Technology, a restricted research only
license to use Fluidigm Technology and Fluidigm Know-How and Fluidigm Patents (including the Fluidigm Method), and all Collaboration Information and Inventions owned solely or jointly by Fluidigm and Collaboration Patents owned solely or jointly by
Fluidigm, in the Primary Field to academic institutions for research purposes only, including in connection with the commencement of new research studies or maintenance of existing research studies (which existing research studies Fluidigm has
disclosed to Novartis prior to the Effective Date), provided that Fluidigm obtains Novartis’ prior written consent to the terms of the new agreements with such academic institutions, which consent shall not be unreasonably withheld. In
no event shall Fluidigm grant to any academic collaborator access to or rights to use Fluidigm Technology or the Fluidigm Method in the Primary Field or Secondary Field to provide a result that will be used in the medical management of a patient or
provide a Result. It is understood and agreed that, prior to the Effective Date, Fluidigm has granted, in connection with and solely for the use of Fluidigm products shipped prior to the Effective Date for research use only, licenses for research
purposes only that do not prohibit use of such products for such research purposes in the Primary Field or Secondary Field, which licenses are ongoing, and that this does not and shall not constitute a breach of this section. For the avoidance of
doubt, Fluidigm may grant, in connection with the sale or other transfer of the Fluidigm Technology, licenses to use Fluidigm Technology and Fluidigm Know-How and Fluidigm Patents (including the Fluidigm Method), and all Collaboration Information
and Inventions owned solely or jointly by Fluidigm and Collaboration Patents owned solely or jointly by Fluidigm, outside the Primary Field and 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -18-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
Secondary Field without restriction (but without limitation of the right of first negotiation set forth in Section 5.3 or any royalties due under Section 6.2 or 9.5(e)). 

5.5 No Encumbrance. Fluidigm shall not (a) assign, transfer, convey or otherwise encumber any of its rights to the Fluidigm
Patents or Fluidigm Know-How, or (b) use any of the foregoing or grant any right, title or interest in or to any of the foregoing, in each case ((a) and (b)) to any Person that is inconsistent with the exclusive licenses or other rights
(including the License Option) granted to Novartis under this Agreement or the Supply Agreement. Novartis shall not grant any right, title or interest in or to any of the Novartis Solely-Owned Collaboration Information and Inventions or Novartis
solely-owned Collaboration Patents to any Person that is inconsistent with the licenses or other rights granted to Fluidigm under this Agreement or the Ancillary Agreements. It is understood and agreed that, prior to the Effective Date, Fluidigm has
granted, in connection with and solely for the use of Fluidigm products shipped prior to the Effective Date, licenses for research purposes only that do not prohibit use of such products for such research purposes in the Primary Field or Secondary
Field, which licenses are ongoing, and that this does not and shall not constitute a breach of this section. 
 5.6 Use of
Materials. Fluidigm shall not and shall cause its Affiliates not to: (a) derivatize, modify, reverse engineer or analyze any primers or probes or any other materials supplied to Fluidigm, or its Affiliates, by or on behalf of Novartis or
any of its Affiliates, or (b) transfer any such primers, probes or other materials to any Third Party. Fluidigm shall return any such unused primers, probes, or other materials to Novartis immediately following a request from Novartis and at
the end of the term of this Agreement. Novartis shall not and shall cause its Affiliates not to derivatize, modify, reverse engineer or analyze any chips, instruments, or any other materials supplied to Novartis, or its Affiliates, by or on
behalf of Fluidigm or any of its Affiliates, except in the case in which Fluidigm breaches this Agreement or any Ancillary Agreement in a manner that triggers, but renders Novartis unable to exercise, its alternate supply rights under the Supply
Agreement, and Novartis may perform such activities only to enable Novartis to exercise such rights. 
 ARTICLE VI

 Payments and Royalties 
 6.1 Collaboration Milestone Payments. In consideration of the exclusive research and development and other rights granted by Fluidigm to Novartis herein and subject to the terms and conditions of
this Agreement, Novartis shall pay Fluidigm the following payments: 
 (a) with respect to Phase 1 of the Collaboration Plan,
(i) seven hundred fifty thousand dollars ($750,000) within fifteen (15) days of the execution of this Agreement and (ii) the following payments set forth below following achievement of the applicable milestones: 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -19-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 Table 1. Milestone Payments 

 

					
	 Milestones
	  	Payment Amounts	 
		
	 Collaboration Milestone 1
	  	 	[***	] 
		
	 Collaboration Milestone 2
	  	 	[***	] 
		
	 Collaboration Milestone 3
	  	 	[***	] 
		
	 Collaboration Milestone 4
	  	 	[***	] 
		
	 Collaboration Milestone 5
	  	 	[***	] 
		
	 All Collaboration Milestones (1-6) and delivery of the Final Report for Phase 1
	  	 	[***	] 

 (b) with respect to each
of Phases 2 and 3, and any anticipated subsequent Phases of the Collaboration Plan, the parties shall mutually agree upon the milestone payments to be made by Novartis to Fluidigm, which shall not be pre-paid, and the timing therefor, prior to the
execution of the License Agreement. Such payments shall partially support Phases 2 and 3 and any subsequent Phases. The JSC shall determine the FTE rate to be used to determine such milestone payments, provided that if the JSC can not reach
unanimous agreement on such milestone payments within thirty (30) days, the dispute shall be escalated to the Executives pursuant to Section 12.6. 
 (c) For each milestone payment other than the first payment in Section 6.1(a), Fluidigm shall report the achievement of the milestone to the JSC and provide related supporting documents to the JSC in
order for the JSC to confirm whether the milestone has been achieved. If there is a dispute concerning whether a milestone has been achieved, the dispute shall be escalated to the Executives pursuant to Section 12.6. Upon the JSC’s or
Executives’, if applicable, confirmation that a milestone has been achieved, Fluidigm shall invoice Novartis for the corresponding milestone payment amount and Novartis shall pay such amount within sixty (60) days of receiving such
invoice. For clarification, each milestone payment shall be payable only once irrespective of the number of times a milestone event set forth in this Section 6.1 is achieved. 

6.2 Royalties to Novartis. Fluidigm shall pay to Novartis, based on worldwide aggregate Net Sales (whether made by Fluidigm, its
Affiliates, (sub)licensees (or a Third Party under agreement with Fluidigm, including a Third Party commercialization partner or customer) of the Results that are generated using a Fluidigm Royalty-Bearing Product outside the Primary Field and
Secondary Field, non-refundable royalties in the amount of [***] of the Net Sales of such Results, but only if the sale of the Fluidigm Royalty-Bearing Product is covered by a Valid Claim of the Collaboration Patents in the country of sale; and
provided, however, that this 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -20-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
royalty shall not apply to any activities that are subject to the royalties set forth in Section 9.5(e) (including, for clarity, that this royalty shall not apply to any activities that are
not royalty-bearing under Section 9.5(e)(i) due to termination of this Agreement by Fluidigm, pursuant to Section 9.2, for non-payment by Novartis). 
 6.3 Royalty Payments. Royalties due under Section 6.2 shall be payable on a quarterly basis, within sixty (60) days after the end of each calendar quarter, based upon the Net Sales during
such calendar quarter, commencing with the calendar quarter in which the first commercial sale of the applicable Results is made. Royalties shall be calculated in accordance with United States generally accepted accounting principles consistently
applied and with the terms of this ARTICLE VI. Each royalty payment hereunder shall be accompanied by a statement showing (a) invoiced sales and Net Sales, (b) the number of applicable Results provided by Fluidigm (or its Affiliates,
(sub)licensees, Third Party commercialization partners or Fluidigm customers) on a country-by-country basis during the applicable calendar quarter, and (c) the amount of royalties due on such Net Sales. 

6.4 Records Retention; Audit.  
 (a) Fluidigm shall keep (and shall cause its Affiliates and (sub)licensees to keep) records of sales (or provision of Results) that trigger a royalty under this Agreement until the third anniversary of
December 31 of the calendar year in which such sales (or provision) occur. For any payment under this Agreement by Novartis that is not based on a fixed amount set forth in this Agreement, Fluidigm shall keep (and cause its Affiliates to keep)
records demonstrating the basis for the amount charged until the third anniversary of December 31 of the calendar year in which such amounts were charged to Novartis under this Agreement. Upon the written request of Novartis and not more than
once in each calendar year, Fluidigm shall permit an independent certified public accounting firm of nationally recognized standing selected by Novartis, and reasonably acceptable to Fluidigm, at Novartis’s expense, to have access during normal
business hours, and upon reasonable prior written notice, to such of the records of Fluidigm as may be reasonably necessary to verify the accuracy of the royalty reports and such amounts charged for any calendar year ending not more than thirty-six
(36) months prior to the date of such request. The accounting firm shall disclose to Fluidigm and Novartis whether the royalty reports are correct or incorrect and the specific details concerning any discrepancies and any identification of any
non-compliance by Fluidigm with respect to such charge. No other information shall be provided to Novartis. Any failure by Novartis to exercise its right under this Section 6.4(a) with respect to a calendar year, within the time period allotted
therefor, shall constitute a waiver by Novartis of its right to later object to the amount of royalties paid by Fluidigm or amounts charged to Novartis under this Agreement during such calendar year. Novartis shall treat all information subject to
review under this Section 6.4 in accordance with the confidentiality provisions of ARTICLE VIII and shall cause its accounting firm to enter into a reasonably acceptable confidentiality agreement with Fluidigm obligating such firm to retain all
such financial information in confidence pursuant to such confidentiality agreement. 
 (b) Adjustments. If such
accounting firm concludes that additional royalties were owed during a given period or that Novartis was overcharged by Fluidigm under 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -21-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
this Agreement, within sixty (60) days after the date on which such accounting firm’s written report is delivered to Fluidigm, Fluidigm shall pay the additional royalties or refund the
amounts overcharged with interest from the date originally due calculated under Section 6.5 as if it were a late payment. Fluidigm shall reimburse Novartis for all costs related to such audit if, and only if, the amount of the underpayment by
Fluidigm or overcharge by Fluidigm is greater than [***] of the total amount owed or charged, as applicable, for such period. 

6.5 Mode of Payment. All payments to Fluidigm or Novartis under this Agreement shall be made by deposit of United States Dollars
in the requisite amount to such bank account as such party may from time to time designate by notice to the other party. Such bank account of Fluidigm as of the Effective Date is Fluidigm Corporation, [***]. With respect to sales outside the United
States, payments shall be calculated based on currency exchange rate for the last day of the calendar quarter for which remittance is made for royalties. Such exchange rate shall be obtained from The Wall Street Journal, Eastern United States
Edition, or, if not so available, as otherwise agreed by the parties. 
 6.6 Taxes. 

(a) The royalties and milestone payments under this Agreement (“Payments”) shall not be reduced on account of any taxes
except as set forth herein. The party on whom any such tax is assessed alone shall be responsible for paying any and all such taxes (other than withholding taxes required by Applicable Law to be withheld and paid by the party making the Payment (the
“Paying Party”)) levied on account of, or measured in whole or in part by reference to, any Payments. The Paying Party shall deduct or withhold from the Payments any taxes assessed on the party receiving the Payment (the
“Payment Receiving Party”) that the Paying Party is required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if the Payment Receiving Party is entitled under any applicable tax treaty to a reduction of rate
of, or the elimination of, applicable withholding tax, it may deliver to the Paying Party or the appropriate governmental authority (with the assistance of the Paying Party to the extent that this is reasonably required and is expressly requested in
writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve the Paying Party of its obligation to withhold tax, and the Paying Party shall apply the reduced rate of withholding, or dispense with withholding, as
the case may be, provided that the Paying Party has received evidence, in a form satisfactory to the Paying Party, of the Payment Receiving Party’s delivery of all applicable forms (and, if necessary, its receipt of appropriate
governmental authorization) at least fifteen (15) days prior to the time that the Payments are due. If, in accordance with the foregoing, the Paying Party withholds any amount, it shall pay to the Payment Receiving Party the balance when due,
make timely payment to the proper taxing authority of the withheld amount, and send to the Payment Receiving Party proof of such payment within sixty (60) days following that payment. For the avoidance of doubt, the parties acknowledge and
agree that none of the milestones or royalties payable under this Agreement are related to the license (or right) to import or any import of any Novartis Licensed Product or Fluidigm Royalty-Bearing Product. 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -22-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 (b) Any prices for Fluidigm Products set forth in this
Agreement are exclusive of any U.S. or foreign sales, use, value added or other similar tax that may be due on the sale or purchase of the Fluidigm Products under this Agreement (provided that Fluidigm shall use any reasonably available tax
exemptions in connection with any such sale). 
 ARTICLE VII 

Intellectual Property Rights 
 7.1 Intellectual Property Ownership. 
 (a) Ownership of Intellectual
Property. Subject to the license grants to each party herein, as between the parties, Novartis shall own and retain all right, title and interest in and to any and all of the Novartis Patents and the Novartis Know-How, including the Novartis
Solely-Owned Collaboration Information and Inventions, and Fluidigm shall own and retain all right, title and interest in and to any and all of the Fluidigm Patents and the Fluidigm Know-How, including the Fluidigm Solely-Owned Collaboration
Information and Inventions. The parties shall jointly and equally own all Collaboration Information and Inventions other than the Novartis Solely-Owned Collaboration Information and Inventions and the Fluidigm Solely-Owned Collaboration Information
and Inventions. Except as may be expressly otherwise set forth in this Agreement or an Ancillary Agreement (including in ARTICLE V), each party shall be entitled to Exploit its joint ownership interest in the jointly owned Collaboration Information
and Inventions and all associated jointly owned intellectual property rights, without any duty of notice or accounting. 
 (b)
Disclosure, Assignment and Use of Collaboration IP. Each party shall, pursuant to a procedure, to be established by the JSC no later than thirty (30) days after the Effective Date, disclose to the other party in writing the conception,
development or making of any Collaboration Information and Inventions by or on behalf of such party (or its Affiliates or subcontractors). Subject to Section 7.2, each party shall, and does hereby, assign, and shall cause its Affiliates and
(sub) licensees to so assign, to the other party, without additional compensation, such right, title and interest in and to any Collaboration Information and Inventions, Collaboration Know-How and Collaboration Patents, as is reasonably necessary to
fully effect the ownership of the foregoing as provided for in Section 7.1(a). For clarity, Novartis has the unrestricted right to Exploit the Novartis Solely-Owned Collaboration Information and Inventions and jointly-owned Collaboration
Information and Inventions for any and all purposes. For clarity and without limitation of Fluidigm’s rights after termination or expiration of this Agreement, during the term of this Agreement Fluidigm shall have the right to Exploit the
Fluidigm Solely-Owned Collaboration Information and Inventions and jointly owned Collaboration Information and Inventions (i) for research purposes (A) without restriction outside the Primary Field and Secondary Field and (B) without
restriction in the Primary Field and Secondary Field except as set forth in Section 5.4; and (ii) for clinical purposes (A) without restriction outside the Primary Field and Secondary Field subject to Novartis’ right of first
negotiation (and any resulting agreement) under Section 5.3 and (B) in the Primary Field and 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -23-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
Secondary Field only as expressly provided for in this Agreement or any Ancillary Agreement. For clarity and without limitation of Fluidigm’s rights after termination or expiration of this
Agreement, during the term of this Agreement Fluidigm shall have the right to Exploit Novartis Solely-Owned Collaboration Information and Inventions (i) for research purposes, only to perform Collaboration Activities or as set forth in
Section 5.1(b); and (ii) for clinical purposes, only with the written permission of Novartis. Fluidigm’s exercise of such rights pursuant to the license grant in Section 5.1(b) includes sales of individual components of Fluidigm
Technology for research purposes; provided, however, that Fluidigm shall ensure that neither Fluidigm nor its Affiliates combine, and shall use reasonable best efforts that no Third Party combines, such components or hardware and software
into a kit used for any purpose where any end user uses such kit to provide a result that will be used in the medical management of a patient or provide clinical results for a fee. Fluidigm may Exploit the data that constitutes Collaboration
Information and Inventions and relates to sample handling, sample preparation, or assay (including primers and probes) or arises from Phase 3, as reasonably required, including for Fluidigm to access in order to secure FDA approval of the Fluidigm
Products, provided that Fluidigm shall obtain Novartis’ written consent to disclose any such data, such consent not to be unreasonably withheld, and provided that any such disclosure shall be subject to ARTICLE VIII. For the
avoidance of doubt, neither party transfers or assigns any Patents existing prior to the Effective Date (and any resulting Patent rights), nor any Patents to the extent claiming inventions within the Excluded Information and Inventions. 

(c) United States Law. The determination of whether Information and Inventions are conceived, developed or made by a party
for the purpose of allocating proprietary rights (including Patent rights, copyrights or other intellectual property rights) therein in accordance with the terms of this Agreement, shall be made in accordance with applicable United States law.

 7.2 Prosecution of Collaboration Patents. Each party, through patent attorneys or agents of its choice, shall have the
first right, but not obligation, to prepare and file Patent applications claiming its respective solely owned Collaboration Information and Inventions and to obtain, prosecute, and maintain its respective solely owned Collaboration Patents
throughout the Territory subject to the remainder of this Section 7.2. Novartis, through patent attorneys or agents of its choice, shall have the first right, but not obligation, to prepare and file Patent applications claiming the jointly
owned Collaboration Information and Inventions and to obtain, prosecute, and maintain the jointly owned Collaboration Patents throughout the Territory subject to the remainder of this Section 7.2. The Parties’ patent counsel shall confer
and coordinate regarding the filing and prosecution of Patents on the Collaboration Information and Inventions. Except as otherwise agreed by the Parties, such Patents shall be initially filed in a jointly owned patent application, provided
that (i) any claims that are solely directed to the design, development, or manufacture of Fluidigm Chips or any other chips, Fluidigm Instruments or any other instruments, or associated control software, shall, at the request of Fluidigm, be
filed in a divisional application prosecuted by Fluidigm and assigned solely to Fluidigm, and (ii) any claims in such Patent application that are solely directed to an assay (including any assay-related algorithms constituting Collaboration
Information and Inventions), but excluding any improvements to the inventions claimed in the Fluidigm Assay Patent Claims (including 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -24-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
Fluidigm algorithms or mathematical models claimed in the Fluidigm Assay Patent Claims) shall, at the request of Novartis, be filed in a divisional application prosecuted by Novartis and assigned
solely to Novartis. It is understood that any Patent claims that are directed both to (x) the design, development, or manufacture of Fluidigm Chips or any other chips, Fluidigm Instruments or any other instruments, or associated control
software, and to (y) an assay (including any assay-related algorithms constituting Collaboration Information and Inventions) shall be jointly owned. Each party shall have the right to request that the other party (if it is the party with
prosecution rights, as described above) obtain, prosecute and maintain a Collaboration Patent in a particular country. If the party with first priority declines, or otherwise fails, to initiate any such requested action with respect to a
Collaboration Patent within sixty (60) days (and thereafter diligently pursues such action), the other party shall have the right to take such action with respect to such Collaboration Patent in the name of such other party or as otherwise
agreed by the parties in writing, provided that each party shall obtain the consent of the other party prior to doing so, which consent shall not be unreasonably withheld, where it shall be reasonable to withhold consent if taking such action
could affect the scope, validity or enforceability of any Collaboration Patent. Each party shall, and shall cause their respective Affiliates, as applicable, to assist and cooperate with one another in filing, prosecuting and maintaining the
Collaboration Patents. Each party shall bear its own expenses under this Section 7.2. The prosecuting party under this Section 7.2 shall consult with the other party as to the strategy and prosecution and maintenance of the Collaboration
Patents under this Section 7.2 and shall provide other party with sufficient opportunity to review and comment on the nature and text of new or pending applications, amendments, registrations, filing, submissions, pleadings, responses or
correspondence with any patent authorities with respect to the jointly owned Collaboration Patents. The prosecuting party shall (A) notify the other party as early as reasonably practicable in advance of all meetings and significant
communications with any patent authorities concerning the Collaboration Patents and shall permit the other party to participate in such meetings, (B) promptly prepare and deliver to the other party complete and accurate minutes of any such
meeting or communications, and (C) promptly forward to the other party copies of all office actions and written communications received from any patent authorities with respect to the Collaboration Patents upon receipt therefrom. 

7.3 Enforcement and Defense of Collaboration Patents. If either party reasonably believes that a Third Party may be infringing any
of the Collaboration Patents in the Primary Field or Secondary Field in the Territory, such party shall promptly notify the other party in writing, identifying the alleged infringer and the alleged infringement complained of and furnishing the
information upon which such determination is based. With respect to its solely owned Collaboration Patents (except as otherwise agreed in the License Agreement, or agreed by the parties upon expiration or termination of this Agreement if the License
Option is not exercised) each party shall have the sole right, but not the obligation, through counsel of its choosing, to take any measures it deems appropriate to stop such infringing activities by such Third Party in any part of the Territory and
to defend such Collaboration Patent against any invalidity or unenforceability action. The parties shall cooperate reasonably with respect to the enforcement and defense of jointly owned Collaboration Patents. 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -25-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 ARTICLE VIII 

Confidentiality and Nondisclosure 
 8.1 Restricted Fluidigm Information. Fluidigm recognizes that Novartis has an interest in Fluidigm’s retention in confidence of the Fluidigm Know-How and the Collaboration Know-How.
Accordingly, until the expiration or termination of this Agreement, Fluidigm shall, and shall cause its Affiliates and their respective officers, directors, employees and agents to, keep completely confidential, and not publish or otherwise disclose
(except as set forth below in this section), and not use for any purpose in the Primary Field or Secondary Field (except for uses expressly permitted under this Agreement or any Ancillary Agreement, which uses for clarity shall be subject to the
restrictions on use set forth in this Agreement and shall be subject to any applicable royalty set forth in this Agreement) any Fluidigm Know-How relating to the Primary Field or Secondary Field or Collaboration Know-How (the “Restricted
Information”); provided that the “Restricted Information” shall not include any Fluidigm Know-How or Collaboration Know-How to the extent (a) it is in the public domain through no fault of Fluidigm, its
Affiliates or any of their respective officers, directors, employees or agents, (b) its disclosure or use by Fluidigm would be expressly permitted under Section 8.3 if it were Confidential Information of Novartis, or (c) its
disclosure or use by Fluidigm is otherwise expressly permitted by the terms of this Agreement or any Ancillary Agreement. Fluidigm shall ensure that each of its and its Affiliates’ employees is bound by a written confidentiality agreement that
is comparable to the protection of the Restricted Information in the provisions set forth in this ARTICLE VIII. Novartis shall ensure that each of its and its Affiliates’ employees who is involved in the performance of Novartis’s
obligations or exercise of Novartis’s rights under this Agreement or any Ancillary Agreement is bound by a written confidentiality agreement that is at least as protective of the Restricted Information as the provisions set forth in this
ARTICLE VIII. If Fluidigm becomes aware of any disclosure of any Restricted Information or Novartis Confidential Information in violation of this Agreement, Fluidigm shall promptly notify Novartis. If Novartis becomes aware of any disclosure of any
Restricted Information or other Fluidigm Confidential Information in violation of this Agreement, Novartis shall promptly notify Fluidigm. For the avoidance of doubt, the treatment of Confidential Information that is also Restricted Information is
governed by the terms of this Section 8.1 while the treatment of Confidential Information that is not also Restricted Information is governed by Section 8.2. Notwithstanding the above restriction on Fluidigm’s disclosure of Restricted
Information, to the extent any Restricted Information also applies to Fluidigm’s business outside of the Primary Field or Secondary Field, Fluidigm shall be entitled to disclose Restricted Information in the normal course of, and under such
terms as Fluidigm customarily requires in, such other Fluidigm business, provided that such terms include terms requiring the maintenance of confidentiality that are comparable to the protection of the Confidential Information of Novartis in
the provisions set forth in this ARTICLE VIII. For clarity, notwithstanding Section 7.1(b) or any other provision of this Agreement, except (i) as set forth in this Agreement with respect to Collaboration Know-How and Collaboration
Patents, and (ii) as set forth in this Section 8.1, Section 5.3, Section 5.4 and Section 11.2(i), there are no restrictions on Fluidigm in this Agreement with respect to its Exploitation, outside of the Primary Field and the
Secondary Field, of Fluidigm Methods, Fluidigm Patents, or any other Information and Inventions and intellectual property rights Controlled by Fluidigm. 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -26-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 8.2 Confidentiality Generally. At all times during the
term of this Agreement and for the applicable confidentiality period specified herein below, each party (the “Receiving Party”) shall, and shall cause its officers, directors, employees, agents, Affiliates and (sub)licensees to,
keep confidential and not publish or otherwise disclose and not use, directly or indirectly, for any purpose, any Confidential Information provided to it by or on behalf of the other party (the “Disclosing Party”), except to the
extent such disclosure or use is otherwise expressly permitted by the terms of this Agreement or is reasonably necessary for the performance of such party’s obligations under this Agreement, or any Ancillary Agreement. Fluidigm shall ensure
that each of its and its Affiliates’ employees is bound by a written confidentiality agreement that is comparable to the protection of the Confidential Information of Novartis in the provisions set forth in this ARTICLE VIII. Novartis shall
ensure that each of its and its Affiliates’ employees who is involved in the performance of Novartis’s obligations or exercise of Novartis’s rights under this Agreement or any Ancillary Agreement is bound by a written confidentiality
agreement that is comparable to the protection of the Confidential Information of Fluidigm in the provisions set forth in this ARTICLE VIII. The confidentiality period for regulatory information (e.g., clinical trial data) shall be [***] years
following termination or expiration of this Agreement, and the confidentiality period for all other information shall be [***] years following disclosure. 
 8.3 Permitted Disclosures. Each party may disclose Confidential Information of the other party to the extent that such disclosure is: 

(a) made in response to a valid order of a court of competent jurisdiction or other competent authority; provided,
however, that the Receiving Party shall first have given notice to the Disclosing Party and given the Disclosing Party a reasonable opportunity to quash any such order or obtain a protective order requiring that the Confidential Information
and documents that are the subject of such order be held in confidence by such court or authority or, if disclosed, be used only for the purpose for which the order was issued; and provided further that if such order is not quashed or a
protective order is not obtained, the Confidential Information disclosed in response to such court or governmental order shall be limited to that information that is legally required to be disclosed in response to such court or governmental order;

 (b) made by a party to a patent authority as may be reasonably necessary or useful for purposes of obtaining or enforcing a
Patent (consistent with the terms and conditions of ARTICLE VII); provided, however, that reasonable measures shall be taken to assure confidential treatment of such information, to the extent such protection is available; 

(c) otherwise required by law; provided, however, that if either party is required to disclose Confidential Information of
the other party, the party required to make the disclosure shall (i) provide to the other party reasonable advance notice of and an opportunity to comment on any such required disclosure, (ii) if requested by the other party, seek
confidential treatment with respect to any such disclosure to the extent available, and (iii) use good faith efforts to incorporate the comments of the other party in any such disclosure or request for confidential treatment; or 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -27-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 (d) made by a party or its Affiliates or (sub)licensees to
Third Parties as may be reasonably necessary in connection with its performance of the Collaboration Activities as contemplated by this Agreement, including subcontracting or sublicensing transactions in connection therewith or in the case of
Novartis, the exercise of its rights or performance of its obligations under the License Agreement. 
 8.4 Exclusions.
Notwithstanding the foregoing, Confidential Information shall not include any information that: (a) is or hereafter becomes part of the public domain by public use, publication, general knowledge or the like through no wrongful act, fault or
negligence on the part of the Receiving Party; (b) can be demonstrated by documentation or other competent proof to have been in the Receiving Party’s or its Affiliates’ possession, without confidentiality restriction, prior to
disclosure by the Disclosing Party; (c) is subsequently received by the Receiving Party or its Affiliates, without confidentiality restriction, from a Third Party or a (sub)licensee who is not bound by any obligation of confidentiality with
respect to said information; (d) is generally made available to Third Parties by the Disclosing Party without restriction on disclosure; or (e) is independently developed by or for the Receiving Party or its Affiliates without reference to
the Disclosing Party’s Confidential Information or, as to Novartis as the Receiving Party, the Restricted Information. 

8.5 Confidentiality of Terms of Agreement. The parties both agree that the terms of this Agreement are the Confidential
Information of each party, and they each shall keep such terms confidential and not disclose this Agreement, except as otherwise provided herein. Notwithstanding the foregoing, the parties acknowledge and agree that either party may be required by
Applicable Law (including by any court or other governmental body) to disclose this Agreement, or the terms hereof, in whole or in part, and in such case, such party shall notify the other party in writing and shall provide the other party with at
least seven (7) business days to request redactions thereof prior to making such filing or disclosure. The Disclosing Party shall seek confidential treatment of any such proposed redactions timely made and use reasonable efforts to procure
confidential treatment of such proposed redactions pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934, in each case as amended, and the rules, regulations and guidelines promulgated thereunder, or any other Applicable Law
or the rules, regulations or guidelines promulgated thereunder, but provided that neither party shall unreasonably withhold its consent in a manner that would prevent the other party from making such public disclosures as it, on advice of
counsel, must make to comply with Applicable Law. In addition, each party shall be entitled to disclose the terms of this Agreement to under obligations of confidentiality comparable to those set forth in this Agreement (a) to legal counsel,
accountants and other professional advisors; (b) banks, investors and other financing sources; or (c) to Third Parties with whom a party is engaged in an actual or prospective merger or acquisition or similar transaction. Each party shall
also be entitled to disclose such portions of this agreements as are necessary (i) to enforce this Agreement or its rights under this Agreement; or (ii) during the course of litigation so long as the disclosure of such terms and conditions
are restricted in the same manner as is the confidential information of other litigating parties and so long as (1) the restrictions are embodied in a court-entered protective order limiting disclosure to outside counsel and (2) the
disclosing party informs the other party in writing at least ten (10)

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -28-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
business days in advance of the disclosure and discusses the nature and contents of the disclosure, in good faith, with the other party. 

8.6 Use of Name. Neither party shall disclose or otherwise use the name, insignia, symbol, trademark, trade name or logotype of
the other party or its Affiliates in any publication, press release, promotional material or other form of publicity without the prior written consent of the other party (which shall not be unreasonably withheld or delayed). Notwithstanding the
foregoing, Novartis and its Affiliates and (sub)licensees shall have the right to use in a reasonable manner the name of Fluidigm and its Affiliates to the extent that Novartis is required by Applicable Law to identify Fluidigm or its applicable
Affiliate as having developed or manufactured Novartis Licensed Products sold in the Primary Field or Secondary Field, in the Territory. 
 8.7 Press Releases. Except pursuant to Section 8.5, no public announcement or press release concerning this Agreement, its subject matter or the transactions described herein, negotiations and
discussions thereof, or any other agreement between the parties, whether contemplated, negotiated or executed, shall be made, either directly or indirectly, by either party or their respective Affiliates. Notwithstanding the foregoing, Fluidigm
shall be entitled to disclose to Third Parties that “Fluidigm has entered into an exclusive relationship with a multinational diagnostic company for development of certain tests in prenatal and women’s health.” In addition, Fluidigm
shall be entitled to disclose the definitions of the Primary Field and Secondary Field to the extent necessary to fulfill its obligations under this Agreement (e.g., in restrictive portions of its sales or license agreements with Third
Parties). 
 8.8 Publications and Presentations. Fluidigm shall not make or otherwise disclose any Publication (as
defined below) without Novartis’s prior written approval, other than Publications that have been submitted for publication prior to the Effective Date and disclosed to Novartis prior to the Effective Date. “Publication” shall
mean any publication, presentation or disclosure to a Third Party that contains material (including abstracts, scientific posters and presentations) related to any Collaboration Activity or any research and development related to the Primary Field
or Secondary Field conducted by Fluidigm prior to the Effective Date. 
 ARTICLE IX 

Term and Termination 
 9.1 Term. This Agreement shall commence upon the Effective Date and shall continue until the earlier of (a) termination in accordance with this ARTICLE IX, (b) expiration of the Option
Term if Novartis has not exercised the License Option pursuant to Section 5.2, or (c) the Completion of Phase 3, unless extended by mutual written agreement by the parties (the “Term”). 

9.2 Termination of this Agreement for Material Breach. Any material breach by a party of any of its material obligations contained
herein, including a party’s failure to comply with its diligence obligations under this Agreement, shall entitle the party not in breach to give to the party in breach notice specifying the nature of the breach, requiring the breaching

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -29-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
party to cure such breach, and stating its intention to terminate if such breach is not cured. If such breach is not cured within thirty (30) days (the “Cure Period”) after
the receipt of such notice (or, if such breach cannot be cured within such thirty (30) day period, if the party in breach does not commence actions to cure such breach within the Cure Period and thereafter diligently continue such actions), the
party not in breach shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement, and in addition to any other remedies available to it by law or in equity, to terminate this Agreement. 

9.3 Termination Upon Insolvency. Either party may terminate this Agreement if, at any time, the other party shall file in any
court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of that party or of its
assets, or if the other party proposes a written agreement of composition or extension of its debts, or if the other party shall be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be
dismissed within sixty (60) days after the filing thereof, or if the other party shall propose or be a party to any dissolution or liquidation, or if the other party shall make an assignment for the benefit of its creditors. 

9.4 Additional Termination Rights. The parties shall have the following additional termination rights: (a) Novartis may, in
its sole discretion, terminate this Agreement upon thirty (30) days’ prior written notice to Fluidigm; (b) if a Third Party institutes a law suit alleging that any Collaboration Activity infringes or misappropriates any Third Party
intellectual property, Novartis may, upon written notice to Fluidigm, terminate this Agreement immediately upon notice to Fluidigm; (c) Novartis may terminate this Agreement upon written notice delivered to Fluidigm in the case of a Change of
Control, which notice shall be provided within ninety (90) days of such Change of Control unless any Acquiring Entity(ies) is a Primary Field Competitor; and (d) upon thirty (30) days’ prior written notice to Novartis, Fluidigm
may terminate this Agreement if Novartis does not provide its consent to progress to the next Phase within ninety (90) days after the later of the Final Report Due Date for the prior Phase and the date on which Fluidigm has completed all of the
Fluidigm milestones for the prior Phase (as described in Section 3.2 or the Collaboration Plan) and delivered all deliverables, including its Final Report, for that Phase to Novartis; provided, however, that Fluidigm shall first discuss
the matter with Novartis in good faith. 
 9.5 Consequences of Expiration or Termination. 

(a) Wind-Down. If this Agreement is terminated (or if a notice of termination has been provided) for any reason, the parties
shall immediately commence a wind-down of the Collaboration Activities. (For clarity, any such wind-down activities shall constitute Collaboration Activities for purposes of the intellectual property provisions and indemnification provisions of this
Agreement, notwithstanding the termination of this Agreement). Except as required to perform such wind-down activities, the licenses granted in Section 5.1(a) shall terminate. 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -30-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 (b) Material Breach by Fluidigm. If Novartis
terminates this Agreement pursuant to Section 9.2 following execution of the License Agreement, Fluidigm shall not directly or with a partner, develop, make, use, sell, or otherwise commercialize or license any Third Party any rights with
respect to a Test in the Primary Field for a period of fifteen (15) months. If Novartis terminates this Agreement pursuant to Section 9.2 at any time, the licenses granted to Fluidigm in Section 5.1(b) shall terminate. Upon any other
termination or expiration of this Agreement, the licenses granted to Fluidigm in Section 5.1(b) shall survive. 
 (c)
Material Breach by Novartis. If Fluidigm terminates this Agreement pursuant to Section 9.2 following execution of the License Agreement, then all rights of Novartis under the License Agreement, and under the Supply Agreement if and when
entered into, shall become non-exclusive. 
 (d) Post-Termination Commercialization. 

(i) (A) If either Party terminates this Agreement prior to the exercise of the License Option, other than pursuant to
Section 9.4(c), Fluidigm shall have the right to pursue other partners or commercialize a Test in the Primary Field or Secondary Field on its own, subject to the royalties payable by Fluidigm to Novartis as provided herein. In addition, unless
the termination is by Novartis pursuant to Section 9.2, the license granted to Fluidigm in Section 5.1(b) shall remain in effect and shall extend to all fields solely for research purposes subject to the restrictions with respect thereto
in Section 7.1. (The foregoing shall not be construed to grant Fluidigm any license rights under any intellectual property of Novartis, except as set forth in Section 5.1(b).) 

(B) If Novartis terminates this Agreement pursuant to Section 9.4(c) prior to exercise of the License Option, but Novartis does not
exercise the License Option pursuant to Section 9.5(d)(iii) or (iv), then Fluidigm shall have the right to pursue other partners or commercialize a Test in the Primary Field or Secondary Field on its own, subject to the royalties payable by
Fluidigm to Novartis as provided herein. In addition, if Novartis terminates this Agreement pursuant to Section 9.4(c) prior to exercise of the License Option, but Novartis does not exercise the License Option pursuant to
Section 9.5(d)(iii) or (iv), unless the termination is by Novartis pursuant to Section 9.4(c) due to a Change of Control in which any Acquiring Entity is a Primary Field Competitor, the license granted to Fluidigm in Section 5.1(b)
shall remain in effect and shall extend to all fields solely for research purposes subject to the restrictions with respect thereto in Section 7.1. (The foregoing shall not be construed to grant Fluidigm any license rights under any
intellectual property of Novartis, except as set forth in Section 5.1(b).) 
 (C) If Novartis terminates this Agreement
pursuant to Section 9.4(c), but Novartis does exercise the License Option pursuant to Section 9.5(d)(iii) or (iv), then unless the termination is by Novartis pursuant to Section 9.4(c) due to a Change of Control in which any Acquiring
Entity is a Primary Field Competitor, the license granted to Fluidigm in Section 5.1(b) shall remain in effect. (The foregoing shall not be construed to grant 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -31-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
Fluidigm any license rights under any intellectual property of Novartis, except as set forth in Section 5.1(b).) 
 (ii) If either Party terminates this Agreement after exercise of the License Option, other than (A) pursuant to Section 9.4(c) where any Acquiring Entity is a Primary Field Competitor or
(B) by Novartis pursuant to Section 9.2, the license granted to Fluidigm in Section 5.1(b) shall remain in effect and, in addition, shall extend to the Primary Field (and the Secondary Field, if such field is repurchased by Fluidigm
pursuant to the License Agreement or if the licenses to Novartis under the License Agreement in the Secondary Field are terminated) for research purposes if and only when Fluidigm exercises its rights under the License Agreement to repurchase
Novartis’ license in the Primary Field (and the Secondary Field, if applicable) (as described further therein). For clarity, the licenses granted to Novartis under the License Agreement remain in effect unless and until such repurchase occurs.

 (iii) If Novartis terminates this Agreement pursuant to Section 9.4(c) due to a Change of Control in which no Acquiring
Entity is a Primary Field Competitor, the following shall apply: 
 (A) If Novartis (or its Affiliates or (sub)licensees) are
commercializing one or more Novartis Licensed Products as of the Change of Control, then the License Agreement and the Supply Agreement shall remain in effect and, if either such agreement is not in effect at the time of such Change of Control,
Novartis shall have the right, on written notice to Fluidigm together with Novartis’ notice of such termination of this Agreement pursuant to Section 9.4(c), to have the parties enter into such agreement as described in Section 5.2 or
Section 4.3, as applicable, provided that under no circumstance shall the Option Term extend past ninety (90) days after the Completion of Phase 1. 
 (B) If the foregoing clause (A) does not apply and Novartis (or its Affiliates or (sub)licensees) desires to continue the development of one or more Novartis Licensed Products, then: 

(x) the License Agreement shall remain in effect or, if not executed, Novartis shall have the right, on written notice to Fluidigm
together with Novartis’ notice of such termination of this Agreement pursuant to Section 9.4(c), to have the parties enter into the License Agreement as described in Section 5.2 (provided that under no circumstance shall the
Option Term extend past ninety (90) days after the Completion of Phase 1), and the licenses granted therein shall be extended to the Exploitation of all products in the Primary Field and the Secondary Field, whether or not they use the Fluidigm
Chips or Fluidigm Instruments; provided, however, that Novartis shall have no right to manufacture or have manufactured any Fluidigm Chips or Fluidigm Instruments or any other products under such agreement other than pursuant to clause
(y) of this Section 9.5(d)(iii)(B), and if Novartis elects to exercise such license using chips or instruments other than Fluidigm Chips or Fluidigm Instruments, then Novartis and Fluidigm shall negotiate a reasonable non-refundable
royalty rate that would apply to such exercise, 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -32-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 (y) at the election of Novartis on written notice to
Fluidigm together with Novartis’ notice of such termination of this Agreement pursuant to Section 9.4(c), either (1) the Supply Agreement shall remain in effect or, if not executed, Novartis shall have the right to have the parties
enter into the Supply Agreement as described in Section 4.3, provided that under no circumstance shall the Option Term extend past ninety (90) days after the Completion of Phase 1, or (2) Novartis may obtain from Fluidigm a
license under any intellectual property rights then Controlled by Fluidigm or any of its Affiliates, which rights are necessary or reasonably useful to manufacture the Novartis Licensed Products (provided that such intellectual property
rights that are Acquisition IP shall be limited to Acquisition IP that is necessary to so use such intellectual property rights Controlled by Fluidigm (or any of its then Affiliates) immediately preceding the Change of Control)
(“Manufacturing License”), in which case the parties shall negotiate reasonable compensation to Fluidigm for such license (“Manufacturing Fee”), it being understood and agreed that no license is granted to
manufacture any Fluidigm chip other than the Fluidigm Chips or to manufacture any Fluidigm instrument other than the Fluidigm Instruments, and 
 (z) at the election of Novartis on written notice to Fluidigm together with Novartis’ notice of such termination of this Agreement pursuant to Section 9.4(c), Fluidigm shall provide technology
transfer to Novartis or its designee to enable Novartis to continue development and, if Novartis has exercised its option for a manufacturing option under clause (y)(2) of this Section 9.5(d)(iii)(B), manufacture, of the Novartis Licensed
Products then in development, in which case Fluidigm shall be compensated by Novartis for such technology transfer at cost. If Fluidigm fails to do so within a reasonable time, Novartis may exercise its escrow rights under the License Agreement as
if it were a Failure to Supply. 
 If the parties cannot agree on a reasonably royalty or compensation for a Manufacturing License pursuant to
this Section 9.5(d)(iii) within ninety (90) days after termination of this Agreement pursuant to Section 9.4(c), the dispute resolution provisions in Section 12.6 shall apply and the arbitrator shall make its determination after
affording each party an opportunity to submit a proposal and thereafter selecting one of the proposals of the parties or a non-refundable royalty rate or compensation, as applicable, that falls within the range established by the parties’
proposals. During the pendency of any negotiation or arbitration of such terms, Novartis shall be deemed licensed to perform the applicable activities and following resolution thereof shall pay any compensation due to Fluidigm based on the
established royalty or other compensation, as applicable. 
 (iv) If Novartis terminates this Agreement pursuant to
Section 9.4(c) due to a Change of Control in which any Acquiring Entity is a Primary Field Competitor, Section 9.5(d)(iii) shall apply, but with the following modifications: (A) no additional amounts shall be due to Fluidigm under
Section 4.1 or Section 4.2 of the License Agreement, (B) any technology transfer described in Section 9.5(d)(iii) shall be at the sole expense of Fluidigm, and (C) Novartis may elect to secure a Manufacturing License whether
or not any Novartis Licensed Product is then being commercialized; provided, however, that Novartis may deduct from the Manufacturing Fee that would apply as described in Section 9.5(d) the amounts paid by Novartis under
Section 6.1 of this Agreement. 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -33-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 (e) Royalties. 

(i) Royalty for Using Collaboration Chip Developments. If this Agreement expires or is terminated by either party, other than a
termination by Fluidigm, pursuant to Section 9.2, based on non-payment by Novartis, Fluidigm shall pay to Novartis, based on worldwide aggregate Net Sales (whether made by Fluidigm, its Affiliates, (sub)licensees (or a Third Party under
agreement with Fluidigm, including a Third Party commercialization partner or customer)) of Results using a Fluidigm Royalty-Bearing Product the sale of which is covered by a Valid Claim of the Collaboration Patents in the country of sale,
non-refundable royalties in the amount of [***] of the Net Sales of such Results. 
 (ii) Royalty for the Primary Field.
If this Agreement expires or is terminated by either party, Fluidigm shall pay to Novartis, (A) in the case of the sale of IVD [***] in the Primary Field by Fluidigm, its Affiliates or (sub)licensees, based on worldwide aggregate Net Sales of
any such IVD [***], if the sale of such IVD [***] are covered by a Valid Claim of the Collaboration Patents (other than improvements to inventions claimed in the Fluidigm Assay Patent Claims) in the country of sale, royalties in the amount of [***]
of the Net Sales of such IVD [***], or (B) in the case of the generation of Results in the Primary Field by Fluidigm, its Affiliates or (sub)licensees or any Third Party under agreement with Fluidigm, including any Third Party commercialization
partners or customers, other than such generation conducted using an IVD [***], based on worldwide aggregate Net Sales of any such Results where (x) the generation of such Results is covered by a Valid Claim of the Collaboration Patents, other
than the Fluidigm solely-owned Collaboration Patents, in the country in which the Results are generated, or (y) such Results are generated using a Fluidigm Product, the sale of which is covered by a Valid Claim of such Collaboration Patents in
the country of sale, non-refundable royalties in the amount of [***] of such Net Sales. 
 For clarity, royalties may be payable under both
clause (i) and clause (ii) of this Section 9.5(e), if applicable (but not under both clauses (A) and (B) of paragraph (ii)). 
 The parties acknowledge that clauses (i) and (ii) of this Section 9.5(e) shall not apply to Fluidigm commercial activities relating to its products sold for research use only, it being
understood and agreed that research use does not include use of products to provide a result that will be used in the medical management of a patient or provide clinical results for a fee. 

(iii) Additional Royalty Provisions. The payments, statements, record retention and audit provisions related to the royalties in
Sections 6.3 to 6.6 of this Agreement shall apply to this Section 9.5(e) as if they were royalties due on Results under ARTICLE VI. 
 (f) Transfer of Materials. Each party shall, and shall cause its Affiliates to, cooperate with the other party in transferring to the other party, within sixty (60) days after the
termination or expiration of this Agreement, all Confidential Information of the other party in the Territory, except that (i) each party may retain one (1) copy of such data, files or materials for its records and for the purpose of
performing any obligations under this Agreement that may 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -34-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
survive such termination or expiration and (ii) Novartis may retain the Confidential Information of Fluidigm as reasonably necessary to exercise its rights under any Ancillary Agreement.

 9.6 Remedies; Accrued Rights; and Surviving Obligations. Except as otherwise expressly provided herein, termination of
this Agreement in accordance with the provisions hereof shall not limit remedies which may otherwise be available in law or equity. Termination or expiration of this Agreement for any reason shall be without prejudice to any rights that shall have
accrued to the benefit of a party prior to such termination or expiration (including accrued payments). Such termination or expiration shall not relieve a party from obligations that are expressly indicated to survive the termination or expiration
of this Agreement pursuant to this Section 9.6. Without limiting the foregoing, Sections 3.6, (if the Supply Agreement is in effect) 4.2, (if the License Agreement is in effect but the Supply Agreement has not been executed or as provided in
Section 9.5(d)(iii) or (iv)) 4.3, (if and to the extent provided in Section 9.5) 5.1(b), (solely as described in Section 9.5(d)(iii) or (iv)) 5.2, (if the License Agreement has been executed) 5.3, 5.6, 6.2 through 6.6, 8.2 through
8.7, (if the License Agreement has been executed) 8.8, 9.5 and 9.6 and ARTICLE VII, ARTICLE X, and ARTICLE XII of this Agreement shall survive the expiration or termination of this Agreement for any reason. 

ARTICLE X 

Indemnity; Limitation of Liability 
 10.1 Indemnification of Fluidigm. In addition to any other remedy available to Fluidigm, Novartis shall indemnify, defend and hold harmless Fluidigm, its Affiliates and its and their respective
directors, officers and employees (each a “Fluidigm Party”) in full and on demand, from and against any and all direct or indirect liabilities or litigation expenses, including interest, penalties and reasonable lawyers’ fees
(as set forth in Section 10.4(b)) and disbursements (collectively, “Losses”) incurred by them to the extent resulting from any claims or allegations made or suits, actions or proceedings brought by a Third Party (collectively,
“Third Party Claims”) against any Fluidigm Party that result from: 
 (a) any intentional misconduct or
negligence on the part of Novartis or any of its Affiliates in performing any activity contemplated by this Agreement, or the breach of any provision of this Agreement by Novartis; 

(b) any infringement claims by a Third Party resulting from any Excluded Cause; or 

(c) the incorporation, at Novartis’ request (and in the manner specified by Novartis), of Additional Excluded Items in Fluidigm
Products; 
 except, in the cases of clause (a) and clause (c), (i) for any Losses for which Fluidigm has an obligation to indemnify
any Novartis Party pursuant to Section 10.2, as to which Loss each party shall indemnify the other to the extent of their respective liability for such Loss, (ii) to the extent such Losses arise or result from the intentional misconduct or
negligence of a Fluidigm Party, or the breach of any provision of this Agreement or any Ancillary Agreement by Fluidigm, and 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -35-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
(iii) to the extent Fluidigm has an obligation to indemnify a Novartis Party for any such Losses pursuant to an Ancillary Agreement. 

10.2 Indemnification of Novartis. In addition to any other remedy available to Novartis, Fluidigm shall indemnify, defend and hold
harmless Novartis and its Affiliates its and their respective directors, officers and employees (each a “Novartis Party”) in full and on demand, from and against any and all Losses incurred by them to the extent resulting from (or
in the case of clause (b), arise out of or in connection with) any Third Party Claims against any Novartis Party that result from (or in the case of clause (b), arise out of): 

(a) (i) (x) any intentional misconduct or negligence on the part of Fluidigm or its Affiliates in performing any activity
contemplated by this Agreement, or the breach of any provision of this Agreement by Fluidigm or (y) the supply of defective or non-conforming Fluidigm Chips or Fluidigm Instruments under this Agreement (only to the extent such Third Party Claim
is a products liability claim or a claim for personal injury or death); or (ii) the Exploitation of any Fluidigm Instrument, Fluidigm Chip, or the Fluidigm System by or on behalf of Fluidigm or any of its Affiliates, which claim(s) is based on
acts or omissions occurring or failing to occur, in whole or in part, prior to the Effective Date, including any violation of Applicable Law in connection with such Exploitation and any Third Party Claims that allege that the claimant has suffered
personal injury or death as a result of the use of any of the foregoing sold or distributed by or on behalf of Fluidigm or any of its Affiliates prior to the Effective Date, except in each case ((i) and (ii)), (A) for any Losses for which
Novartis has an obligation to indemnify any Fluidigm Party pursuant to Section 10.1, as to which Loss each party shall indemnify the other to the extent of their respective liability for such Loss, (B) to the extent such Losses arise or
result from the intentional misconduct or negligence of a Novartis Party, or the breach of any provision of this Agreement or any Ancillary Agreement by Novartis, and (C) to the extent Novartis has an obligation to indemnify a Fluidigm Party
for any such Losses pursuant to an Ancillary Agreement; 
 (b) the Exploitation of any Fluidigm Instrument, Fluidigm Chip, or
Fluidigm Royalty-Bearing Product by or on behalf of Fluidigm or its Affiliates, licensees, or (sub)licensees anywhere in the world, including claims that arise from any violation of Applicable Law in connection with such Exploitation or allege that
the claimant has suffered personal injury or death as a result of the use of any of the foregoing sold or distributed by or on behalf of Fluidigm or its Affiliates or (sub)licensees (in each case excluding any such sale, distribution, or other
Exploitation by Novartis or any of its Affiliates or (sub)licensees hereunder or under any Ancillary Agreements); or 
 (c) any
infringement claims by a Third Party resulting from Exploitation under this Agreement of the Fluidigm Technology in general, i.e., the infringement claim would have occurred regardless of specific assay or Tests (where Exploitation of the Fluidigm
Technology in general includes the performance of digital PCR using Fluidigm Products), provided that Fluidigm shall have no liability under this Section 10.2(c) with respect to any claim resulting from (i) modification of Fluidigm
Technology by Novartis or any of its Affiliates or sublicensees unless Fluidigm has been notified of such modification in writing and fails to 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -36-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
reasonably object to such modification by written notice to Novartis within sixty (60) days following such notification; (ii) the combination by Novartis, its Affiliates, its
sublicensees and their respective customers of Fluidigm Technology with any product or item not provided by or on behalf of Fluidigm or any of its Affiliates unless Fluidigm has been notified of such combination in writing and fails to reasonably
object to such combination by written notice to Novartis within sixty (60) days following such notification; (iii) Fluidigm’s compliance with Novartis’ specifications or designs if, prior to such compliance, Fluidigm reasonably
objects to such compliance by written notice to Novartis; or (iv) any name or mark included on a Novartis Licensed Product not applied by Fluidigm (or applied at Novartis’ request) (collectively (i)-(iv), “Excluded
Causes”). 
 In addition, Fluidigm shall have no liability or obligation under this Section 10.2 with respect to items
incorporated into Fluidigm Products at Novartis’ request (and in the manner specified by Novartis, if Novartis has specified a manner in writing), including reagents and mastermixes if, prior to such incorporation, Fluidigm reasonably objects
to such incorporation by written notice to Novartis within thirty (30) days of such request (“Additional Excluded Items”). 
 10.3 Notice of Claim. An Indemnified Party shall give the Indemnifying Party prompt written notice of any Loss or discovery of fact upon which such Indemnified Party intends to base a request for
indemnification under Section 10.1 or 10.2. The Indemnifying Party shall not be liable for any Loss that results from any delay in providing such notice. Such notice shall contain a description of the claim and the nature and amount of the Loss
claimed (to the extent that the nature and amount of such Loss is known at such time). The Indemnified Party shall furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of any such Loss.

 10.4 Indemnification Procedures. The obligations of an Indemnifying Party under this ARTICLE X shall be governed by
and contingent upon the following: 
 (a) Assumption of Defense. At its option, the Indemnifying Party may assume the
defense of any Third Party Claim by giving written notice to the Indemnified Party within fourteen (14) days after receipt of notice pursuant to Section 10.3. Such assumption shall not be construed as an acknowledgement of liability or a
waiver of any defenses (and the Indemnifying Party shall be reimbursed by the Indemnified Party in the case in which the Indemnifying Party is not liable under this ARTICLE X). 

(b) Control of Defense. Upon the assumption of the defense of a Third Party Claim by the Indemnifying Party, such party may
appoint lead counsel in the defense of the Third Party Claim, which shall be reasonably acceptable to the Indemnified Party, and except as expressly provided in this Section 10.4(b), the Indemnifying Party shall not be liable to the Indemnified
Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis, defense or settlement of the Third Party Claim. The Indemnified Party shall be entitled to participate in, but not control, the defense of
a Third Party Claim and to retain counsel of its choice for such purpose at its expense unless the interests of the Indemnified Party and the Indemnifying Party with respect to such Third Party Claim are sufficiently adverse

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -37-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
to prohibit the representation by the same counsel of both parties under Applicable Law, ethical rules or equitable principles, in which latter case such retention shall be at the expense of the
Indemnifying Party. 
 (c) Settlement. With respect to all Losses resulting from or arising out of or in connection with
Third Party Claims, where the Indemnifying Party has assumed the defense of a Third Party Claim in accordance with Section 10.4(a), (i) the Indemnifying Party shall have authority to consent to the entry of any judgment, enter into any
settlement or otherwise dispose of such Losses, provided that it obtains the prior written consent of the Indemnified Party, which consent shall not be unreasonably withheld or delayed and (ii) no Indemnified Party shall admit any
liability with respect to, or settle, compromise or discharge, any such Third Party Claim without the prior written consent of the Indemnifying Party, which consent shall not be unreasonably withheld or delayed. 

(d) Cooperation. If the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party that is a
party to this Agreement shall, and shall cause each of its Affiliates and each of their respective directors, officers, employees and agents to reasonably cooperate in the defense or prosecution thereof and shall furnish such records, information
and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours by the
Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim, and making the Indemnified Party, its Affiliates and its and their respective directors,
officers, employees and agents available on a mutually convenient basis to provide additional information and explanation of any records or information provided, and the Indemnifying Party shall reimburse the Indemnified Party for all of its related
reasonable out-of-pocket expenses. 
 (e) Expenses. Any reasonable and verifiable costs and expenses incurred by the
Indemnified Party in connection with any claim and reimbursable as set forth above in this ARTICLE X shall be reimbursed on a calendar quarter basis by the Indemnifying Party, without prejudice to the Indemnifying Party’s right to contest the
Indemnified Party’s right to indemnification and subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. 

10.5 Limitation on Damages; Indemnity Cap. 
 (a) General Limitations. EXCEPT IN CIRCUMSTANCES OF RECKLESSNESS OR INTENTIONAL MISCONDUCT BY A PARTY OR ITS AFFILIATES, OR A PARTY’S INDEMNIFICATION OBLIGATIONS WITH RESPECT TO THIRD PARTY
CLAIMS UNDER SECTION 10.1 OR 10.2, NEITHER PARTY OR ANY OF ITS AFFILIATES SHALL BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, OR FOR LOST PROFITS, UNEARNED MILESTONES OR ROYALTIES, WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE,
TORT, STRICT LIABILITY OR OTHERWISE, ARISING OUT OF OR IN CONNECTION WITH THIS 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -38-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
AGREEMENT, INCLUDING (a) THE COLLABORATION ACTIVITIES, OR (b) ANY BREACH OF OR FAILURE TO PERFORM ANY OF THE PROVISIONS OF THIS AGREEMENT. IN NO EVENT SHALL FLUIDIGM OR ANY OF ITS
AFFILIATES BE LIABLE FOR COSTS OF SUBSTITUTE PRODUCTS, SERVICES, OR TECHNOLOGY. 
 (b) Indemnity Caps. NOVARTIS’
MAXIMUM AGGREGATE LIABILITY UNDER SECTION 10.1 AND FLUIDIGM’S MAXIMUM AGGREGATE LIABILITY UNDER SECTION 10.2(a)(i) AND (c) (COLLECTIVELY), RESPECTIVELY, SHALL EQUAL [***] (THE “CAP”); PROVIDED, HOWEVER, THAT NO LOSSES
RESULTING FROM SUCH PARTY’S RECKLESSNESS OR INTENTIONAL MISCONDUCT SHALL BE COVERED BY OR COUNTED TOWARDS SUCH PARTY’S CAP. THESE LIMITATIONS, HOWEVER, SHALL NOT APPLY TO LIABILITY FOR PERSONAL INJURY, DEATH, OR PHYSICAL DAMAGE TO TANGIBLE
PROPERTY. 
 10.6 Insurance. During the term of this Agreement and any other period during which Exploitation of Fluidigm
Royalty-Bearing Products or Results occurs and triggers a royalty hereunder, Fluidigm shall secure and maintain in full force and effect insurance coverage covering the risks associated with the business of Fluidigm in the amounts typically carried
by a business similarly situated to Fluidigm. If requested by Novartis, Fluidigm shall provide to Novartis certificates of insurance evidencing compliance with the above requirements. 

ARTICLE XI 

Representations, Warranties and Covenants 
 11.1 Representations, Warranties and Covenants. Each party hereby represents, warrants and covenants to the other party as of the Effective Date as follows: 

(a) Such party (i) has the power and authority and the legal right to enter into this Agreement and perform its obligations
hereunder, and (ii) has taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed and delivered on behalf of
such party and constitutes a legal, valid and binding obligation of such party and is enforceable against it in accordance with its terms subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement
of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity, whether enforceability is considered a proceeding at law or equity. 

(b) Except as otherwise disclosed to the other party in the Side Letter, to such party’s Knowledge, there is no pending or
threatened litigation (and it has not received any communication) that alleges that such party’s activities related to this Agreement have violated, or that by conducting the activities as contemplated herein such party would violate, any of
the intellectual property rights of any Third Party. 
 (c) All necessary consents, approvals and authorizations of all
regulatory and governmental authorities and other Persons required to be obtained by such party 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -39-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained. 

(d) The execution and delivery of this Agreement and the performance of such party’s obligations hereunder (i) do not conflict
with or violate any requirement of applicable law or regulation or any provision of the articles of incorporation, bylaws, limited partnership agreement or any similar instrument of such party, as applicable, in any material way, and (ii) do
not conflict with, violate, or breach or constitute a breach or require any consent under, any contractual obligation or court or administrative order by which such party is bound. 

11.2 Additional Representations, Warranties and Covenants of Fluidigm. Fluidigm represents, warrants and covenants to Novartis
that: 
 (a) To Fluidigm’s Knowledge as of the Effective Date, the Core Fluidigm Know-How and any other data, clinical
studies and other Information and Inventions in its or its Affiliates’ possession or Control in each case relating to the Core Fluidigm Technology that Fluidigm has made available to Novartis is not materially incomplete or inaccurate.

 (b) During the term of this Agreement, Fluidigm will make available, to Novartis, Core Fluidigm Know-How and any other data,
clinical studies and other Information and Inventions in its or its Affiliates’ possession or Control relating to the Core Fluidigm Technology as set forth in Section 3.7(b) and, to Fluidigm’s Knowledge, as of the time of delivery,
all such Core Fluidigm Know-How and other Information and Inventions that Fluidigm delivers pursuant to Section 3.7(b) will not be materially incomplete or inaccurate. 
 (c) To Fluidigm’s Knowledge as of the Effective Date, Fluidigm has disclosed all material adverse information with respect to the Core Fluidigm Technology, which information is Known to Fluidigm as
of the Effective Date. For the purpose of this Section 11.2(c), “material adverse information” [***]. 
 (d)
Fluidigm is the sole and exclusive owner of all right, title and interest in and to the Patents listed as “Owned” on Schedule 11.2(d) (the “Owned Core Fluidigm Patents”) and, except as provided in Schedule
11.2(d), as of the Effective Date such rights are not subject to any encumbrance, lien or claim of ownership by any Third Party. Fluidigm is the licensee of and Controls rights, title and interest in and to the Patents listed on Schedule
11.2(d) as “Licensed” (the “In-Licensed Core Fluidigm Patents”), in each case on either an exclusive or non-exclusive basis, as indicated in such schedule, and, except as provided in Schedule 11.2(d), as of the
Effective Date such rights are not subject to any encumbrance, lien or claim of ownership by any Third Party. True, complete and correct copies of all license agreements in which Fluidigm receives any right or license to any In-Licensed Core
Fluidigm Patents (the “Core Fluidigm In-License Agreements”), as amended to the date hereof, have been provided to Novartis, and a list of such agreements is set forth in Schedule 11.2(d). Upon request of Novartis during the
Option Term, Fluidigm shall use its commercially reasonable efforts (i) to obtain from its Third Party licensors the right for Novartis (if it were to enter into the License Agreement) to further sublicense any rights that are sublicensed to
Novartis under by 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -40-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
Fluidigm under the License Agreement and (ii) to modify the diligence requirements under the Core Fluidigm In-License Agreements so that they are consistent with the terms of the License
Agreement. 
 (e) During the term of this Agreement, Fluidigm shall not encumber or diminish the rights granted to Novartis
hereunder with respect to the Fluidigm Patents, including by not (i) committing any acts or permitting the occurrence of any omissions that would cause the material breach or termination of any Core Fluidigm In-License Agreement, or
(ii) amending or otherwise modifying, or permitting to be amended or modified, any Core Fluidigm In-License Agreement, in the case of clause (ii) in a manner that is inconsistent with the grants, assignments and other rights reserved to
Novartis and its Affiliates in this Agreement (including its option rights set forth in this Agreement). Fluidigm shall promptly provide Novartis with notice of any alleged, threatened, or actual breach of any Core Fluidigm In-License Agreement of
which Fluidigm is aware and that is likely to have a material adverse effect on the grants, assignments and other rights reserved to Novartis and its Affiliates in this Agreement. As of the Effective Date, none of Fluidigm, its Affiliates and, to
Fluidigm’s Knowledge, any Third Party is in breach of any Core Fluidigm In-License Agreement that is likely to have a material adverse effect on the grants, assignments and other rights reserved to Novartis and its Affiliates in this Agreement
(including its option rights set forth in this Agreement). 
 (f) To Fluidigm’s knowledge as of the Effective Date except
as disclosed in the Side Letter, (i) the Core Fluidigm Patents are subsisting and are not invalid or unenforceable, in whole or in part, (ii) the conception, development and reduction to practice of the Core Fluidigm Patents and Core
Fluidigm Know-How existing as of the Effective Date have not constituted or involved the misappropriation of trade secrets or other rights or property of any Third Party, (iii) there are no claims, judgments or settlements against or amounts
with respect thereto owed by Fluidigm or any of its Affiliates relating to the Core Fluidigm Patents or Core Fluidigm Know-How, (iv) no claim or litigation has been brought or threatened against Fluidigm or any of its Affiliates (or to
Fluidigm’s Knowledge) by any Person alleging, that any Core Fluidigm Patents or Core Fluidigm Know-How or the disclosing, copying, making, assigning, licensing or Exploiting of any Core Fluidigm Patents or Core Fluidigm Know-How, or products
and services embodying the Core Fluidigm Patents or Core Fluidigm Know-How, including the Exploitation of the Novartis Licensed Products using the Core Fluidigm Technology, violates, infringes or otherwise conflicts or interferes with any
intellectual property or proprietary right of any Third Party, and (v) Fluidigm has not received any written notice alleging that any Third Party rights would be infringed or misappropriated by Exploiting the Core Fluidigm Technology or
otherwise suggesting that Fluidigm obtain a license in order to Exploit the Core Fluidigm Technology, Core Fluidigm Patents or Core Fluidigm Know-How. 
 (g) Except for products shipped by or on behalf of Fluidigm or its Affiliates to Third Parties prior to the Effective Date for research-use-only (and not clinical use) that are not subject to restrictions
with respect to the Primary Field or Secondary Field, Fluidigm and its Affiliates have not, directly or indirectly, expressly or by implication, by action or omission or otherwise (i) assigned, transferred, conveyed or otherwise encumbered any
right, title or interest in or to any Core Fluidigm Patents or Core Fluidigm Know-How, (ii) granted any 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -41-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
license or other right, title or interest in or to any Core Fluidigm Patents or Core Fluidigm Know-How in any manner, or (iii) agreed to or is otherwise bound by any covenant not to sue for
any infringement, misuse or otherwise with respect to any Core Fluidigm Patents or Core Fluidigm Know-How, in each case ((i), (ii), and (iii)) that is inconsistent with the grants, assignments and other rights reserved to Novartis and its Affiliates
in this Agreement (including the exclusive options set forth herein). 
 (h) During this Agreement, Fluidigm and its Affiliates
shall not, directly or indirectly, expressly or by implication, by action or omission or otherwise (i) assign, transfer, convey or otherwise encumber any right, title or interest in or to any Core Fluidigm Patents or Core Fluidigm Know-How,
(ii) grant any license or other right, title or interest in or to any Core Fluidigm Patents or Core Fluidigm Know-How in any manner, or (iii) agree to or become otherwise bound by any covenant not to sue for any infringement, misuse or
otherwise with respect to any Core Fluidigm Patents or Core Fluidigm Know-How, in each case ((i), (ii), and (iii)) in a manner that is inconsistent with the grants, assignments and other rights reserved to Novartis and its Affiliates in this
Agreement (including the exclusive options set forth herein). Novartis acknowledges that Fluidigm shall be entitled, from time-to-time, to make intercompany transfers of intellectual property rights between Fluidigm and its Affiliates. 

(i) Prior to the Effective Date, Fluidigm has not granted to any Third Party a license to use any Fluidigm chips or instruments for
diagnostic or other clinical use in the Primary Field or the Secondary Field. Fluidigm has disclosed to Novartis prior to the Effective Date the current (as of the Effective Date) version of those certain standard terms and conditions that Fluidigm
uses to govern the sale of its chips and instruments. On and after the Effective Date, Novartis shall have the right to review and approve a revision to those portions, of Fluidigm’s standard terms and conditions for the sale of Fluidigm’s
chips and instruments, that govern licenses granted by Fluidigm, which approval may be denied solely on the basis of protecting Novartis’ rights under this Agreement and the Ancillary Agreements, including its exclusive rights in the Primary
Field and the Secondary Field (as such exclusivity is described in this Agreement, the License Agreement and the Supply Agreement). Novartis shall respond promptly to each Fluidigm request for approval of such a change, and, in any case, any failure
of Novartis to so respond in writing (including an explanation of the basis for any refusal to approve) within fifteen (15) days after receipt of Fluidigm’s proposed change(s) shall constitute Novartis’ approval thereof. Such terms
and conditions shall prohibit any Exploitation of such chips and instruments in the Primary Field and the Secondary Field but may permit research-only use (but not use to generate clinical results for a fee or results for use in the medical
management of a patient) in the Secondary Field. 
 (j) Fluidigm shall obtain from each of its Affiliates, and from the
employees of its Affiliates, who are involved in the manufacture of the Novartis Licensed Product(s) sold to Novartis under this Agreement, are otherwise participating in the Exploitation of the Fluidigm Patents or Fluidigm Know-How under this
Agreement, or who have access to any Confidential Information of Novartis, rights to any and all Information and Inventions that relate to the Fluidigm Patents or Fluidigm Know-How, such that Novartis shall, by virtue of this

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -42-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
Agreement, receive from Fluidigm, without payments beyond those required herein, the licenses and other rights granted to Novartis and its Affiliates hereunder. 

(k) Except as disclosed in the Side Letter, to Fluidigm’s Knowledge as of the Effective Date, there is no actual or threatened
infringement or misappropriation by a Third Party of the Core Fluidigm Patents or the Core Fluidigm Know-How that is likely to have a material adverse effect on Novartis’ Exploitation of the Core Fluidigm Patents and the Core Fluidigm Know-How
contemplated by this Agreement. 
 ARTICLE XII 
 Miscellaneous 
 12.1 Force Majeure. Neither party shall be held
liable or responsible to the other party or be deemed to have breached under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement when such failure or delay is caused by or results from causes beyond
the reasonable control of the non-performing party, including fires, floods, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), insurrections, riots, civil commotion, strikes, lockouts or other labor
disturbances, acts of God or acts, omissions or delays in acting by any governmental authority. The non-performing party shall notify the other party of such force majeure within ten (10) days after such occurrence by giving written notice to
the other party stating the nature of the event, its anticipated duration, and any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than is necessary and the
non-performing party shall use commercially reasonable efforts to remedy its inability to perform. 
 12.2 Assignment; Change
of Control. 
 (a) Neither party may assign its rights or delegate its obligations under this Agreement, in whole or in
part, without the prior written consent of the other party, except that (i) Novartis shall have the right, without such consent, to assign any or all of its rights and delegate any or all of its obligations hereunder to any of its Affiliates or
to any successor in interest (whether by merger, acquisition, asset purchase, or otherwise) to all or substantially all of the assets to which this Agreement relates and (ii) Fluidigm shall have the right, without such consent, to assign any or
all of its rights and delegate any or all of its obligations hereunder to any company that acquires all or substantially all of Fluidigm’s assets (whether by merger, acquisition, asset purchase, or otherwise). Any permitted successor of a party
or any permitted assignee of all of a party’s rights under this Agreement that has also assumed all of such party’s obligations hereunder in writing shall, upon any such succession or assignment and assumption, be deemed to be a party to
this Agreement as though named herein in substitution for the assigning party, whereupon the assigning party shall cease to be a party to this Agreement and shall cease to have any rights or obligations under this Agreement. All validly assigned
rights of a party shall inure to the benefit of and be enforceable by, and all validly delegated obligations of such party shall be binding on and be enforceable against, the permitted successors and assigns of such party. Any attempted assignment
or delegation in violation of this Section 12.2 shall be void and without effect. 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -43-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 (b) Notwithstanding Section 12.2(a), Novartis shall
have the right (i) to perform any or all of its obligations and exercise any or all of its rights hereunder; (ii) to perform any or all of its obligations and exercise any or all of its rights under this Agreement through any of its
Affiliates; and (iii) to subcontract its obligations hereunder to a Third Party, provided that Novartis remains liable for such Third Party’s performance of such obligations. 

(c) Fluidigm shall provide Novartis with fifteen (15) days’ prior written notice of any Change of Control. Following the
Change of Control, unless and until Novartis elects its right to terminate this Agreement pursuant to Section 9.4(c), the following shall apply: 
 (i) If Fluidigm or any of its Affiliates engages in development or commercialization of products in the Primary Field or Secondary Field other than the performance of its obligations under this Agreement,
including the Collaboration Activities, or any Ancillary Agreement, Fluidigm and its Affiliates shall establish and enforce appropriate firewall procedures between such activities and the activities performed by or on behalf of Fluidigm or
Affiliates pursuant to its other programs to ensure that no Collaboration Information and Inventions or Confidential Information of Novartis is used in connection with such other programs (such programs conducted in compliance with this Agreement,
including the exclusivity afforded to Novartis with respect to the Fluidigm Patents, the Fluidigm Know-How and the Fluidigm Technology under this Agreement and the Ancillary Agreements, (“Independent Programs”). 

(ii) The Fluidigm Know-How, Fluidigm Patents and Fluidigm Technology shall exclude (A) any technology or intellectual property
rights, [***] (collectively, “Acquiring Entities”) and (B) any technology or intellectual property [***] in accordance with this Agreement (“Acquisition IP”); provided, however, that such exclusions (in
clauses (A) and (B)) shall not apply to any Acquisition IP that is either (1) [***]. 
 (iii) [***] 

(iv) Without limitation of any other obligation of Fluidigm hereunder, Fluidigm shall ensure that it devotes adequate resources to the
performance of the Collaboration Activities assigned to Fluidigm hereunder and shall maintain at least the level of support therefor consistent with the level of support afforded by Fluidigm prior to the Change of Control, including being diligent
and using reasonable efforts to achieve the milestones set forth in this Agreement in accordance with ARTICLE III of this Agreement. If Novartis reasonably determines that such level of support is not being afforded by Fluidigm following the Change
of Control, Novartis may so notify Fluidigm in writing, and if Fluidigm does not cure such failure within thirty (30) days after such notice, then Novartis shall have the right, on further written notice to Fluidigm at any time after such
failure to cure by Fluidigm, to assume the performance of such activities promptly following written notice to Fluidigm and Fluidigm shall assist with the transfer of such activities to Novartis. If Novartis does so, then Novartis may deduct from
the payments due to Fluidigm under this Agreement or any Ancillary Agreement any costs and expenses incurred by Novartis in performing such activities. 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -44-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 12.3 Severability. If any provision of this Agreement
is held to be illegal, invalid or unenforceable under any present or future law, and if the rights or obligations of any party under this Agreement will not be materially and adversely affected thereby, (a) such provision shall be fully
severable, (b) this Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement shall remain in full force and effect
and shall not be affected by the illegal, invalid or unenforceable provision or by its severance herefrom, and (d) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this Agreement a
legal, valid and enforceable provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the parties herein. To the fullest extent permitted by applicable law, each party hereby
waives any provision of law that would render any provision hereof prohibited or unenforceable in any respect. 
 12.4
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California without reference to the rules of conflict of laws thereof that would require the application of the laws of another
jurisdiction. The parties expressly agree to exclude application of the United Nations Convention of the International Sale of Goods to this Agreement. 
 12.5 Notices. All notices or other communications that are required or permitted hereunder shall be in writing and delivered personally, sent by facsimile (and promptly confirmed by personal
delivery, registered or certified mail or overnight courier as provided herein), sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: 

If to Fluidigm, to: 
 7000 Shoreline Court, Suite 100 
 South San Francisco, CA 94080 

Attention: [***] 
 Facsimile: (650) 871-7152 
 with a copy to: 

7000 Shoreline Court, Suite 100 
 South San Francisco, CA 94080 
 Attention: General Counsel 

Facsimile: (650) 871-7195 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -45-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 If to Novartis, to: 

Novartis Vaccines and Diagnostics, Inc. 
 4560 Horton Street, Emeryville, CA 94608 
 Attention: President, Diagnostics

 Facsimile: (510) 655-9910 
 with copies to: 
 Novartis Vaccines and Diagnostics, Inc. 

350 Massachusetts Avenue 
 Cambridge, MA 02139 
 Attention: General Counsel 

Facsimile: (617) 871-8911 
 Covington & Burling 
 One Front Street 

San Francisco, CA 94111 
 Attention: Amy L. Toro 
 Facsimile: (415) 955-6586 

or to such other address as the party to whom notice is to be given may have furnished to the other party in writing in accordance herewith. Any such
communication shall be deemed to have been given (i) when delivered, if personally delivered or sent by facsimile on a business day, (ii) on the business day after dispatch, if sent by nationally-recognized overnight courier, and
(iii) on the fifth business day following the date of mailing, if sent by mail. It is understood and agreed that this Section 12.5 is not intended to govern the day-to-day business communications necessary between the parties in performing
their duties, in due course, under the terms of this Agreement. 
 12.6 Dispute Resolution. Any matter that is unable to
be resolved by the JSC shall be referred to Fluidigm’s Chief Executive Officer and Novartis’ President, Diagnostics for resolution (collectively, the “Executives”). The Executives shall negotiate in good faith to resolve
any such dispute for up to forty-five (45) days of such dispute being referred to them. Any dispute regarding the validity, interpretation or construction of, or the compliance with or breach of this Agreement or any Ancillary Agreement, and is
not resolved by the Executives shall be solely and exclusively settled by final and binding arbitration in accordance with the commercial arbitration rules of the American Arbitration Association (“AAA”), subject to the terms and
conditions of this Section 12.6. Either party may initiate the arbitration of a dispute by sending written notice of such election to the other party clearly marked “Arbitration Demand” (the “Arbitration Demand”). The
arbitration shall be adjudicated by one arbitrator appointed in accordance with the commercial rules of the AAA. The decision of the arbitrator shall be final and binding upon the parties hereto, and may be entered in any competent court for
judicial acceptance of such an award and order of enforcement. The place of arbitration shall be San 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -46-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 
Francisco, California. Notwithstanding anything to the contrary in this Section 12.6, each party may, and expressly reserves the right to, seek judicial relief from any court of competent
jurisdiction in order to obtain an injunction or other equitable relief pending the outcome of an arbitration hereunder or to enforce a breach of the confidentiality provisions in ARTICLE VIII. Subject to the foregoing, the state and federal courts
situated in the city of San Francisco, California, shall have sole jurisdiction and venue to enforce any arbitration award and over proceeding for such injunctive or equitable relief brought pursuant to this Section 12.6. The parties
irrevocably submit to such jurisdiction and venue, waive any claim to an inconvenient forum posed by such venue, and agree that process may be served in any manner permitted by such court before which a dispute is pending. 

12.7 Entire Agreement; Modifications. This Agreement sets forth and constitutes the entire agreement and understanding between the
parties with respect to the subject matter hereof and all prior agreements, understanding, promises and representations, whether written or oral, with respect thereto, including that certain Letter Of Intent dated December 23, 2009 and that
certain Mutual Confidential Disclosure Agreement dated September 15, 2009, are superseded hereby. Each party confirms that it is not relying on any representations or warranties of the other party except as specifically set forth herein. No
amendment, modification, release or discharge hereof shall be binding upon the parties unless in writing and duly executed by authorized representatives of both parties. 
 12.8 Relationship of the Parties. It is expressly agreed that Fluidigm, on the one hand, and Novartis, on the other hand, shall be independent contractors and that the relationship between the two
parties shall not constitute a partnership, joint venture or agency. Neither Fluidigm, on the one hand, nor Novartis, on the other hand, shall have the authority to make any statements, representations or commitments of any kind, or to take any
action, which shall be binding on the other, without the prior written consent of the other party to do so. All persons employed by a party shall be employees of such party and not of the other party and all costs and obligations incurred by reason
of any such employment shall be for the account and expense of such party. 
 12.9 Equitable Relief. Each party
acknowledges and agrees that the restrictions set forth in ARTICLE VIII of this Agreement are reasonable and necessary to protect the legitimate interests of the other party and that the other party would not have entered into this Agreement in the
absence of such restrictions, and that any violation or threatened violation of any provision of ARTICLE VIII will result in irreparable injury to the other party. Each party also acknowledges and agrees that in the event of a violation or
threatened violation of any provision of ARTICLE VIII, the other party shall be entitled to preliminary and permanent injunctive relief, without the necessity of proving irreparable injury or actual damages and without the necessity of having to
post a bond, as well as to an equitable accounting of all earnings, profits and other benefits arising from any such violation. The rights provided in the immediately preceding sentence shall be cumulative and in addition to any other rights or
remedies that may be available to either party. 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -47-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 12.10 Waiver. Any term or condition of this Agreement
may be waived at any time by the party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the party waiving such term or condition. The waiver by
either party hereto of any right hereunder or of the failure to perform or of a breach by the other party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other party whether of a similar nature or
otherwise. 
 12.11 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 12.12 No Benefit to
Third Parties. The representations, warranties, covenants and agreements set forth in this Agreement are for the sole benefit of the parties hereto and their successors and permitted assigns, and they shall not be construed as conferring any
rights on any other Persons. 
 12.13 Further Assurance. Each party shall duly execute and deliver, or cause to be duly
executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other party may reasonably
request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other party its rights and remedies under this Agreement. 

12.14 References; Construction. Unless otherwise specified, (a) references in this Agreement to any Article, Section,
Schedule or Exhibit shall mean references to such Article, Section, Schedule or Exhibit of this Agreement, (b) references in any section to any clause are references to such clause of such section, and (c) references to any agreement,
instrument or other document in this Agreement refer to such agreement, instrument or other document as originally executed or, if subsequently varied, replaced or supplemented from time to time, as so varied, replaced or supplemented and in effect
at the relevant time of reference thereto. Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word
“or” is used in the inclusive sense (i.e., meaning “and/or”). The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or
the intent of any provision contained in this Agreement. The term “including” as used herein shall mean including, without limiting the generality of any description preceding such term. The language of this Agreement shall be deemed to be
the language mutually chosen by the parties and no rule of strict construction shall be applied against either party hereto. 

[Remainder of page left blank intentionally.] 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -48-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 IN WITNESS WHEREOF, the parties hereto have caused
this Agreement to be executed by their duly authorized representatives as of the date first above written. 
  

									
	 NOVARTIS VACCINES & DIAGNOSTICS, INC.
	 		 	 FLUIDIGM CORPORATION

					
	By:	 	  
	 		 	By:	 	  

	Name:	 	  
	 		 	Name:	 	  

	Title:	 	  
	 		 	Title:	 	  

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 -49-

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

Confidential 
  

Exhibit A 

Novartis Development Quality Agreement 
 Incorporated by reference to Exhibit 10.23 to the registrant’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on January 18, 2011. 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 Exhibit A - 1

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

Confidential 
  

Exhibit B 

Collaboration Plan 
 Novartis-Fluidigm Research Collaboration Activities and Milestones 
 The goal for the
research collaboration is to develop and validate digital PCR [***] for use in the diagnosis of fetal aneuploidy from a [***] sample from a pregnant woman. 
 Phase 1: Evaluation 
 Goals: 

1) [***] 
 2)
[***] 
 Fluidigm tasks 
  

					
	 Tasks
	  	 Expected
Completion
Date (post
effective date)
	  	 Details/Metrics

	Fluidigm Collaboration Milestone 1	  		  	
	[***]	  	[***]	  	[***]
	Fluidigm Collaboration Milestone 2	  		  	
	[***]	  	[***]	  	[***]
	Fluidigm Collaboration Milestone 3	  		  	
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	Fluidigm Collaboration Milestone 4	  		  	
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	Fluidigm Collaboration Milestone 5	  		  	
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	
	Fluidigm Collaboration Milestone 6	  		  	
	[***]	  	[***]	  	[***]

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 Exhibit B - 1

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 Novartis Tasks 

 

					
	 Tasks
	  	 Expected
Completion
Date (post
effective date)
	  	 Details/Metrics

	Novartis Collaboration Milestone 1	  		  	
	[***]	  	[***]	  	[***]
	Novartis Collaboration Milestone 2	  		  	
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	Novartis Collaboration Milestone 3	  		  	
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	Novartis Collaboration Milestone 4	  		  	
	[***]	  	[***]	  	[***]
	Novartis Collaboration Milestone 5	  		  	
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 Exhibit B - 2

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 Phase 2: [***] 

Note: 
  

	•	 	 [***] 

  

	•	 	 [***] 

 Goals: 

1.[***] 

2.[***] 

3.[***] 
 Fluidigm tasks

  

					
	 Tasks
	  	 Expected
Completion
Date (post
start of Phase

2)
	  	 Details/Metrics

	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	
	[***]	  	[***]	  	
	[***]	  	[***]	  	
	[***]	  	[***]	  	
	[***]	  	TBD	  	[***]
	[***]	  	TBD	  	[***]
	[***]	  	TBD	  	¡ TBD
	[***]	  	TBD	  	¡ TBD
	[***]	  	TBD	  	¡ TBD
	[***]	  	TBD	  	¡ TBD

Novartis Tasks 
  

					
	 Tasks
	  	 Expected
Completion
Date (post
start of Phase
2)
	  	 Details/Metrics

	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 Exhibit B - 3

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
  

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 Exhibit B - 4

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 Phase 3: [***] 

Goals: 
 1. [***] 

Fluidigm tasks 
  

					
	 Tasks
	  	 Expected
Completion
Date (post
start of Phase
3)
	  	 Details/Metrics

	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 Novartis Tasks 

 

					
	 Tasks
	  	 Expected
Completion
Date (post
start of Phase

3)
	  	 Details/Metrics

	[***]	  	[***]	  	
	[***]	  	[***]	  	
	[***]	  	[***]	  	

 [***] 
 Quality Milestones 
  

					
	 Milestone
	  	 Expected
completion
time
	  	 Details / Metrics

	QA Milestone 1[***]	  	[***]	  	[***]
	QA Milestone 2[***]	  	[***]	  	[***]
	QA Milestone 3[***]	  	[***]	  	[***][***][***]
	QA Milestone 4[***]	  	[***]	  	[***][***][***]
	QA Milestone 5[***]	  	[***]	  	[***][***][***]

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 Exhibit B - 5

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

Confidential 
  

Exhibit C 

Assay Patents 
  

													
	 Client
	 	 Case No.

Client Case #
	 	 Title
	 	 Country
	 	 Application

Number
	 	 Filing

Date
	 	 Status

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	[***]	 		 	 [***]
	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	 	 [***]
	 	 [***]
	 	 [***]
	 		 	 [***]
	 	 [***]

  

	*	No foreign filing planned. 

	**	To be filed in EPO only. 

  
 Exhibit C - 1

  

			
	[***]	 	Information has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted
portions.

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
  

													
	 Client
	 	 Case No.

Client Case #
	 	 Title
	 	 Country
	 	 Application

Number
	 	 Filing

Date
	 	 Status

	[***]	 	 [***]
	 	 [***]
	 	[***]	 		 	 [***]
	 	[***]
	[***]	 	 [***]
	 	 [***]
	 	[***]	 		 	 [***]
	 	[***]
	[***]	 	 [***]
	 	 [***]
	 	[***]	 		 	 [***]
	 	[***]
	[***]	 	 [***]
	 	 [***]
	 	[***]	 		 	 [***]
	 	[***]
	[***]	 	 [***]
	 	 [***]
	 	[***]	 		 	 [***]
	 	[***]
	[***]	 	 [***]
	 	 [***]
	 	[***]	 		 	 [***]
	 	[***]
	[***]	 	 [***]
	 	 [***]
	 	[***]	 		 	 [***]
	 	[***]
	[***]	 	 [***]
	 	 [***]
	 	[***]	 		 	 [***]
	 	[***]

  

	*****	Fluidigm’s rights (including prosecution rights) have been sublicensed to Artemis Health with respect to sequencing. 

  
 Exhibit C - 2

  

			
	[***]	 	Information has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted
portions.

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

Confidential 
  

Exhibit D 

Description of Current Fluidigm Technology 
 [Attached] 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 Exhibit D - 1

 Exhibit D 
 BioMark Real-Time System 

 

 

 Fluidigm® 
 BioMarkTM Real-Time PCR System 
 HIGH-THROUGHPUT
GENETIC ANALYSIS 
 Gene Expression 
 SNP Genotyping 
 Digital PCR 

Real-Time PCR ANALYSIS 
 Genotyping ANALYSIS 
 Digital PCR ANALYSIS

 Fluidigm 
 The BioMark system comes with a suite of software applications: 
 Real-time PCR, SNP genotyping, and digital PCR. 

The BioMark Real-Time PCR System sets the new standard for high throughput real-time qPCR assays, integrating thermal
cycling and flourescence detection on Digital ArrayTM IFCs and Dynamic ArrayTM IFCs. The BioMark system – together with the IFC Controller for integrated fluidic circuit (IFC) loading – streamlines workflow for applications demanding
sensitivity and dynamic range, at extremely high throughput. 
 Key Benefits - 

Real-time and end-point detection of PCR assays on Fluidigm IFCs 

Powerful, easy to use software for gene expression, SNP genotyping, and digital PCR 

Compatibility with your 5’ nuclease assays 
 High-Throughput Real-Time Detection 
 The system
integrates thermal cycling and detection of PCR assays for all Dynamic Array IFCs and Digital Array IFCs. It acquires data for each reaction chamber on the IFC simultaneously and can operate in either end-point or real-time detection mode.

 Analysis Software 
 The BioMark Real-Time PCR System is bundled with data collection and data analysis software. Real-Time PCR Analysis Software displays the analyzed data in multiple formats, including
color-coded maps of every reaction chamber on the IFC, amplification curves, and numeric tables. Results may be easily managed, annotated, and archived. 
 5’ Nuclease Assays 
 Because the BioMark
system is designed for licensed 5’ nuclease assays, laboratories may easily switch to Dynamic Array IFCs and Digital Array IFCs for PCR while continuing to use their tried and true reagents and protocols. Also, the entire system, from the
footprint of the chips to the architecture of analysis and database software, adheres to industry standards, ensuring integration with established workflows. 
 BioMark 

 

 

 BioMark Real-Time PCR System 

CCD Camera 
 Specifications 
 PARALLEL REACTIONS 

Real-Time qPCR 2,304 / 9,216* 
 SNP Genotyping 2,304 / 9,216* 
 Digital PCR 9,180 /
36,960 
 COMPONENTS 
 PARAMETER 
 Excitation filters 485-20, 530-20,
580-25 
 (center-width, in nm) (two empty positions) 

Emission filters 525-25, 570-30, 645-75 
 (center-width, in nm) (two empty positions) 
 CCD
camera 9 MPixel, 12 um x 12 urn pixel size 
 Illumination 300-watt Xenon arc lamp 

Thermal control 4°C-99°C range 
 Heating (65°C-90°C) > 2°C/sec 

Cooling (90°C-65°C) > 1°C/sec 
 Software BioMark Real-Time PCR Analysis software 

BioMark Genotyping Analysis software 
 BioMark Digital PCR Analysis software 
 BioMark
Data Collection software 
 Computer and accessories Windows XP, having at least 512 MB memory, 40 GB hard drive,
4 USB ports, LCD flat screen monitor, keyboard and mouse, CD-RW/DVD-ROMData 
 Data storage 1 GB/sec Ethernet
connection 
 40 GB hard disk space 
 Read-write DVD 
 USB port for memory stick

 * Number of parallel reactions depends on IFC architecture, either the 48.48 Dynamic Array IFC or 96.96
Dynamic Array IFC. 
 Xenon Lamp with Excitation Filter Wheel 

Emission Filter Wheel 
 Lenses 
 Thermal Control with Vacuum 

Interface to IFC 
 Light Tight Box 
 The BioMark Real-Time PCR System
is comprised of a thermal cycler, high-end optics, and a high-resolution camera that ensure reliable instrument performance. 
 Fluidigm System for Genetic Analysis 
 Dynamic
ArrayTM IFCs 
 Consumable IFCs for high-throughput gene expression analysis and SNP genotyping. 

Digital ArrayTM IFCs 
 Consumable IFCs for digital PCR. 
 IFC Controller

 Integrated hardware/software for loading IFCs. 

FC1TM Cycler 
 Integrated hardware/software for thermal cycling of IFCs. 
 EP1TM Reader | Real-Time PCR System 
 Integrated
hardware/software for detection of fluorescent signal within IFCs. 
 Software Suite 

Analysis software for gene expression analysis, SNP genotyping, and digital PCR. 

Service Plans 
 Hardware service and software maintenance plans. 

Gene Expression 
 SNP Genotyping 
 Digital PCR 

BioMark 
 Corporate Headquarters 
 Fluidigm Corporation

 7000 Shoreline Court, Suite 100 
 South San Francisco, CA 94080 USA 
 Toll-free:
1.866.FLUIDLINE 
 Fax: 650.871.7152 
 www.fluidigm.com 
 Sales 

North America 
 650.266.6170 | biomark@fluidigm.com 
 Europe/EMEA

 +33 1 60 92 42 40 | biomarkeurope@fluidigm.com 

Japan/Korea 
 +81 3 3555 2351 | biomarkasia@fluidigm.com 
 Asia

 +65 9431 3790 | biomarkasia@fluidigm.com 

© Fluidigm Corporation. All rights reserved. 
 Fluidigm, the Fluidigm logo, BioMark, EP1, FC1, Digital Array, Dynamic Array, and FLUIDLINE are trademarks or registered trademarks of Fluidigm Corporation in the U.S. and/or other
countries. All other trademarks are the property of their respective owners. Fluidigm recommends that you only purchase TaqMan® dual-labeled probes and/or other licensed PCR assay reagents from authorized sources. 

FOR RESEARCH USE ONLY. 
 MRKT00079h 

 EP1 Reader 

 

 

 Fluidigm 
 EP1TM Reader 
 END POINT DETECTION OF PCR ASSAYS ON
DYNAMIC ARRAYS AND DIGITAL ARRAYS 
 SNP Genotyping 

Digital PCR 
 The Fluidigm EP1 Reader opens the door to the power of integrated fluidic circuits (IFCs) for high-throughput SNP genotyping and digital PCR. The EP1 Reader is part of a cost-effective
system to streamline the entire workflow, from the setup of Dynamic ArrayTM IFCs and Digital ArrayTM IFCs to PCR thermal cycling, endpoint detection, and data analysis. Its economy and flexibility will make it a mainstay in any research lab.

 Key Benefits - 
 An economical solution for high throughput SNP genotyping 
 A modular system design that is easily scalable 

Data analysis with a powerful and easy to use suite of software 

Scalable with Your Research 
 As your research grows, the throughput of your EP1 system can be expanded, too. Simply add IFC Controllers and FC1TM Cyclers to scale up the number of experiments per day on a single EP1
Reader. 
 Powerful Analysis Software 
 The EP1 Reader is bundled with data collection and analysis software for SNP genotyping and digital PCR. Genotyping Analysis Software is user friendly and displays results in multiple
formats, including scatter plots, heat maps, and tabular reports. Digital PCR Software allows automated analysis to easily determine copy number variations (CNVs) among samples. 

Compatible with Your Existing Reagents and Protocols 

The EP1 system is designed for licensed 5’ nuclease assays. Therefore, laboratories may easily switch to genotyping
on Dynamic Array IFCs without the inconvenience of switching their reagents and protocols. 
 Genotyping ANALYSIS

 Fluidigm 
 Digital PCR ANALYSIS 
 Fluidigm 

The EP1 system includes a suite of software for SNP genotyping and digital PCR. 

FLUIDIGM EPT 
 GENETIC ANALYSIS 

 

 

 EP1TM Reader 
 HIGH PERFORMANCE PCR PRODUCT NEWS 
 Specifications

 PARALLEL REACTIONS 
 SNP Genotyping 2,304/9,216* 
 Digital PCR
9,180/36,960 
 COMPONENTS 
 PARAMETER 
 Excitation filters (center-width, in
nm) 485-20, 530-20, 580-25 
 Emission filters (center-width, in nm) 525-25, 570-30, 630-30 

Illumination 175-watt Xenon arc lamp 
 Software Data Collection software 
 Genotyping
Analysis software 
 Digital PCR Analysis software 

Computer Windows XP, having at least 512 MB and accessories memory, 40+GB hard drive, USB ports, LCD flat screen monitor,
keyboard, mouse 
 * Number of parallel reactions depends on IFC architecture, either the 48.48 Dynamic Array IFC
or 96.96 Dynamic Array IFC. 
 Fluidigm System for Genetic Analysis 

Dynamic ArrayTM IFCs 
 Consumable IFCs for high-throughput gene expression analysis and SNP genotyping. 
 Digital ArrayTM IFCs 
 Consumable IFCs for digital
PCR. 
 IFC Controller 
 Hardware/software for loading IFCs. 
 FC1TM Cycler

 Hardware/software for thermal cycling of IFCs. 

EP1TM Reader | Real-Time PCR System 
 Hardware/software for detection of fluorescent signal within IFCs. 
 Software Suite 
 Analysis software for gene
expression analysis, SNP genotyping, and digital PCR. 
 Service Plans 

Hardware service and software maintenance plans. 
 Fast and Easy Work Flow 
 Thermal 

1 Prime 2 Transfer 3 Load 4 Cycle 5 Read 6 Analyze 

Prime the IFC to prepare for samples and assays. 
 Transfer samples and assays into separate inlets on the IFC. 
 Place the IFC on the IFC controller to automatically setup reaction chambers. 
 Place the IFC onto the FC1 Cycler and start the PCR protocol. 
 Place the IFC on the EP1 Reader for fluorescence detection. 
 Use analysis software to view and interact with results for the run or for multiple runs. 
 Fluidigm® 
 Corporate Headquarters 

Fluidigm Corporation 
 7000 Shoreline Court, Suite 100 
 South San
Francisco, CA 94080 USA 
 Toll-free: 1.866.FLUIDLINE 

Fax: 650.871.7152 
 www.fluidigm.com 
 Sales 

North America 
 650.266.6170 | biomark@fluidigm.com 
 Europe/EMEA

 +33 1 60 92 42 40 | biomarkeurope@fluidigm.com 

Japan/Korea 
 +81 3 3555 2351 | biomarkasia@fluidigm.com 
 Asia

 +65 9431 3790 | biomarkasia@fluidigm.com 

© Fluidigm Corporation. All rights reserved. 
 Fluidigm, the Fluidigm logo, BioMark, EP1, FC1, Dynamic Array, Digital Array, and FLUIDLINE are trademarks or registered trademarks of Fluidigm Corporation in the U.S. and/or other
countries. All other trademarks are the property of their respective owners. 
 Fluidigm recommends that you only
purchase TaqMan® dual-labeled probes and/or other licensed PCR assay reagents from authorized sources. 
 FOR
RESEARCH USE ONLY. 
 MRKT00123b 

 IFC Controller MX 

 

 

 Fluidigm 
 Fluidigm 
 IFC Controller MX 

- Gene Expression, 
 SNP Genotyping, 
 Digital PCR 

HIGH THROUGHPUT GENETIC ANALYSIS 
 Gene Expression SNP Genotyping Digital PCR 
 The
touch screen provides simple, intuitive controls for the IFC loading process. 
 The Fluidigm IFC Controller MX
is part of a complete system for high-throughput genetic analysis, which includes Fluidigm Dynamic ArrayTM IFCs and Digital ArrayTM IFCs as well as the instrumentation for thermal cycling and detection. With the IFC Controller MX, high-density
reactions can be setup easily and simply within the integrated fluidic circuit (IFCs), without arduous pipetting. 
 Key Benefits - 
 Automated setup of 48.48 Dynamic
Array IFCs and 12.765 Digital Array IFCs 
 Compact, fully integrated design 

Vivid touch screen display and easy-to-use software 

Easy IFC Setup 
 The IFC Controller MX automates the setup of Dynamic Array IFCs or Digital Array IFCs. After samples and assays have been pipetted into the inlets of the input frame, the IFC is placed
onto the IFC Controller MX. A few taps of the touch screen are all that are required to begin loading samples and assays into the IFCs. When setup is complete, the IFCs are thermal cycled, and the data are collected using the BioMarkTM Real-Time PCR
System or EP1TM Reader. 
 Sleek, Compact Design 

The IFC Controller MX is a fully integrated system, including built in software and a self contained gas source for
pressure-loading assay components into the IFCs. The compact design minimizes space requirements and allows labs to accommodate multiple units. 
 User Friendly Software 
 The software for the IFC
Controller MX has been designed to be simple yet powerful. Preloaded scripts are included, and navigating through menus is effortless with controls that are clear and intuitive. 

 

 

 IFC Controller MX 
 Specifications 
 IFC COMPATIBILITY 

Gene Expression Analysis 48.48 Dynamic Array IFC 
 SNP Genotyping 48.48 Dynamic Array IFC 
 Digital
PCR 12.765 Digital Array IFC 
 48.770 Digital Array IFC 

COMPONENTS 
 PARAMETER 
 Experiment tracking Barcode 

Gas pressure Internal compressor 
 Interface USB and Ethernet 
 IFC Controller MX
software Touch screen interface for 
 operating and tracking 

Dimensions (approx.) 19 x 9.5 x 13 inches 
 48.5 x 24 x 33 cm 
 Fluidigm System for Genetic
Analysis 
 Dynamic ArraysTM IFCs 
 Consumable IFCs for high-throughput gene expression analysis and SNP genotyping. 
 Digital ArraysTM IFCs 
 Consumable IFCs for digital
PCR. 
 IFC Controller 
 Hardware/software for loading IFCs. 
 FC1TM Cycler

 Hardware/software for thermal cycling of IFCs. 

EP1TM Reader | Real-Time PCR System 
 Hardware/software for detection of fluorescent signal within IFCs. 
 Software Suite 
 Analysis software for gene
expression analysis, SNP genotyping, and digital PCR. 
 Service Plans 

Hardware service and software maintenance plans. 
 Gene Expression 
 SNP Genotyping 

Digital PCR 
 Fluidigm 
 Corporate Headquarters 

Fluidigm Corporation 
 7000 Shoreline Court, Suite 100 
 South San
Francisco, CA 94080 USA 
 Toll-free: 1.866.FLUIDLINE 

Fax: 650.871.7152 
 www.fluidigm.com 
 Sales 

North America 
 650.266.6170 | biomark@fluidigm.com 
 Europe/EMEA

 +33 1 60 92 42 40 | biomarkeurope@fluidigm.com 

Japan/Korea 
 +81 3 3555 2351 | biomarkasia@fluidigm.com 
 Asia

 +65 9431 3790 | biomarkasia@fluidigm.com 

© Fluidigm Corporation. All rights reserved. Fluidigm, the Fluidigm logo, BioMark, EP1, FC1, Dynamic Array, Digital
Array, and FLUIDLINE are trademarks or registered trademarks of Fluidigm Corporation in the U.S. and/or other countries. All other trademarks are the property of their respective owners. 

Fluidigm recommends that you only purchase TaqMan® dual-labeled probes and/or other licensed PCR assay reagents from

 authorized sources. 
 FOR RESEARCH USE ONLY 
 MRKT00108b 

 IFC Controller HX 

 

 

 Fluidigm 
 Fluidigm 
 IFC Controller HX 

- Gene Expression and SNP Genotyping 
 HIGH THROUGHPUT GENETIC ANALYSIS 
 Gene Expression

 SNP Genotyping 
 Fluidigm 
 IFC CONTROLLER 

The IFC Controller HX offers a vivid touch screen and easy to use controls. 

The Fluidigm IFC Controller HX is part of a complete system for high-throughput genetic analysis, including 96.96 Dynamic
ArrayTM IFCs, instrumentation for thermal cycling and fluorescence detection, and data analysis software for SNP genotyping and gene expression. With the IFC Controller HX, 9,216 reactions can be setup quickly and easily within integrated fluidic
circuit (IFCs). 
 Key Benefits - 
 Automated setup of 96.96 Dynamic Array IFCs 

Significantly fewer liquid handling steps compared to conventional platforms 

Self-contained and fully integrated design 
 Easy Setup of 96.96 Dynamic Array IFCs 
 After
samples and assays have been pipetted into the inlets of the input frame of the 96.96 Dynamic Array IFC, the Dynamic Array IFC is placed onto the IFC Controller HX. Because the software interface is simple yet powerful, a few taps of the touch
screen are all that’s required to begin loading samples and primer-probe sets. 
 Minimal Liquid Handling
Steps 
 The IFC Controller HX – in conjunction with a single 96.96 Dynamic Array IFC – facilitates the
setup of 9,216 parallel PCR reactions using only 192 liquid handling steps. This represents a significant savings in time and resources when compared to conventional platforms for genetic analysis. 

Compact Design With User Friendly Software 
 The IFC Controller HX is a compact single-bay unit that includes built-in software and a self-contained gas source for pressure-loading assay components into IFCs. Because the IFC
Controller HX takes up minimal space, labs can accommodate multiple units to increase chip-loading capacity. 

 

 

 IFC Controller HX 
 Specifications 
 IFC COMPATIBILITY 

Gene Expression Analysis 96.96 Dynamic Array IFC 
 SNP Genotyping 96.96 Dynamic Array IFC 
 COMPONENTS

 PARAMETER 
 Experiment tracking Barcode 
 Gas pressure Internal
compressor 
 Interface USB and Ethernet 
 IFC Controller HX software Touch screen interface for 
 operating and tracking 
 Dimensions (approx.) 19 x
9.5 x 13 inches 
 48.5 x 24 x 33 cm 
 Fluidigm System for Genetic Analysis 
 Dynamic
ArrayTM IFCs 
 Consumable IFCs for high-throughput gene expression analysis and SNP genotyping. 

Digital ArrayTM IFCs 
 Consumable IFCs for digital PCR. 
 IFC Controller

 Hardware/software for loading IFCs. 
 FC1TM Cycler 
 Hardware/software for thermal
cycling of IFCs. 
 EP1TM Reader | Real-Time PCR System 

Hardware/software for detection of fluorescent signal within IFCs. 

Software Suite 
 Analysis software for gene expression analysis, SNP genotyping, and digital PCR. 
 Service Plans 
 Hardware service and software
maintenance plans. 
 Gene Expression 
 SNP Genotyping 
 Fluidigm 

Corporate Headquarters 
 Fluidigm Corporation 
 7000 Shoreline Court, Suite
100 
 South San Francisco, CA 94080 USA 
 Toll-free: 1.866.FLUIDLINE 
 Fax: 650.871.7152

 www.fluidigm.com 
 Sales 
 North America 

650.266.6170 | biomark@fluidigm.com 
 Europe/EMEA 
 +33 1 60 92 42 40 |
biomarkeurope@fluidigm.com 
 Japan/Korea 

+81 3 3555 2351 | biomarkasia@fluidigm.com 
 Asia 
 +65 9431 3790 | biomarkasia@fluidigm.com

 © Fluidigm Corporation. All rights reserved. 

Fluidigm, the Fluidigm logo, BioMark, EP1, FC1, Dynamic Array, Digital Array, and FLUIDLINE are trademarks or registered
trademarks of Fluidigm Corporation in the U.S. and/or other countries. All other trademarks are the property of their respective owners. 
 Fluidigm recommends that you only purchase TaqMan® dual-labeled probes and/or other licensed PCR assay reagents from authorized sources. 

FOR RESEARCH USE ONLY. 
 MRKT00109b 

 96.96 Dynamic Array IFC 

 

 

 fluidigim® 
 96.96 Dynamic ArrayTM IFC 
 – Gene
Expression 
 HIGH-THROUGHPUT MULTIPLEX PCR 

The Fluidigm 96.96 Dynamic Array IFC – Gene Expression provides the flexibility of a microwell plate and the density
of a microarray in one easy-to-use, consumable integrated fluidic circuit (IFC). 
 Key Benefits –

 Easy multiplexing of 96 primer-probe sets against 96 samples 

9,216 individual data points per Dynamic Array IFC 

192 liquid-transfer steps per 9,216 reactions, with complete setup flexibility 

The New Standard in High Throughput Profiling Fluidigm Dynamic Array IFCs radically reduce the cost per data point and
time to results while radically raising the bar for parallel throughput. The chart below shows parameters to complete a study of 2,000 samples against 96 genes using 384-well plates compared to 96.96 Dynamic Array IFCs: 

Gene expression results may be viewed as real-time curves and as a heat map showing 9,216 reactions per run. 

384-WELL MICROPLATES 96.96 DYNAMIC ARRAY IFCS 
 TOTAL RUNS 500 21 
 REACTIONS PER RUN 384 9,216

 TOTAL LIQUID-TRANSFER STEPS 384,000 4,032 

TOTAL MASTER MIX 960 ml 5.1 ml 
 The Power of Microfluidics 
 With a Dynamic Array
IFC, high-throughput multiplexing is easy because the microfluidic architecture does the work of combining samples and primer-probe sets into 9,216 PCR reactions. That’s twenty four-fold more data than is produced by a 384-well plate. This
radical advance in experiment density is fully leveraged through a hardware/software system that automates setup and data analysis. 

 

 

 96.96 Dynamic Array IFC – Gene Expression 

Specifications 
 PARAMETER 
 Quantitative resolution 2-fold
difference in starting copy 
 with 99.7 % confidence and 6-log of dynamic range 

Chip format SBS Compatible 
 (128 mm x 85 mm x 14 mm) 
 Inlet spacing on input
frame 4.5 mm pitch 
 Liquid transfer steps 192 

Primer-probe inlets 96 
 Sample inlets 96 
 Reaction chambers 9,216

 Reaction volume 6.7 nl 
 Instrument compatibility BioMark Real-Time PCR System, 
 IFC Controller HX Fluidigm System for Genetic Analysis 
 Dynamic ArrayTM IFCs 
 Consumable IFCs for
high-throughput gene expression analysis and SNP genotyping. 
 Digital ArrayTM IFCs 

Consumable IFCs for digital PCR. 
 IFC Controller 
 Integrated hardware/software for
loading IFCs. 
 FC1TM Cycler 
 Integrated hardware/software for thermal cycling of IFCs. 
 EP1TM Reader | Real-Time PCR System 

Integrated hardware/software for detection of fluorescent signal within IFCs. 

Software Suite 
 Analysis software for gene expression analysis, SNP genotyping, and digital PCR. 
 Service Plans 
 Hardware service and software
maintenance plans. 
 Work Flow 
 1 Prime 2 Transfer 3 Load 4 Run 5 Analyze 
 Prime
the Pipette samples, Place the Dynamic Place the Dynamic Use real-time 
 Dynamic Array premixed with Array IFC
on the Array IFC on the qPCR Analysis 
 IFC to close the master mix, into IFC controller, and BioMark Real-Time
software to view 
 interface valves, separate sample use the software PCR System for and to interact 

preventing inlets and the interface to pressure thermal cycling with amplification 

premature mixing primer-probe load the assay and fluorescence curves, color- 

of samples sets into separate components into detection. coded heat maps, 

and assays. primer-probe reaction chambers. and Ct data for the 

inlets on the IFC. Assay components run. 
 are automatically 
 combined on-chip. 

For Use with Gold-Standard PCR Assays The BioMark system runs licensed 5’ nuclease assays, so it integrates easily
into established workflow. The footprint of the Dynamic Array IFC and spacing of fluid inlets comply with SBS* standards, so the laboratory may continue to use existing liquid-handling equipment. Fluidigm has adopted SBS standards for all of its
systems, ensuring compatibility of BioMark instrumentation with higher density IFCs in future releases. 
 * The
Society for Biomolecular Sciences 
 Fluidigm® 

Corporate Headquarters 
 Fluidigm Corporation 7000 Shoreline Court, Suite 100 South San Francisco, CA 94080 USA Toll-free: 1.866.FLUIDLINE Fax: 650.871.7152 www.fluidigm.com 

Sales 
 North America 650.266.6170 | biomark@fluidigm.com Europe/EMEA 
 +33 1 60 92 42 40 | biomarkeurope@fluidigm.com 

Japan/Korea 
 +81 3 3555 2351 | biomarkasia@fluidigm.com 
 Asia

 +65 9431 3790 | biomarkasia@fluidigm.com 

© Fluidigm Corporation. All rights reserved. Fluidigm, the Fluidigm logo, BioMark, EP1, FC1, Dynamic Array, Digital
Array, and FLUIDLINE are trademarks or registered trademarks of Fluidigm Corporation in the U.S. and/or other countries. All other trademarks are the property of their respective owners. Fluidigm recommends that you only purchase TaqMan®
dual-labeled probes and/or other licensed PCR assay reagents from 
 authorized sources. FOR RESEARCH USE ONLY.

 MRKT00110b 

 48.770 Digital Array IFC 

 

 

 fluidigm® 
 48.770 Digital ArrayTM IFC 
 – Digital PCR

 INDIVIDUAL MOLECULE QUANTIFICATION 
 Copy Number Variation Studies — 
 Absolute
Quantification — 
 Mutation Detection — 

The Fluidigm 48.770 Digital Array Integrated Fluidic Circuit (IFC) delivers high-throughput digital PCR — the most
powerful technique for individual molecule quantification. The 48.770 Digital Array IFC enables up to 48 individual samples to be tested at a time. 
 Key Benefits – 
 Unique – the only
commercially proven solution for digital PCR. 
 High throughput – up to 48 samples per run. 

Accurate – detection and quantification for individual molecules. 

The Power of Digital PCR 
 Digital PCR significantly improves the performance of standard PCR assays. Therefore, resolution is higher for CNV experiments, selectivity is better for mutation detection, and molecule
quantification is absolute. 
 Panel24-02D1H- 

Each bright spot indicates a positive PCR reaction. The total number of positives is used to calculate the number of
target molecules in an individual sample. Forty eight samples can be tested on a single 48.770 Digital Array IFC. 

 

 

 48.770 Digital Array IFC – Digital PCR 

Specifications 
 PARAMETER 
 Detection sensitivity Single copy (if
copy is present in the reaction chamber) 
 Footprint dimensions 128 mm x 85 mm x 14 mm 

Inlet spacing on input frame 4.5 mm pitch 
 Minimum input volume/sample 4 uL (48 samples per array) 
 Liquid transfer steps 48 
 Sample inlets 48

 Reactions per sample 770 
 Total reaction chambers 36,960 
 Individual
reaction volume 0.84 nL 
 Total reaction volume/sample 0.65 uL (per sample) 

Instrument compatibility BioMark Real-Time PCR System, 

EP1TM Reader, IFC Controller MX 
 Fluidigm System for Genetic Analysis 
 Dynamic
ArrayTM IFCs 
 Consumable IFCs for high-throughput gene expression analysis and SNP genotyping. 

Digital ArrayTM IFCs 
 Consumable IFCs for digital PCR. 
 IFC Controller

 Integrated hardware/software for loading IFCs. 

FC1TM Cycler 
 Hardware/software for thermal cycling of IFCs. 

EP1TM Reader | Real-Time PCR System 
 Integrated hardware/software for detection of fluorescent signal within IFCs. 
 Software Suite 
 Analysis software for gene
expression analysis, SNP genotyping, and digital PCR. 
 Service Plans 

Hardware service and software maintenance plans. 
 Digital Accuracy — Fast, Easy, and Reliable The 48.770 Digital Array IFC uses IFC technology to automatically partition each of the 48 samples into 770 PCR reactions (36,960
individual qPCR reactions). This partitioning, of as little as 4 uL of total reaction volume, eliminates the need for time consuming pipetting steps while minimizing reagent costs. Digital Array IFCs are compatible with off-the-shelf reagents and
standard SBS* format dispensing layouts. 
 48.770 Digital Array Work Flow 

DNA 1 Prime. 
 00:20 
 2 Dispense. Pipette DNA samples, premixed
with 
 master mix and primer-probe sets, into inlets on the 

00:25 IFC. 
 3 Load. Place the Digital Array IFCs on the IFC 

controller to automatically load the sample mixture 00:55 into reaction chambers. 

4 Run. Place the Digital Array IFC on the BioMark Real-Time qPCR System (or FC1 Cycler and EP1 Reader) 03:20 for thermal
cycling and fluourescence detection. 
 Analyze. Use Digital PCR Analysis software to count 5 the number of
positive PCR reactions per sample and calculate the sample concentration. 
 * Society of Biomolecular Sciences

 Corporate Headquarters 
 Fluidigm® 
 Fluidigm Corporation 7000 Shoreline
Court, Suite 100 South San Francisco, CA 94080 USA Toll-free: 1.866.FLUIDLINE Fax: 650.871.7152 www.fluidigm.com 

Sales 
 North America 650.266.6170 | biomark@fluidigm.com Europe/EMEA 
 +33 1 60 92 42 40 | biomarkeurope@fluidigm.com 

Japan/Korea 
 +81 3 3555 2351 | biomarkasia@fluidigm.com 
 Asia

 +65 9431 3790 | biomarkasia@fluidigm.com 

© Fluidigm Corporation. All rights reserved. Fluidigm, the Fluidigm logo, BioMark, EP1, FC1, Dynamic Array, Digital
Array, and FLUIDLINE are trademarks or registered trademarks of Fluidigm Corporation in the U.S. and/or other countries. All other trademarks are the property of their respective owners. Fluidigm recommends that you only purchase TaqMan®
dual-labeled probes and/or other licensed PCR assay reagents from 
 authorized sources. FOR RESEARCH USE ONLY
MRKT00132b 

 FC1 Cycler 

 

 

 Fluidigm® 
 Fluidigm FC1TM Cycler 
 THERMAL CYCLING ON
DYNAMIC ARRAY AND DIGITAL ARRAY IFCS 
 SNP Genotyping 

Digital PCR 
 The FC1 Cycler is specially designed for PCR on Fluidigm integrated fluidic circuits. 
 The Fluidigm FC1 Cycler provides thermal cycling for high sample throughput SNP genotyping and digital PCR applications on Fluidigm integrated fluidic circuits (IFCs). 

Key Benefits – 
 Fast thermal cycling for SNP genotyping applications 
 Scalability of throughput 
 Intuitive, easy-to-use
interface 
 Faster Time-to-Results 
 The FC1 Cycler is capable of fast thermal cycling protocols to greatly increase throughput of Fluidigm IFCs. After PCR is complete, the IFC is placed on the Fluidigm EP1TM Reader or
BioMarkTM Real-Time PCR System for end-point data collection. The entire workflow, from loading the IFC to end point detection, is complete in a matter of hours with only minutes of hands-on time. 

Scalable Throughput 
 The FC1 Cycler, together with IFC Controller, provide a modular solution for scaling throughput according to laboratory needs. Simply adding FC1 Cyclers greatly increases capacity without
modifying the existing platform. 
 Easy-to-Use Controls 

The FC1 Cycler offers a streamlined design, including a self-contained vacuum source, to minimize lab space requirements
and maximize productivity. A touchscreen interface with intuitive controls offers easy editing of thermal protocols. 

 

 

 Fluidigm FC1 Cycler 
 HIGH PERFORMANCE PCR PRODUCT NEWS 
 Specifications

 IFC COMPATIBILITY 
 SNP Genotyping 48.48 and 96.96 Dynamic ArrayTM IFCs 
 Digital PCR 12.765 Digital ArraysTM IFCs 

COMPONENTS 
 PARAMETER 
 Dimensions (approx.) 9 x 8 x 19 in.

 23 x 20 x 48 cm 
 Software Touchscreen interface for 
 operation and
protocol editing 
 Vacuum Source Internal vacuum pump 

Voltage 100-230V, 50-60 Hz 
 THERMAL CONTROL 
 Temperature range 4°C to
99°C 
 Max Heating Rate >5°C/sec 

Max Cooling Rate >5°C/sec Fluidigm System for Genetic Analysis 

Dynamic Array IFCs 
 Consumable IFCs for high-throughput gene expression analysis and SNP genotyping. 
 Digital Array IFCs 
 Consumable IFCs for digital
PCR. 
 IFC Controller 
 Hardware/software for loading IFCs. 
 FC1TM
Cycler 
 Hardware/software for thermal cycling of IFCs. 

EP1TM Reader | BioMarkTM Real-Time PCR System Hardware/software for detection of fluorescent signals within IFCs.

 Software Suite 
 Analysis software for gene expression analysis, SNP genotyping, and digital PCR. 
 Service Plans 
 Hardware service and software
maintenance plans. 
 Fast and Easy Work Flow 

Thermal 
 1 Prime 2 Transfer 3 Load 4 Cycle 5 Read 6 Analyze 

Prime the IFC Transfer Place the IFC Place the IFC Place the IFC Use analysis 

to prepare for samples and on the IFC onto the FC1 on the EP1 software to 

samples and assays into controller to Cycler and Reader for view and 

assays. separate inlets automatically start the PCR fluorescence interact with 

on the chip. setup reaction protocol. detection. results for 

chambers. the run or for 
 multiple runs. 
 Fluidigm® 

Corporate Headquarters 
 Fluidigm Corporation 7000 Shoreline Court, Suite 100 South San Francisco, CA 94080 USA Toll-free: 1.866.FLUIDLINE Fax: 650.871.7152 www.fluidigm.com 

Sales 
 North America 650.266.6170 | biomark@fluidigm.com Europe/EMEA 
 +33 1 60 92 42 40 | biomarkeurope@fluidigm.com 

Japan/Korea 
 +81 3 3555 2351 | biomarkasia@fluidigm.com 
 Asia

 +65 9431 3790 | biomarkasia@fluidigm.com 

© Fluidigm Corporation. All rights reserved. Fluidigm, the Fluidigm logo, BioMark, EP1, FC1, Dynamic Array and
Digital Array are trademarks or registered trademarks of Fluidigm Corporation in the U.S. and/or other countries. All other trademarks are the property of their respective owners. Fluidigm recommends that you only purchase TaqMan® dual-labeled
probes and/or other licensed PCR assay reagents 
 from authorized sources. FOR RESEARCH USE ONLY. MRKT00145

 Stand-Alone Thermal Cycler 

 

 

 fluidigm® 
 Stand-Alone Thermal Cycler 
 THERMAL CYCLING ON
DYNAMIC ARRAYS 
 AND DIGITAL ARRAYS 
 SNP Genotyping — 
 Digital PCR —

 The Fluidigm Stand-Alone Thermal Cycler (STC) provides an ideal solution for end-point PCR assays on Fluidigm
integrated fluidic circuits (IFCs). 
 Key Benefits – 

Highly efficient workflow for SNP genotyping or digital PCR 

Scalability of throughput 
 Familiar, easy-to-use interface 
 Fast
Time-to-Results 
 After PCR is complete, the integrated fluidic circuit — either a dynamic array or digital
array — is placed on the Fluidigm EP1TM Reader or BioMarkTM Real-Time PCR System for end-point data collection. Final results are available in a matter of hours, yet the hands-on time is only minutes. 

Scalable Throughput 
 The Stand-Alone Thermal Cycler, together with the EP1 Reader or BioMark system, provides a modular solution for scaling throughput according to laboratory needs. Simply adding STC units
greatly increases capability without modifying the basic platform. 
 Easy-to-Use Controls 

The STC consists of a standard thermal cycler and a vacuum accessory to accommodate IFCs. As such, its use will be
familiar to anyone running PCR assays. 
 The Stand-Alone Thermal Cycler is specially designed for PCR on
Fluidigm integrated fluidic circuits. 

 

 

 Stand-Alone Thermal Cycler 

HIGH PERFORMANCE PCR PRODUCT NEWS 
 Specifications 
 IFC COMPATIBILITY 

SNP Genotyping 48.48 and 96.96 Dynamic Arrays 
 Digital PCR 12.765 Digital Arrays 
 COMPONENTS

 PARAMETER 
 Dimensions (approx.) 10 x 14.5 x 14 in. 25.4 x 37 x 35.5 cm 
 Software Built-in control software 
 Interface
Electronic Display and Touchpad 
 Vacuum Accessory Included with the system 

Electrical Region-specific power settings 
 requirements Fluidigm System for Genetic Analysis 

Dynamic Arrays 
 Consumable IFCs for high-throughput gene expression analysis and SNP genotyping. 
 Digital Arrays 
 Consumable IFCs for digital PCR.
IFC Controller 
 Integrated hardware/software for loading IFCs. 

Stand-Alone Thermal Cycler 
 Integrated hardware/software for thermal 
 cycling
of IFCs. 
 EP1 Reader bar Real-Time PCR System Integrated hardware/software for detection of fluorescent signal
within IFCs. 
 Software Suite 
 Analysis software for gene expression analysis, SNP genotyping, and digital PCR. 
 Service Plans 
 Hardware service and software
maintenance plans. 
 Fast and Easy Work Flow 

Thermal 
 1 Prime 2 Transfer 3 Load 4 Thermal Cycle 5 Read 6 Analyze 
 Prime the IFC Transfer Place the IFC Place the IFC Place the IFC Use analysis 
 to prepare for samples and on the IFC onto the Stand- on the EP1 software to 
 samples and assays into controller to Alone Thermal Reader for view and 
 assays. separate inlets automatically Cycler and fluorescence interact with 
 on the chip. setup reaction start the PCR detection. results for 
 chambers. protocol. the run or for 
 multiple runs.

 Practice of the patented polymerase chain reaction (PCR) process requires a license. The Mastercycler is an
Authorized Thermal Cycler and may be used with PCR licenses available from Applied Biosystems. Its use with Authorized Reagents also provides a limited PCR license in accordance with the label rights accompanying such reagents. 

Corporate Headquarters 
 Fluidigm Corporation 7000 Shoreline Court, Suite 100 South San Francisco, CA 94080 USA Toll-free: 1.866.FLUIDLINE Fax: 650.871.7152 www.fluidigm.com 

Sales 
 North America 650.266.6170 | biomark@fIuidigm.com Europe/EMEA 
 +31 20 578 8853 | biomarkeurope@fluidigm.com 

Japan/Korea 
 +81 3 3555 2351 | biomarkasia@fluidigm.com 
 Asia

 +65 9431 3790 | biomarkasia@fluidigm.com 

© Fluidigm Corporation. All rights reserved. Fluidigm, the Fluidigm logo, BioMark, EP1, SlingShot, and FLUIDLINE are
trademarks or registered trademarks of Fluidigm Corporation in the U.S. and/or other countries. All other trademarks are the property of their respective owners. Fluidigm recommends that you only purchase TagMan® dual-labeled probes and/or other
licensed PCR assay reagents from authorized sources. FOR RESEARCH USE ONLY. 
 MRKT00124 

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 Exhibit E 

Fluidigm Patents 
  

													
	 Client
	 	 Case No.

Client Case #
	 	 Title
	 	 Country
	 	 Application

Number
	 	 Filing

Date
	 	 Status

	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]

  
 Exhibit E - 1

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 

													
	 Client
	 	 Case No.

Client Case #
	 	 Title
	 	 Country
	 	 Application

Number
	 	 Filing

Date
	 	 Status

	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]

  
 Exhibit E - 2

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 

													
	 Client
	 	 Case No.

Client Case #
	 	 Title
	 	 Country
	 	 Application

Number
	 	 Filing

Date
	 	 Status

	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]

  
 Exhibit E - 3

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 

													
	 Client
	 	 Case No.

Client Case #
	 	 Title
	 	 Country
	 	 Application

Number
	 	 Filing

Date
	 	 Status

	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]

  
 Exhibit E - 4

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 

													
	 Client
	 	 Case No.

Client Case #
	 	 Title
	 	 Country
	 	 Application

Number
	 	 Filing

Date
	 	 Status

	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]

  

	*	No foreign filing planned. 

  
 Exhibit E - 5

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 

													
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 		 	
	 Fluidigm Corporation (FLUIDIGM)
	 	[***]	 	[***]	 	[***]	 		 		 	
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 		 	[***]	 	[***]

  

	*	No foreign filing planned. 

	**	To be filed in EPO only. 

	***	To be filed in EPO and SG only. 

	****	Undetermined but foreign filing in EPO likely. 

  
 Exhibit E - 6

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 

													
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  

	*****	Fluidigm’s rights (including prosecution rights) have been sublicensed to Artemis Health with respect to sequencing. 

  
 Exhibit E - 7

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 

													
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

  
 Exhibit E - 8

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

Confidential 
  

Exhibit F 

License Agreement 

Incorporated by reference to Exhibit 10.22 to the registrant’s Registration Statement on Form S-1 filed with the Securities and Exchange
Commission on January 18, 2011. 

  

  
 Exhibit F - 1

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 Confidential 

Exhibit G 

Key Supply Terms in Supply Agreement 
  

			
	Parties	  	 Supplier – Fluidigm Corporation
 Purchaser – Novartis Vaccines and Diagnostics, Inc. or its applicable Affiliate

		
	Products	  	 Commercial Chips (or such other chips for conducting digital PCR as may be mutually agreed by the parties).

 
 Fluidigm Instruments.

		
	Use of Products	  	Use of Products by Purchaser shall be limited to the Primary Field and Secondary Field.
		
	Exclusivity	  	In the Primary Field and the Secondary Field in the Territory during the term of the Supply Agreement, Supplier shall exclusively supply Purchaser with its requirements of Products,
and Purchaser shall exclusively purchase Products from Supplier (except as otherwise provided in the Supply Agreement with respect to a Failure to Supply). Such exclusivity shall not affect Supplier’s right to supply academic institutions with
Product under a restricted research only license, and Supplier’s research only rights in the Secondary Field, as permitted in the Collaboration Agreement. Purchaser shall have the right for audit of Supplier’s manufacturing facilities and
Quality Systems, including third-party facilities, with prior approval before the purchase of Fluidigm Chips and Fluidigm Instruments for clinical development and Commercial Chips and associated Fluidigm Instruments.
		
	Alternate supplier	  	Purchaser may engage a Third Party to supply Products, only to Purchaser, in (and only for use in) the Primary Field and the Secondary Field in the Territory only in the case of a
Failure to Supply that Product (as defined below). [***]
		
	Failure to Supply	  	 “Failure to Supply” a Product shall mean (a) failure of Supplier to deliver [***] of the quantity of conforming Product
ordered, to the extent Supplier was obligated to, or did, accept the order, within a reasonable time after the due date therefor in [***] calendar months, or (b) the occurrence of any event that (i) for so long as Novartis or a Novartis Affiliate is
Purchaser, Purchaser reasonably determines in good faith will render Supplier persistently and materially unable to fulfill its supply obligations under the Supply Agreement for that Product for a period of time in excess of the inventories then
held by Purchaser and Supplier of such Product, or (ii) in all other cases, will render Supplier persistently and materially unable to fulfill its supply obligations under the Supply Agreement for that Product for a period of time in excess of the
inventories then held by Purchaser and Supplier of such Product.
  
 To reduce
the likelihood of a Failure to Supply, Supplier shall qualify (from a capability of supply and quality standpoint (including quality approval by Novartis)) an alternative manufacturing location, which can but need not be owned or controlled by
Fluidigm, such location to be in a distinct geographic location from its primary manufacturing location.

		
	Shortage Allocation	  	Novartis open orders are filled on a priority basis, i.e. right of first refusal in the event of product shortages, up to the quantity for which Supplier is obligated to accept
orders under the order procedure.
		
	Quality/Documentation	  	Product shall be manufactured in accordance with the specifications for the Products and applicable law and Purchaser’s Quality System standards.
All

  
 Exhibit G - 1

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 

			
		  	 Product (and critical components) must be manufactured at a cGMP approved facility, which facility shall have been pre-approved by
Novartis in accordance with its then current quality standards. At the time of delivery, Product shall conform to the specifications therefor. Supplier shall provide appropriate certificates and import documentation to Purchaser for each unit
supplied. Purchaser shall have the right to reject any lot that does not meet agreed criteria within an agreed timeframe and request release test data at any time.
  

Purchaser’s Manufacturing Quality Agreement must be signed by the Supplier’s Quality function Representative in conjunction with the Supply
Agreement. Quality requirements including but not limited to:
  
 1.       Product shall be manufactured in accordance with the specifications for the Products and applicable law and Purchaser’s Quality System
standards.
  

2.       Manufacturing Facility, equipment and manufacturing processes and
test methods used in the manufacturing and product release must be validated for the intended purposes.
  

3.       All Product (and critical components) must be manufactured at a cGMP
approved facility, which facility shall have been pre-approved by Novartis in accordance with its then current quality standards. Where manufacturer outsources the manufacturing or warehousing to external 3rd party subcontractor(s), the same
quality standards must be applied and quality agreements must be established between the manufacturer and the 3rd party subcontractor. Purchaser shall have the rights to inspect manufacturer’s subcontractors to assure compliance to
Purchaser’s quality system requirements.
  
 4.       All changes including raw materials, manufacturing processes, test methods must be communicated to Purchaser prior to implementation of the change.

 

5.       Purchaser shall have the rights to inspect Supplier’s
manufacturing facility on an annual basis. Any nonconformity must be investigated, corrected and documented promptly.
  

6.       Key performance indicators shall be established between Supplier and
Purchaser.
  

7.       Supplier must notify Purchaser on any identified deviation and
potential failure that will affect the quality, safety and efficacy of the products in order for Purchaser to determine course of actions including potential recall and field corrections.

 

8.       At the time of delivery, Product shall conform to the specifications
therefor. Supplier shall provide appropriate certificate of conformance and import documentation to Purchaser for each unit supplied. Purchaser shall have the right to reject any lot based on agreed criteria and within an agreed timeframe
and request release test data at any time.

		
	Safety Stock	  	Purchaser and Supplier will agree upon a reasonable quantity of safety stock of Products to be held by each of the parties. Increased safety stock levels may
be

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 Exhibit G - 2

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 

															
		  	agreed above [***] requirements made for new product launches or product improvements where actual demand data is modeled and not based on historic consumption.
Purchaser bears the ultimate responsibility for eventual purchase of all safety stock (provided that such safety stock satisfies the applicable product warranties) that Purchaser does not purchase and cannot be readily sold to third parties
following a termination of the Supply Agreement by Supplier for cause or by Purchaser without cause.
		
	Forecasting	  	Commencing [***] prior to launch, Purchaser shall provide Supplier with a [***] rolling, non-binding forecast. The Supply Agreement shall include, for months [***] of
such forecast, restrictions upon the upward and downward deviations from the quantities forecast for such months in the prior forecast.
		
	Binding Orders	  	The [***] of each forecast shall be firm orders, on a rolling basis. Supplier will accept orders for volumes within [***] of the amount last forecasted for the
applicable month (provided that such forecasted amount does not vary more than an agreed percentage from certain prior forecasts, as described above), and will in any event use reasonable efforts to accept all orders.
		
	Delivery	  	All Product shall be supplied in finished, final form per Novartis’ specifications, Ex Works, ready for commercial sale.
		
	Term	  	Unless terminated, for so long as Purchaser is commercializing Products under the License Agreement or the surviving provisions thereof.
		
	Termination	  	At all times during the Term (a) for breach and insolvency; (b) by Purchaser for a Failure to Supply; or (c) automatically upon termination of the License
Agreement.
		
	Price	  	For Commercial Chips used in an IVD [***] in the Primary Field, Purchaser shall pay to Supplier a fixed fee plus a variable percentage based on the Net Sales (to be
defined in a manner analogous to the definition of Net Sales in the Collaboration Agreement, but with application of IFRS rules rather than GAAP) of the IVD [***], each as set forth in the table below.
								
		  	Number of samples per chip	  	1	  	2	  	3	  	4	  	5	  	6
								
		  	Fixed fee per sample (US$)	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
								
		  	Variable percentage	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		
		  	 For Commercial Chips in the Primary Field that are not used in an IVD [***], the price for such chips shall include a fixed
fee equal to [***] per Commercial Chip plus an [***] non-refundable royalty on Commercial Chip Net Sales and an [***] non-refundable royalty on Liquid ASR Net Sales (to be defined in a manner analogous to the definition of Net Sales in the
Collaboration Agreement, but with application of IFRS rules rather than GAAP).
  
 If a lab that is a Novartis Affiliate is generating Results using Fluidigm Products, then solely for purposes of determining Net Sales under this Exhibit

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 Exhibit G - 3

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 

																	
		  	 F and the Supply Agreement, Net Sales will be calculated based on sales of IVD [***], as applicable, by Novartis (or its
Affiliate) to such lab (on an arm’s length basis). The financial compensation to Fluidigm for the supply of Commercial Chips set forth herein is premised on the assumption that neither Novartis, nor any Novartis Affiliate to which Novartis
assigns the Supply Agreement (nor any other successor to Novartis), will itself generate Results using Fluidigm Products, and therefore no provision is required or made for compensating Fluidigm based on such activities. If Novartis (or such
Affiliate or successor) desires to generate Results using Fluidigm Products, the Parties shall negotiate and agree upon financial compensation to Fluidigm for such supply comparable to the financial compensation provided to Fluidigm for supply, as
described herein.
  
 Payment, recordkeeping, audit and related rights of
Supplier and obligations of Purchaser will mirror the Collaboration Agreement provisions.
  
 The prices for chips used in Tests in the Secondary Field shall be negotiated between Supplier and Purchaser at an appropriate time.

 
 Supplier shall supply Fluidigm Instruments (including instrument software) to
Purchaser at [***] below the previous [***].

		
	Price Adjustments	  	 If, after a successful proof of concept, Purchaser is unable to show commercial feasibility in models prior to commercial
launch, then the parties shall enter into good faith negotiations to renegotiate the chip supply pricing.
  
 The fixed fee for chips in the Primary Field shall be discounted based on sales of Commercial Chips by Supplier to Purchaser on the following schedule:

									
		  	 Yearly volume of chip sales
	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
									
		  	Volume discount off base fixed fee above	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
		
		  	If there is no applicable Valid Claim within the Fluidigm Patents (other than the Collaboration Patents) covering the sale of the applicable product (IVD [***] as
applicable) in the country of sale, then Purchaser and Supplier shall negotiate the fixed and variable (or non-refundable royalty) payments to Supplier (which rates shall be below the fixed and variable (royalty) rate that otherwise apply). Such
principle shall also apply prior to expiration of the last to expire of any such Valid Claim and such reduced rates shall take effect immediately after such expiration.

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 Exhibit G - 4

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 

			
		  	If Purchaser needs to obtain, after the Effective Date of the Collaboration Agreement, an arms’ length license from a Third Party to Exploit Fluidigm Technology in general
regardless of specific assay (including the performance of digital PCR using the Fluidigm Products), provided that such Fluidigm Technology is incorporated or used in Licensed Products sold by Purchaser or by a Third Party, Purchaser shall be
able to deduct [***] of Third Party royalties paid by Purchaser for a Licensed Product unit from the variable percentage (or non-refundable royalty) amount due to Supplier for the corresponding Product unit, provided that no variable
percentage amount or non-refundable royalty payment by Purchaser for any Product unit shall be reduced by more than [***]. Any credits not exhausted with respect to any Product unit may not be used against any other payment payable to
Supplier.
		
	Payment terms	  	[***] days after the later of the delivery of the applicable order of conforming Product and the receipt of invoice for such Product.
		
	Technology Transfer	  	In the case of a Failure to Supply a Product that establishes a right to use a Third Party supplier, Supplier shall provide technology transfer applicable to that Product to the
agreed alternate supplier and shall cooperate and assist fully to effect such transfer.
		
	Sale of Chips by Purchaser (other than as part of IVD [***])	  	Purchaser shall not Exploit, alone or with any third party, any Products outside the Primary Field or Secondary Field. If Purchaser sells Fluidigm Chips or Fluidigm Instruments
to a Third Party, other than as part of an IVD [***], such Third Party shall not be licensed for use outside the Primary Field or Secondary Field, and the sale shall include a covenant of the buyer not to use the Product outside the Primary Field or
Secondary Field.
		
	Audit Right	  	 Purchaser shall have the right to visit Supplier’s sites (including sites of contract manufacturers, second source facilities
and sites used to manufacture key components of the Products) to audit the manufacturing of Product, manufacturing and quality records, and Quality Systems of Supplier upon reasonable advance notice, during regular business hours. Without limitation
of the foregoing, Purchaser shall have the right to audit any new manufacturing site (including sites at which critical components are manufactured) in connection with its qualification. Supplier shall ensure that its agreements with third party
suppliers of Product and such components permit Purchaser to exercise the foregoing rights. Details to be set forth in the Supply and Quality Agreements.
  

Supplier shall have audit rights equivalent to those of Purchaser in Section 6.4 of this Agreement.

		
	Representations and Warranties	  	In addition to other customary representations and warranties to be agreed, the Supply Agreement shall include (a) warranties that as of the date on which the Fluidigm Products
are delivered (i) they conform to specifications, (ii) their manufacture was conducted in accordance with Applicable Law and the terms of the Supply Agreement and related quality agreement, and (iii) they are not adulterated or misbranded (as
defined by applicable law) and (b) only with respect to the first sale of such Fluidigm Product to Novartis, except as otherwise disclosed, a Knowledge representation as of the date on which the Fluidigm Products are delivered that the manufacture
and sale of the Fluidigm

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 Exhibit G - 5

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 

			
		  	Products do not infringe any intellectual property rights of Third Parties.
		
	Indemnification	  	 Indemnification of Fluidigm parallel to Section 10.1 of the Collaboration Agreement.

 
 Indemnification of Novartis parallel to Section 10.2(a)(i) and (c) of the
Collaboration Agreement, including for breach of the warranties described above. The Supply Agreement will address the allocation of responsibility for expenses associated with recalls caused by the failure of Fluidigm products to conform to the
product warranties therefor.
  
 Indemnification obligations under the Supply
Agreement would be capped (aggregated with License Agreement) based on amounts paid by Purchaser to Supplier during the preceding 12 months, except for (i) infringement, which would be allocated on a [***] basis, as described more fully in the
License Agreement, subject to the limitations/exceptions set forth therein and (ii) (A) recklessness or intentional misconduct and (B) product liability (i.e., personal injury, death, or physical damage to tangible property), which liability is
caused by non-conforming Fluidigm Products, which in each case ((A) and (B)) would not be capped.

		
	Limitation of Liability	  	No lost profits or similar, except in the case of recklessness or intentional misconduct or pursuant to the indemnification provisions.
		
	Governing Law	  	California
		
	Other Terms	  	This list of key terms does not contain all of the terms that will be contained in the Supply Agreement.
		
	Assignment	  	Supplier and Purchaser may each assign the Supply Agreement to an Affiliate without prior written consent of the other party or in connection with a permitted assignment of the
License Agreement.

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 Exhibit G - 6

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 Schedule 11.2(d) 

Owned Core Fluidigm Patents 
  

													
	 Party Name
	  	 Reference No.
	  	 Title
	  	 Country
	  	 Filing Date
	  	Application No.	  	 Status

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 Schedule
11.2(d) - 1 

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
  

													
	 Party Name
	  	 Reference No.
	  	 Title
	  	 Country
	  	 Filing Date
	  	Application No.	  	 Status

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

  

	*	No foreign filing planned 

	***	To be filed in EPO & SG only. 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 Schedule
11.2(d) - 2 

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
  

													
	 Party Name
	  	 Reference No.
	  	 Title
	  	 Country
	  	 Filing Date
	  	Application No.	  	 Status

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	
	 Fluidigm Corporation (FLUIDIGM)
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	

  

	*	No foreign filing planned 

	**	To be filed in EPO only. 

	****	Undetermined but foreign filing in EPO likely. 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 Schedule
11.2(d) - 3 

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 Schedule 11.2(d) 

In-Licensed Core Fluidigm Patents 
  

													
	 Party Name
	  	 Reference No.
	  	 Title
	  	 Country
	  	 Filing Date
	  	Application No.	  	 Status

	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  

	*****	Fluidigm’s rights (including prosecution rights) have been sublicensed to Artemis Health with respect to sequencing. 

	†	Field co-exclusive. 

	††	Field exclusive. 

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 Schedule
11.2(d) - 4 

 CONFIDENTIAL TREATMENT REQUESTED BY FLUIDIGM CORPORATION 

 
 Schedule 11.2(d) 

Core Fluidigm In-License Agreements 
  

							
	  	  	 Agreement
	  	 Date
	  	 Grant

	[***]	  	[***]	  	[***]	  	[***]
		  	[***]	  		  	
		  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]

  

			
	[***]	  	 Information has been omitted and filed separately with the Securities and Exchange Commission.

Confidential treatment has been requested with respect to the omitted portions.

  
 Schedule
11.2(d) - 5Letter Agreement

 Exhibit 10.2 

 

 

 January 10, 2011 
 Thomas J. Vozzo 
  

	Re:	Letter Agreement – As Amended 

 Dear Tom:

 This Letter Agreement will confirm our agreement regarding the separation of your employment with ARAMARK. For purposes of
this Letter Agreement, “ARAMARK” shall include ARAMARK Holdings Corporation, ARAMARK Corporation, and their subsidiaries, divisions, lines of business and any corporation, joint venture, or other entity in which ARAMARK Holdings
Corporation or its subsidiaries has an equity interest in excess of ten percent (10%). 
 We have agreed as follows: 

1. Separation from Employment: Your separation as an employee of ARAMARK will be effective June 30, 2011, unless prior
to that date ARAMARK terminates you for “Cause” as defined in Article 6B of your Agreement Relating to Employment and Post-Employment Competition dated July 18, 2007 (the “Post Employment Competition Agreement”) (the
“Effective Date of Separation”). You will be deemed to have resigned from any officer or director positions you may hold with ARAMARK effective January 9, 2011, but you will continue to serve as President, ARAMARK Uniform and Career
Apparel until the Effective Date of Separation, at which time you will be deemed to have resigned from that latter position. You will continue to remain reasonably available to ARAMARK to advise with respect to matters for which you were
responsible. You will not be expected to report to your office at ARAMARK Uniform & Career Apparel’s office in Burbank as of the date of this Letter Agreement. You also agree to resign, effective as of the date of this Letter
Agreement, from any officer or director positions which you hold with any organization in which your service to that organization is related to your position with ARAMARK. 
 2. Severance Payments:  
 (a) In consideration for your obligations
under this Letter Agreement, subject to the other provisions of this Letter Agreement, and on the condition that ARAMARK not terminate you for “Cause” as defined in Article 6B of the Post-Employment Competition Agreement, you shall receive
severance payments of $11,442.30 per week, for a period of 18 months, beginning with the first week following the Effective Date of Separation (the “Severance Payments”). Severance payments shall be paid bi-weekly, less all applicable

 
withholding taxes and payroll deductions. The period during which you are eligible to receive your severance payments (the “Severance Pay Period”) shall commence with the Effective Date
of Separation, assuming that you execute and do not revoke this Letter Agreement and the Release and Waiver of Claims attached as Appendix A to this Letter Agreement both within the 21-day period following the date of this letter, and again on or
about your Effective Date of Separation. These payments shall constitute full satisfaction of any severance obligation to you. 

(b) In consideration for your obligations under this Letter Agreement and subject to the other provisions of this Letter Agreement and on
the condition that ARAMARK not terminate you for “Cause” as defined in Article 6B of the Post Employment Competition Agreement, you shall receive a lump sum payment of $225,000, minus applicable withholding taxes in December 2011, assuming
that you execute and do not revoke this Letter Agreement and the Release and Waiver of Claims attached as Appendix A to this Letter Agreement both within the 21-day period following the date of this letter, and again on or about your Effective Date
of Separation. 
 (c) Until the end of the Severance Payment Period (or, if earlier, the date you first obtain full time
employment after your Effective Date of Separation), ARAMARK shall directly pay for professional outplacement services by qualified consultants selected by you in an amount not to exceed $50,000. These expenses shall be promptly paid directly to the
qualified consultant following your submission of the invoices received by you from such consultants in respect of such services to ARAMARK (to be sent to the attention of Valerie Wandler, Senior Vice President, HR Services, (215) 238-7197),

 3. Bonus Payments: In accordance with the terms of the Senior Executive Annual Performance Bonus Plan, an
employee must be an employee of ARAMARK on the last day of the fiscal year in order to be eligible to receive a bonus for such fiscal year. Accordingly, you are not eligible to receive a bonus for fiscal year 2011. 

4. Vacation; Car Allowance; Reimbursement of Business Expenses; Group Health Insurance: 

(a) You will receive payment for any earned, accrued and unused vacation through the Effective Date of Separation. You will not accrue
any vacation days following the Effective Date of Separation. 
 (b) You will continue to receive your current car allowance
during the Severance Pay Period. 
 (c) All outstanding business expenses you incurred as an active employee on or before
January 9, 2011 should be submitted to ARAMARK for reimbursement on or before March 15, 2011. All outstanding business expenses you incurred after January 9, 2011 that have been authorized and approved by ARAMARK should be submitted
to ARAMARK for reimbursement on or before June 30, 2011. 
 (d) You and/or your dependents may elect to continue, under the
terms then in effect, your (and/or your dependents’) group health insurance coverage during the Severance Pay Period, at the end of which time this coverage will terminate; provided, 

 
however, that if you become employed by a new employer during the Severance Pay Period, continued coverage under this Paragraph 4(d) shall become secondary to any such coverage provided to you by
the new employer (the period of time during which you receive the relevant coverage from ARAMARK shall be referred to hereinafter as the “Benefits Continuation Period”). You and/or your dependents may also remain enrolled in the Healthcare
Reimbursement Account for 2011. 
 During the Benefits Continuation Period, your share of the group health premium will be deducted from your
Severance Payments. You and/or your dependents also have certain rights under the Consolidated Omnibus Budget Reconciliation Act (as modified by the American Recovery and Reinvestment Act of 2009) (“COBRA”) to continue your (and/or your
dependents’) group health insurance coverage at your expense; however, your (and your dependents’) rights under COBRA will not commence until the end of the Severance Pay Period. You are responsible in full for the cost of COBRA
continuation coverage, and your premium for such COBRA continuation coverage will be in compliance with COBRA. Further information regarding coverage continuation and conversion may be obtained from the Senior Vice President of Human Resources,
ARAMARK Uniform & Career Apparel. 
 5. Executive Leadership Council Benefits: Your membership in the
Executive Leadership Council shall terminate as of the Effective Date of Separation. Except as otherwise provided in this Letter Agreement, all Executive Leadership Council benefits including, but not limited to, your Executive Health Plan,
Executive Physical Program, Executive Supplemental Long-Term Disability, and Executive Term Life shall terminate as of that date. 
 You will
receive information regarding your option to continue your Executive Supplemental Long-Term Disability coverage on an individual basis. Further information regarding coverage continuation and conversion may be obtained from Valerie Wandler, Senior
Vice President, HR Services. 
 You will continue to be eligible to participate in the ARAMARK Uniform & Career Apparel Retirement
Savings Plan under the terms of the plan through the Effective Date of Separation. 
 6. Equity Plans: In
consideration for your obligations under this Letter Agreement and subject to the other provisions of this Letter Agreement, your rights with respect to any outstanding ARAMARK stock options or other equity-based awards that you may hold immediately
prior to the Effective Date of Separation will be treated as if you were involuntarily terminated by ARAMARK without Cause as set forth in the terms of the applicable ARAMARK incentive plan and award documents or agreements, including the
Stockholders Agreement dated January 26, 2007, as amended (the “Stockholders Agreement”). You may receive separate correspondence from ARAMARK regarding these awards, but, in the meantime, you can obtain further details as to the
effect your termination will have on such awards from Shareholder Services at (215) 238-3194. 
 7. Withholding;
Set-Off: Notwithstanding any other provision of this Letter Agreement, ARAMARK may, to the extent permitted by law, withhold applicable federal, state and local income and other taxes from any payments due to you hereunder. 

 8. Return of ARAMARK Property: Within ten days of the date of this letter, you
shall return to ARAMARK all documents, manuals, computers, computer programs, diskettes, customer lists, notebooks, reports and other written or graphic materials, including all copies thereof, relating in any way to ARAMARK’s business and
prepared by you or obtained by you from ARAMARK, its affiliates, clients or its suppliers during the course of your employment with ARAMARK; provided that you may retain your computer and Blackberry until the Effective Date of Separation; provided
further that you may purchase any generic network equipment installed in your home that does not contain any ARAMARK proprietary information for an amount equal to its current value as mutually agreed between you and ARAMARK. 

9. Post-Employment Restrictions; Entire Agreement: This Letter Agreement and its Appendix constitutes the entire agreement
between the parties on the subject of payments and benefits due to you upon your termination from service with ARAMARK and post-employment termination and benefits; and, except as expressly provided herein, supersedes all other prior agreements
concerning the terms of any and all payments and benefits to which you may be entitled upon termination of employment, including the Post Employment Competition Agreement, except that the provisions of Articles 1 (Non-Disclosure and
Non-Disparagement), 2 (Non-Competition), 3 (Non-Solicitation), 4 (Discoveries and Works), 5 (Remedies), 6B (Cause), and 8.A, B, F, G, H, I, J, and L (Miscellaneous) of the Post Employment Competition Agreement shall continue to apply and are hereby
made a part of this Letter Agreement by reference. 
 Notwithstanding any provision in this Letter Agreement to the contrary, all payments
hereunder are expressly made contingent on your compliance in all respects with all of the terms and conditions of the above-referenced Articles of the Post Employment Competition Agreement. 

10. Agreement and Obligation to Cooperate: In exchange for the benefits provided to you by ARAMARK under this Letter
Agreement, you agree to cooperate fully with reasonable requests by ARAMARK in any investigation instituted by ARAMARK or any other person or entity into any ARAMARK business involving the time period during which you were employed by ARAMARK. This
duty to cooperate will include, but not be limited to, meeting with representatives of ARAMARK at times and places reasonably designated by ARAMARK, and shall continue beyond the Severance Pay Period. ARAMARK will pay for any reasonable out of
pocket expenses and loss of income incurred by you in any such investigation. Notwithstanding any provision in this Letter Agreement to the contrary, all payments hereunder are expressly made contingent on your compliance in all respects with all of
the terms and conditions of this Paragraph 10 and the other provisions of this Letter Agreement. 
 11. Certification of
Compliance with Business Conduct Policy and Laws: By signing this Letter Agreement, you are certifying that you are not aware of any violation by you or anyone else of ARAMARK’s Business Conduct Policy. Notwithstanding any provision in
this Letter Agreement to the contrary, all payments hereunder are expressly made contingent on the accuracy of your certification in this Paragraph 11 and your compliance in all respects with all of the terms and conditions of this Paragraph 11 and
the other provisions of this Letter Agreement. 

 12. Deferred Compensation Tax Rules: In the event that it is reasonably
determined by ARAMARK that, as a result of the new deferred compensation tax rules under Section 409A of the Internal Revenue Code of 1986, as amended (and any related regulations or other pronouncements there under)(“the Deferred
Compensation Tax Rules”), any of the payments or benefits that you are entitled to under the terms of this Letter Agreement, the Post Employment Competition Agreement or any other nonqualified deferred compensation plan or arrangement
maintained by ARAMARK in which you participate, may not be made at the time contemplated by the terms hereof or thereof, as the case may be, without causing you to be subject to tax under the Deferred Compensation Tax Rules, ARAMARK shall, in lieu
of providing such payment or benefit when otherwise due under this Letter Agreement or any other nonqualified deferred compensation plan or arrangement maintained by ARAMARK in which you participate, instead provide such payment or benefit on the
first day on which such provision would not result in you incurring any tax liability under the Deferred Compensation Tax Rules. In the event that any payments or benefits that ARAMARK would otherwise be required to provide under this Letter
Agreement or any other nonqualified deferred compensation plan or arrangement maintained by ARAMARK in which you participate cannot be provided in the manner contemplated herein without subjecting you to tax under Deferred Tax Rules, ARAMARK shall
provide such intended payments or benefits to you in an alternative manner that conveys an equivalent economic benefit to you as soon as practicable as may otherwise be permitted under the Deferred Compensation Tax Rules. 

13. No Mitigation; No Offset: You shall have no duty to mitigate or to seek or accept employment or work elsewhere
following the Effective Date of Separation. If you do become employed or engaged elsewhere, the payments and benefits set forth in this Letter Agreement shall continue and shall not be offset or reduced by any compensation or benefits you may
receive from such other source, subject only to the requirements of the Post Employment Competition Agreement provisions incorporated herein and paragraph 4(d). 
 14. Applicable Law: This Letter Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania, without regard to conflicts of laws principles
thereof. 
 15. Amendment: This Letter Agreement may only be amended or modified by a written agreement executed
by you and ARAMARK (or any successor). 
 16. Place of Payment: All payments to you hereunder shall be sent
to you at such address as you may direct in writing, or to such banks as you may instruct in writing for direct deposit. 

17. Counterparts: This Letter Agreement may be executed in one or more counterparts, which shall, collectively or
separately, constitute one agreement. 

 Please sign the enclosed copy of this Letter Agreement to signify your understanding and
acceptance of the terms and conditions contained herein and return one original to me by no later than February 7, 2011. 
  

			
	Very truly yours,
		
	By:	 	 /s/ Lynn B. McKee

		 	 Lynn B. McKee

		 	 Executive Vice President, Human Resources

 The foregoing has been read and accepted as a binding agreement between ARAMARK and the undersigned this 7th day of February 2011. 

 

			
		 	 /s/ Thomas J. Vozzo

		 	 Thomas J. Vozzo

 APPENDIX A 
 Release and Waiver of Claims 
 1. In consideration for the payments
provided for under the Letter Agreement between me, Thomas J. Vozzo, and ARAMARK Corporation dated January 10, 2011 (the “Letter Agreement”) and the Agreement Relating to Employment and Post-Employment Competition between me, Thomas
J. Vozzo, and ARAMARK Corporation dated July 18, 2007 (“Post Employment Competition Agreement”), and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, I hereby agree on behalf of
myself, my spouse, agents, assignees, attorneys, successors, assigns, heirs and executors, to fully and completely release ARAMARK (which term shall be deemed to include ARAMARK Holdings Corporation and all subsidiary and affiliated and successor
companies of ARAMARK Holdings Corporation or other entity in which ARAMARK Holdings Corporation or its subsidiaries or affiliates has an equity interest in excess of ten percent (10%)), its predecessors and successors and all of their respective
past and/or present officers, directors, partners, members, managing members, managers, employees, agents, representatives, administrators, attorneys, insurers and fiduciaries in their individual and/or representative capacities (hereinafter
collectively referred to as the “Company Releasees”), from any and all causes of action and claims whatsoever, which I or my heirs, executors, administrators, successors and assigns ever had, now have or may have against the Company
Releasees or any of them, in law, admiralty or equity, whether known or unknown to me, for, upon, or by reason of, any matter, action, omission, course or thing in connection with or in relationship to: (a) my employment or other service
relationship with ARAMARK; (b) the termination of any such employment or service relationship; (c) any applicable employment, benefit, compensatory or equity arrangement with ARAMARK occurring or existing up to the Effective Date of
Separation; and (d) any equity or stock plans of ARAMARK (such released claims are collectively referred to herein as the “Released Claims”). 
 2. The Released Claims include, without limitation of the language of paragraph 1, (i) any and all claims under Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act of
1967, the Civil Rights Act of 1991, the Employee Retirement Income Security Act of 1974, the Americans with Disabilities Act, the Family and Medical Leave Act of 1993, and any and all other federal, state or local laws, statutes, rules and
regulations pertaining to employment or otherwise and (ii) any claims for wrongful discharge breach of contract, fraud, misrepresentation or any claims relating to benefits, compensation or equity, or any other claims under any statute, rule or
regulation or under the common law, including compensatory damages, punitive damages, attorney’s fees, costs, expenses and all claims for any other type of damage or relief. 
 I acknowledge that this Release and Waiver of Claims resolves all legal claims I may have against Company Releasees as of the date of this Release and Waiver of Claims, whether known or unknown. It is
understood and agreed that I expressly waive any and all rights under Section 1542 of the California Civil Code or any similar statute of the United States or any state or territory of the United States pertaining to the matters covered by the
Letter Agreement. California Civil Code Section 1542 states: “CERTAIN CLAIMS NOT AFFECTED BY GENERAL RELEASE – A general release does not extend to claims which the creditor 

 
does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor.” 

3. The Released Claims shall not include my rights under, or with respect to, the items listed in Article 6(F)(i)(1)-(6) of the Post
Employment Competition Agreement. 
 4. I expressly understand and agree that the obligations of ARAMARK as set forth in the
Letter Agreement are in lieu of any and all other amounts which I might be, are now, or may become, entitled to receive from ARAMARK upon any claim released herein. 
 5. I represent that I have read carefully and fully understand the terms of this Release and that I have been advised by this writing to consult with an attorney and further have had the opportunity to
consult with an attorney prior to signing this Release. I further acknowledge that I fully understand the Release that I am signing. I acknowledge that I am signing this Release voluntarily and knowingly and that I have not relied on any
representations, promises or agreements of any kind made to me in connection with my decision to accept the terms of this Release, other than those set forth in this Release. I acknowledge that I have been given at least twenty-one (21) days to
consider whether I want to sign this Release. 
 6. I acknowledge that the federal Age Discrimination in Employment Act gives me
the right to revoke this Release within seven (7) days after it is signed by me. I further acknowledge that I will not receive any payments or benefits due to me under the Letter Agreement before the seven (7) day revocation period under
the Age Discrimination in Employment Act (the “Revocation Period”) has passed and then, only if I have not revoked this Release. To the extent I have executed this Release within less than twenty-one (21) days after its delivery to
me, I hereby acknowledge that my decision to execute this Release prior to the expiration of such twenty-one (21) day period was entirely voluntary. 
 This Release shall take effect on the first business day following the expiration of the Revocation Period, provided this Release has not been revoked by me as provided above during such Revocation
Period. 
  

	
	     /s/ Thomas J. Vozzo

	Thomas J. Vozzo

DATED:        2/7/11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00184-of-00352.parquet"}]]